<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>1400</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="1400"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=1400&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=1300&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=1500&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928667962"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928667962?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928667962&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928667962&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002324"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928667962</prism:url><dc:identifier>SCOPUS_ID:84928667962</dc:identifier><eid>2-s2.0-84928667962</eid><dc:title>Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction</dc:title><dc:creator>Moreno Velásquez I.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>477-481</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.014</prism:doi><pii>S0021915015002324</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objective: To investigate the association between circulating levels of the soluble interleukin 6 receptor (sIL6R) and the soluble gp130 (sgp130) with myocardial infarction (MI) and to explore the potential interaction between sIL6R and sgp130 in this association. Methods: Study population is the Stockholm Heart Epidemiology Program (SHEEP), a population-based case-control study. SIL6R (ng/mL) and sgp130 (ng/mL) levels were measured in serum samples from 682 and 664 MI cases and 1103 and 1062 controls, respectively. Odds ratios (with 95% CIs) for MI were calculated using unconditional logistic regression. We adjusted for age, sex, hospital catchment area (crude) and for hypertension, diabetes, hypercholesterolemia, body mass index and smoking (adjusted model). Synergy index (S) and attributable proportion (AP) were estimated as measures of biological interaction. Results: Elevated concentrations of sIL6R (&gt;75th percentile value) were associated with an increased occurrence of MI (compared to ≤75th percentile), with an adjusted OR of 1.4 (95% CI, 1.1-1.8). Very high (&gt;90th percentile value) levels of sgp130 were associated with a reduced occurrence of MI [OR 0.7 (95% CI, 0.5-0.9)] (adjusted). There was an indication of a possible interaction between high sIL6R and low sgp130 (adjusted S score 1.7, 95% CI=0.5-6.1; AP 0.19, 95% CI=-0.2-0.5), suggesting that low sgp130 levels may synergize with high sIL6R levels to increase risk of MI. Conclusions: sIL6R and sgp130 had opposing associations with MI. Indeed, circulating sgp130 levels may modify the association of elevated sIL6R levels with MI.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012311</affiliation-url><afid>60012311</afid><affilname>Karolinska Institutet</affilname><name-variant>Karolinska Institutet</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019295</affiliation-url><afid>60019295</afid><affilname>Karolinska University Hospital</affilname><name-variant>Karolinska University Hospital</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026150</affiliation-url><afid>60026150</afid><affilname>Danderyd Hospital</affilname><name-variant>Danderyd Hospital</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56499291900</author-url><authid>56499291900</authid><authname>Moreno Velásquez I.</authname><surname>Moreno Velásquez</surname><given-name>Ilais</given-name><initials>I.</initials><afid>60012311</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56557114900</author-url><authid>56557114900</authid><authname>Golabkesh Z.</authname><surname>Golabkesh</surname><given-name>Zahra</given-name><initials>Z.</initials><afid>60012311</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:11739765700</author-url><authid>11739765700</authid><authname>Källberg H.</authname><surname>Källberg</surname><given-name>Henrik</given-name><initials>H.</initials><afid>60012311</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55388819100</author-url><authid>55388819100</authid><authname>Leander K.</authname><surname>Leander</surname><given-name>Karin</given-name><initials>K.</initials><afid>60012311</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7103145439</author-url><authid>7103145439</authid><authname>de Faire U.</authname><surname>de Faire</surname><given-name>Ulf</given-name><initials>U.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7103145439</author-url><authid>7103145439</authid><authname>de Faire U.</authname><surname>de Faire</surname><given-name>Ulf</given-name><initials>U.</initials><afid>60012311</afid><afid>60019295</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003480904</author-url><authid>7003480904</authid><authname>Gigante B.</authname><surname>Gigante</surname><given-name>Bruna</given-name><initials>B.</initials><afid>60012311</afid><afid>60026150</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003480904</author-url><authid>7003480904</authid><authname>Gigante B.</authname><surname>Gigante</surname><given-name>Bruna</given-name><initials>B.</initials><afid>60012311</afid><afid>60026150</afid></author><authkeywords>Biomarkers | Interleukin 6 receptor | Myocardial infarction | SIL6R | Soluble gp130</authkeywords><intid>1785825004</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925047583"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925047583?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925047583&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925047583&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0041010115000677"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925047583</prism:url><dc:identifier>SCOPUS_ID:84925047583</dc:identifier><eid>2-s2.0-84925047583</eid><dc:title>The relative toxicity of Delphinium stachydeum in mice and cattle</dc:title><dc:creator>Cook D.</dc:creator><prism:publicationName>Toxicon</prism:publicationName><prism:issn>00410101</prism:issn><prism:eIssn>18793150</prism:eIssn><prism:volume>99</prism:volume><prism:pageRange>36-43</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.toxicon.2015.03.005</prism:doi><pii>S0041010115000677</pii><dc:description>Larkspurs (Delphinium spp.) are poisonous plants on rangelands throughout the Western United States and Canada. Larkspur-induced poisoning in cattle is due to norditerpene alkaloids that are represented by two main structural groups of norditerpene alkaloids, the N-(methylsuccinimido) anthranoyllycoctonine type (MSAL-type) and the non-MSAL type. Information on the alkaloid composition and resulting toxicity in mice and cattle is lacking for a number of Delphinium species, including Delphinium stachydeum. The objective of this study was to determine the alkaloid composition of D. stachydeum and to characterize its relative toxicity in mice and cattle compared to two reference species Delphinium barbeyi and Delphinium occidentale. D. stachydeum contains the non-MSAL-type alkaloids but not the MSAL-type alkaloids. D. stachydeum was less toxic than D. barbeyi and D. occidentale in the mouse model. D. stachydeum was less toxic than the MSAL-containing D. barbeyi but much more toxic than the non-MSAL-containing D. occidentale in cattle as measured by heart rate and time of exercise. These results indicate that predictions of Delphinium toxicity can't be accurately made based solely on results from the mouse model or the absence of the MSAL-type alkaloids in the plant.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>United States Department of Agriculture-Poisonous Plant Research Laboratory</affilname><affiliation-city>Logan</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55612099700</author-url><authid>55612099700</authid><authname>Cook D.</authname><surname>Cook</surname><given-name>Daniel</given-name><initials>D.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7201515275</author-url><authid>7201515275</authid><authname>Welch K.</authname><surname>Welch</surname><given-name>Kevin D.</given-name><initials>K.D.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55854426700</author-url><authid>55854426700</authid><authname>Green B.</authname><surname>Green</surname><given-name>Benedict T.</given-name><initials>B.T.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54383168100</author-url><authid>54383168100</authid><authname>Gardner D.</authname><surname>Gardner</surname><given-name>Dale R.</given-name><initials>D.R.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006829877</author-url><authid>7006829877</authid><authname>Pfister J.</authname><surname>Pfister</surname><given-name>James A.</given-name><initials>J.A.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56509215700</author-url><authid>56509215700</authid><authname>Constantino J.</authname><surname>Constantino</surname><given-name>John R.</given-name><initials>J.R.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:52264672600</author-url><authid>52264672600</authid><authname>Stonecipher C.</authname><surname>Stonecipher</surname><given-name>Clinton A.</given-name><initials>C.A.</initials><afid/></author><authkeywords>Cattle | Delphinium | Norditerpene alkaloids | Toxic plant</authkeywords><intid>1035262903</intid><source-id>22319</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921628207"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921628207?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921628207&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921628207&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306460315000118"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921628207</prism:url><dc:identifier>SCOPUS_ID:84921628207</dc:identifier><eid>2-s2.0-84921628207</eid><dc:title>Smoking cue reactivity in current smokers, former smokers and never smokers</dc:title><dc:creator>Balter L.</dc:creator><prism:publicationName>Addictive Behaviors</prism:publicationName><prism:issn>03064603</prism:issn><prism:eIssn>18736327</prism:eIssn><prism:volume>45</prism:volume><prism:pageRange>26-29</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.addbeh.2015.01.010</prism:doi><pii>S0306460315000118</pii><dc:description>© 2015 Elsevier Ltd. Introduction: Smoking related stimuli are known to increase both subjective craving and heart rate in smokers; however, little is currently known about the effects of such stimuli in former smokers. Methods: Subjective craving and heart rate were measured in 38 never smokers, 20 former smokers, and 30 current smokers exposed to video clips containing neutral and smoking related cues. Results: Compared with neutral cues, smoking cues significantly increased both heart rate and self-reported craving in current smokers, while in former smokers smoking cues were associated with a significant decrease in heart rate as well as with a relatively diminished increase in subjective craving. Neither craving nor heart rate was impacted by the smoking cues in never smokers. Conclusions: Findings suggest that while smoking related stimuli continue to elicit modest subjective cravings in former smokers, there appears to be a marked change in the typical physiological response associated with such stimuli.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015913</affiliation-url><afid>60015913</afid><affilname>Dalhousie University</affilname><name-variant>Dalhousie University</name-variant><affiliation-city>Halifax</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015913</affiliation-url><afid>60015913</afid><affilname>Dalhousie University</affilname><name-variant>Dalhousie University</name-variant><affiliation-city>Halifax</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56492860800</author-url><authid>56492860800</authid><authname>Balter L.</authname><surname>Balter</surname><given-name>Leonie J T</given-name><initials>L.J.T.</initials><afid>60015913</afid><afid>60015913</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56492860800</author-url><authid>56492860800</authid><authname>Balter L.</authname><surname>Balter</surname><given-name>Leonie J T</given-name><initials>L.J.T.</initials><afid>60015913</afid><afid>60015913</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003692577</author-url><authid>7003692577</authid><authname>Good K.</authname><surname>Good</surname><given-name>Kimberley P.</given-name><initials>K.P.</initials><afid>60015913</afid><afid>60015913</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003692577</author-url><authid>7003692577</authid><authname>Good K.</authname><surname>Good</surname><given-name>Kimberley P.</given-name><initials>K.P.</initials><afid>60015913</afid><afid>60015913</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201982845</author-url><authid>7201982845</authid><authname>Barrett S.</authname><surname>Barrett</surname><given-name>Sean P.</given-name><initials>S.P.</initials><afid>60015913</afid><afid>60015913</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201982845</author-url><authid>7201982845</authid><authname>Barrett S.</authname><surname>Barrett</surname><given-name>Sean P.</given-name><initials>S.P.</initials><afid>60015913</afid><afid>60015913</afid></author><authkeywords>Craving | Cue reactivity | Former smokers | Heart rate | Smoking</authkeywords><intid>1034666415</intid><source-id>24763</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924663650"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924663650?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924663650&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924663650&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0166432815001126"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924663650</prism:url><dc:identifier>SCOPUS_ID:84924663650</dc:identifier><eid>2-s2.0-84924663650</eid><dc:title>Cardioacceleration in alloparents in response to stimuli from prairie vole pups: The significance of thermoregulation</dc:title><dc:creator>Kenkel W.</dc:creator><prism:publicationName>Behavioural Brain Research</prism:publicationName><prism:issn>01664328</prism:issn><prism:eIssn>18727549</prism:eIssn><prism:volume>286</prism:volume><prism:pageRange>71-79</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbr.2015.02.033</prism:doi><pii>S0166432815001126</pii><dc:description>© 2015 Elsevier B.V. Autonomic responses, including changes in heart rate and respiratory sinus arrhythmia (RSA) can provide indications of emotional reactivity to social stimuli in mammals. We have previously reported that male prairie voles (. Microtus ochrogaster) spontaneously care for unfamiliar infants, showing a robust and sustained increase in heart rate in the presence of a pup, thus providing an opportunity to examine the physiology of care-giving in reproductively naïve animals. However, the purpose of such heart rate increases has not been explained by previous efforts. In the present study, we first compared male and female prairie vole cardiac responses in the presence of a pup and found no evidence of sex differences in heart rate or RSA. Using male prairie voles, we then examined the characteristics of pups that were capable of eliciting physiological responses, including age of the pup and pup odors. As prairie vole pups increased in age they vocalized less and there was an associated decline in alloparental cardioacceleration. Exposure to pup-related odors induced cardioacceleration in adult males, and this effect also diminished with increasing pup age. Finally, we were able to block the cardioacceleratory effect when the testing environment was warmed to a temperature of 36. °C [vs ambient room temperature (approximately 22. °C)]. These findings suggest that pup-induced cardioacceleration is a robust phenomenon across alloparental prairie voles of both sexes, and depends on multi-modal processing of different stimuli from the pups. Young pups require care-giving behavior, which appears to drive cardioacceleration in the alloparents. This study also supports the usefulness of autonomic measures in the evaluation of social experiences.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028628</affiliation-url><afid>60028628</afid><affilname>Northeastern University</affilname><name-variant>Northeastern University</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017717</affiliation-url><afid>60017717</afid><affilname>The University of North Carolina System</affilname><name-variant>University of North Carolina</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021121</affiliation-url><afid>60021121</afid><affilname>Indiana University</affilname><name-variant>Indiana University</name-variant><affiliation-city>Bloomington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55214989500</author-url><authid>55214989500</authid><authname>Kenkel W.</authname><surname>Kenkel</surname><given-name>William M.</given-name><initials>W.M.</initials><afid>60028628</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56524023300</author-url><authid>56524023300</authid><authname>Yee J.</authname><surname>Yee</surname><given-name>Jason R.</given-name><initials>J.R.</initials><afid>60028628</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006116851</author-url><authid>7006116851</authid><authname>Porges S.</authname><surname>Porges</surname><given-name>Stephen W.</given-name><initials>S.W.</initials><afid>60017717</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7103194834</author-url><authid>7103194834</authid><authname>Ferris C.</authname><surname>Ferris</surname><given-name>Craig F.</given-name><initials>C.F.</initials><afid>60028628</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55817552070</author-url><authid>55817552070</authid><authname>Carter C.</authname><surname>Carter</surname><given-name>C. Sue</given-name><initials>C.S.</initials><afid>60021121</afid></author><authkeywords>Alloparenting | Autonomic | Heart rate | Prairie vole | Pup | Social behavior | Thermoregulation</authkeywords><intid>1535188069</intid><source-id>14285</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924132863"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924132863?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924132863&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924132863&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1567134815000568"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924132863</prism:url><dc:identifier>SCOPUS_ID:84924132863</dc:identifier><eid>2-s2.0-84924132863</eid><dc:title>Isolation, identification, and pathogenicity of O142 avian pathogenic Escherichia coli causing black proventriculus and septicemia in broiler breeders</dc:title><dc:creator>Wang X.</dc:creator><prism:publicationName>Infection, Genetics and Evolution</prism:publicationName><prism:issn>15671348</prism:issn><prism:eIssn>15677257</prism:eIssn><prism:volume>32</prism:volume><prism:pageRange>23-29</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.meegid.2015.02.013</prism:doi><pii>S1567134815000568</pii><dc:description>© 2015 Elsevier B.V. Avian colibacillosis, characterized by black proventriculus and caused by avian pathogenic Escherichia coli (APEC) with an uncommon O142 serogroup, was diagnosed in young broiler breeders. Colonization and persistence assays performed in 7-day-old broilers showed that the bacterial load of the APEC 4d/9-1 O142 proventricular isolate in the lung was about 10-fold higher than that of the APEC 4d/9-1 O142 heart blood isolate (P&lt;0.01), and about 100-fold higher in the heart blood, livers, spleens, kidneys, and proventriculi of inoculated broilers (P&lt;0.001). When 32 common virulence genes of APEC were tested, the two isolates had nearly identical profiles, except that only the APEC 4d/9-1 O142 proventricular isolate carried the feoB gene. Furthermore, 100% mortality was observed in both 1-day-old Arbor Acres (AA) broilers and 1-day-old specific-pathogen-free (SPF) chickens inoculated with 106 colony-forming units of the APEC 4d/9-1 O142 proventricular isolate. However, black proventriculus was only observed in the dead AA broilers, consistent with the clinical occurrence of the disease. This implies that the black proventriculi seen in the dead birds, caused by the APEC 4d/9-1 O142 proventricular isolate, was breed-specific. Both the APEC 4d/9-1 O142 proventricular and heart blood isolates belong to phylogroup B2. However, the former was assigned to ST131 and the latter to ST2704 with multilocus sequence typing, demonstrating the genetic heterogeneity of these two bacterial isolates, although they were derived from the same dead broiler. These results suggest that the O142 APEC isolate was the main pathogenic agent for black proventriculi in 7-day-old broiler breeders.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007381</affiliation-url><afid>60007381</afid><affilname>Yangzhou University</affilname><name-variant>Yangzhou University</name-variant><affiliation-city>Yangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115034591</affiliation-url><afid>115034591</afid><affilname>Huaiyin Normal University School of Life Science</affilname><name-variant>Huaiyin Normal University School of Life Science</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56451250400</author-url><authid>56451250400</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiaobo</given-name><initials>X.</initials><afid>60007381</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56537534800</author-url><authid>56537534800</authid><authname>Cao C.</authname><surname>Cao</surname><given-name>Chunguang</given-name><initials>C.</initials><afid>60007381</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56538161000</author-url><authid>56538161000</authid><authname>Huan H.</authname><surname>Huan</surname><given-name>Haixia</given-name><initials>H.</initials><afid>115034591</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56538202500</author-url><authid>56538202500</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Liuli</given-name><initials>L.</initials><afid>60007381</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55786957100</author-url><authid>55786957100</authid><authname>Mu X.</authname><surname>Mu</surname><given-name>Xiaohui</given-name><initials>X.</initials><afid>60007381</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:26657296700</author-url><authid>26657296700</authid><authname>Gao Q.</authname><surname>Gao</surname><given-name>Qingqing</given-name><initials>Q.</initials><afid>60007381</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56537358000</author-url><authid>56537358000</authid><authname>Dong X.</authname><surname>Dong</surname><given-name>Xianglei</given-name><initials>X.</initials><afid>60007381</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:53063485900</author-url><authid>53063485900</authid><authname>Gao S.</authname><surname>Gao</surname><given-name>Song</given-name><initials>S.</initials><afid>60007381</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35362360500</author-url><authid>35362360500</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiufan</given-name><initials>X.</initials><afid>60007381</afid></author><authkeywords>Avian pathogenic escherichia coli | Black proventriculus | Heart blood isolate | Proventricular isolate | Virulence</authkeywords><intid>535085121</intid><source-id>14677</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929939663"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929939663?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929939663&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929939663&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929939663</prism:url><dc:identifier>SCOPUS_ID:84929939663</dc:identifier><eid>2-s2.0-84929939663</eid><dc:title>Vinexin-β exacerbates cardiac dysfunction post-myocardial infarction via mediating apoptotic and inflammatory responses</dc:title><dc:creator>Liu X.</dc:creator><prism:publicationName>Clinical science (London, England : 1979)</prism:publicationName><prism:eIssn>14708736</prism:eIssn><prism:volume>128</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>923-936</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1042/CS20140648</prism:doi><dc:description>Vinexin-β is one of the adaptor proteins that are primarily involved in signal transduction and cytoskeletal organization under various pathological conditions, including cardiac hypertrophy. However, the role of Vinexin-β in myocardial infarction (MI) remains unknown. In this study, dramatically up-regulated Vinexin-β expression was observed in both ischaemic human hearts and infarcted animal hearts. To explore the potential involvement of Vinexin-β in MI further, we induced MI injury in global Vinexin-β-knockout mice and wild-type (WT) controls as well as in mice with cardiac-specific over-expression of the human Vinexin-β gene-transgenic (TG) and -non-transgenic (NTG) littermates. Compared with that observed in WT controls, Vinexin-β deficiency significantly decreased MI-induced infarct size, concomitant with an improved cardiac function, leading to an increase in the survival rate. The myocardial apoptosis in the border zone was dramatically reduced by Vinexin-β deficiency, resulting from the altered expression of apoptotic factors. Furthermore, Vinexin-β depletion mitigated the inflammatory response, as evidenced by reduced inflammatory cell infiltration, decreased expression of cytokines and the inactivation of NF-κB (nuclear factor κB) signalling. In contrast, Vinexin-β-TG mice were much more susceptible to MI injury compared with NTG controls. Further mechanism analyses suggested that Vinexin-β exerted detrimental effects largely dependent on blocking AKT signalling. The effects and mechanisms of Vinexin-β on MI observed in vivo were further confirmed by our in vitro assays. When collected, these data demonstrate for the first time that Vinexin-β increases MI-induced mortality and worsens cardiac dysfunction through aggravation of myocardial apoptosis and inflammatory response.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080982</affiliation-url><afid>60080982</afid><affilname>Hubei General Hospital</affilname><name-variant>Renmin Hospital of Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080982</affiliation-url><afid>60080982</afid><affilname>Hubei General Hospital</affilname><name-variant>Renmin Hospital of Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022317</affiliation-url><afid>60022317</afid><affilname>University of Macau</affilname><name-variant>University of Macau</name-variant><affiliation-city>Taipa</affiliation-city><affiliation-country>Macao</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087536</affiliation-url><afid>60087536</afid><affilname>Renji Hospital</affilname><name-variant>Shanghai Second Medical University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080982</affiliation-url><afid>60080982</afid><affilname>Hubei General Hospital</affilname><name-variant>Renmin Hospital of Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080982</affiliation-url><afid>60080982</afid><affilname>Hubei General Hospital</affilname><name-variant>Renmin Hospital of Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115276365</affiliation-url><afid>115276365</afid><affilname>Second Artillery General Hospital of Chinese People's Liberation Army Qinghe Clinic</affilname><name-variant>Second Artillery General Hospital of Chinese People's Liberation Army Qinghe Clinic</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029306</affiliation-url><afid>60029306</afid><affilname>Wuhan University</affilname><name-variant>Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029306</affiliation-url><afid>60029306</afid><affilname>Wuhan University</affilname><name-variant>Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080982</affiliation-url><afid>60080982</afid><affilname>Hubei General Hospital</affilname><name-variant>Renmin Hospital of Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080982</affiliation-url><afid>60080982</afid><affilname>Hubei General Hospital</affilname><name-variant>Renmin Hospital of Wuhan University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><pubmed-id>25658191</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56123769500</author-url><authid>56123769500</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiaoxiong</given-name><initials>X.</initials><afid>60080982</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56603850300</author-url><authid>56603850300</authid><authname>Wan N.</authname><surname>Wan</surname><given-name>Nian</given-name><initials>N.</initials><afid>60080982</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56603514300</author-url><authid>56603514300</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiao Jing</given-name><initials>X.J.</initials><afid>60022317</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56603725200</author-url><authid>56603725200</authid><authname>Zhao Y.</authname><surname>Zhao</surname><given-name>Yichao</given-name><initials>Y.</initials><afid>60087536</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56657547200</author-url><authid>56657547200</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60080982</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56603531100</author-url><authid>56603531100</authid><authname>Hu G.</authname><surname>Hu</surname><given-name>Gangying</given-name><initials>G.</initials><afid>60080982</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56603730500</author-url><authid>56603730500</authid><authname>Wan F.</authname><surname>Wan</surname><given-name>Fengwei</given-name><initials>F.</initials><afid>115276365</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56603412700</author-url><authid>56603412700</authid><authname>Zhang R.</authname><surname>Zhang</surname><given-name>Rui</given-name><initials>R.</initials><afid>60029306</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56566907200</author-url><authid>56566907200</authid><authname>Zhu X.</authname><surname>Zhu</surname><given-name>Xueyong</given-name><initials>X.</initials><afid>60029306</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56652960600</author-url><authid>56652960600</authid><authname>Xia H.</authname><surname>Xia</surname><given-name>Hao</given-name><initials>H.</initials><afid>60080982</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56118488800</author-url><authid>56118488800</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hongliang</given-name><initials>H.</initials><afid>60080982</afid></author><intid>536039183</intid><source-id>29710</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929593950"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929593950?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929593950&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929593950&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929593950</prism:url><dc:identifier>SCOPUS_ID:84929593950</dc:identifier><eid>2-s2.0-84929593950</eid><dc:title>A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization</dc:title><dc:creator>Litwin J.</dc:creator><prism:publicationName>Antimicrobial Agents and Chemotherapy</prism:publicationName><prism:issn>00664804</prism:issn><prism:eIssn>10986596</prism:eIssn><prism:volume>59</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>3469-3473</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1128/AAC.04813-14</prism:doi><dc:description>Copyright © 2015, American Society for Microbiology. All Rights Reserved. A randomized, double-blind, placebo-controlled, 4-period crossover study was conducted in 52 healthy adults to assess the effect of delafloxacin on the corrected QT (QTc) interval. The QT interval, corrected for heart rate using Fridericia's formula (QTcF), was determined predose and at 0.5, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 12, 18, and 24 h after dosing with delafloxacin at 300 mg intravenously (i.v.; therapeutic), delafloxacin at 900 mg i.v. (supratherapeutic), moxifloxacin at 400 mg orally (p.o.; positive control), and placebo. The pharmacokinetic profile of delafloxacin was also evaluated. At each time point after delafloxacin administration, the upper limit of the 90% confidence interval (CI) for the placebo-corrected change from the predose baseline in QTcF (ΔΔQTcF) was less than 10 ms (maximum, 3.9 ms at 18 h after dosing), indicating an absence of a clinically meaningful increase in the QTc interval. The lower limit of the 90% CI of ΔΔQTcF for moxifloxacin versus placebo was longer than 5 ms at all 5 time points selected for assay sensitivity analysis, demonstrating that the study was adequately sensitive to assess QTc prolongation. There was no positive relationship between delafloxacin plasma concentrations and ΔΔQTcF. Treatment-emergent adverse events (AEs) were more frequent among subjects receiving a single supratherapeutic dose of 900 mg delafloxacin. There were no deaths, serious AEs, or AEs leading to study discontinuation and no clinically meaningful abnormalities in laboratory values or vital signs observed at any time point after any dose of the study drug.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108519513</affiliation-url><afid>108519513</afid><affilname>ERT</affilname><name-variant>ERT, inc.</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101827629</affiliation-url><afid>101827629</afid><affilname>PPD</affilname><name-variant>PPD</name-variant><affiliation-city>Austin</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115291406</affiliation-url><afid>115291406</afid><affilname>Statistical Resources</affilname><name-variant>Statistical Resources</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115071972</affiliation-url><afid>115071972</afid><affilname>Melinta Therapeutics</affilname><name-variant>Melinta Therapeutics</name-variant><affiliation-city>New Haven</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005500910</author-url><authid>7005500910</authid><authname>Litwin J.</authname><surname>Litwin</surname><given-name>Jeffrey S.</given-name><initials>J.S.</initials><afid>108519513</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56650722700</author-url><authid>56650722700</authid><authname>Benedict M.</authname><surname>Benedict</surname><given-name>Michael S.</given-name><initials>M.S.</initials><afid>101827629</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56650746800</author-url><authid>56650746800</authid><authname>Thorn M.</authname><surname>Thorn</surname><given-name>Michael D.</given-name><initials>M.D.</initials><afid>115291406</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56443663300</author-url><authid>56443663300</authid><authname>Lawrence L.</authname><surname>Lawrence</surname><given-name>Laura E.</given-name><initials>L.E.</initials><afid>115071972</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003558547</author-url><authid>7003558547</authid><authname>Cammarata S.</authname><surname>Cammarata</surname><given-name>Sue K.</given-name><initials>S.K.</initials><afid>115071972</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56650669500</author-url><authid>56650669500</authid><authname>Sun E.</authname><surname>Sun</surname><given-name>Eugene</given-name><initials>E.</initials><afid>115071972</afid></author><intid>35980312</intid><source-id>19615</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928919993"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928919993?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928919993&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928919993&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928919993</prism:url><dc:identifier>SCOPUS_ID:84928919993</dc:identifier><eid>2-s2.0-84928919993</eid><dc:title>Hospital Admissions Greater Than 30 Days Following Bariatric Surgery: Patient and Procedure Matter</dc:title><dc:creator>Telem D.</dc:creator><prism:publicationName>Surgical Endoscopy and Other Interventional Techniques</prism:publicationName><prism:issn>09302794</prism:issn><prism:eIssn>14322218</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1310-1315</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00464-014-3834-x</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Introduction: Assessment of hospital admission in the 30-day period following bariatric surgery likely underestimates true hospital utilization. The purpose of this study is to assess hospital admissions for 2 years following bariatric surgery to identify potential differences by patient and procedure. Methods: New York State Planning and Research Cooperative System (SPARCS) longitudinal administrative data were used to identify 22,139 adult patients who underwent a primary bariatric surgery from 2006 to 2008. Bariatric operations included laparoscopic gastric banding (LGB), laparoscopic Roux-en-y gastric bypass (RYGB), and laparoscopic sleeve gastrectomy (LSG). Patients were followed for 2 years after surgery to identify all-cause hospital admissions. Statistical correlation between postoperative hospital admission and patient demographics, comorbid conditions, and bariatric procedure was performed. Results: Of the 22,139 patients, 5,718 (26 %) patients were admitted within 2 years of surgery for a total of 9,502 admissions. Thirty-day admission rate was 5 %. The number of admissions per patient ranged from 1 to 22. Assessing the number of admissions per patient demonstrated that 3,741 (17 %) patients had one, 1,575 (7 %) had 2–3, and 402 (2 %) patients had greater than 4 admissions. LSG had both the highest admission rate and percentage of patients with &gt;4 admissions, followed by RYGB and then LGB (p &lt; 0.001). Risk factors for admission included black race, female gender, age &gt; 50, Medicaid/Medicare as payer, congestive heart failure, pulmonary disease, diabetes, rheumatoid arthritis, history of substance abuse, and psychoses/depression. Conclusion: One out of four bariatric patients will be admitted to the hospital within 2 years of surgery. While most patients are admitted only once, a subset of patients requiring numerous hospital admissions was identified. LSG is associated with both the highest rate as well as highest frequency of hospital admissions. Several patient factors were also identified that significantly increased admission risk. Consideration and attention to these factors are necessary for operative planning, preoperative patient education, and postoperative monitoring.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002053</affiliation-url><afid>60002053</afid><affilname>Stony Brook University Medical Center</affilname><name-variant>University Medical Center</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028134</affiliation-url><afid>60028134</afid><affilname>New York State Department of Health</affilname><name-variant>New York State Dept. Hlth</name-variant><affiliation-city>Albany</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002053</affiliation-url><afid>60002053</afid><affilname>Stony Brook University Medical Center</affilname><name-variant>University Medical Center</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002053</affiliation-url><afid>60002053</afid><affilname>Stony Brook University Medical Center</affilname><name-variant>University Medical Center</name-variant><affiliation-city>Stony Brook</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24480209600</author-url><authid>24480209600</authid><authname>Telem D.</authname><surname>Telem</surname><given-name>Dana A.</given-name><initials>D.A.</initials><afid>60002053</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005288103</author-url><authid>7005288103</authid><authname>Talamini M.</authname><surname>Talamini</surname><given-name>Mark</given-name><initials>M.</initials><afid>60002053</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507072449</author-url><authid>6507072449</authid><authname>Gesten F.</authname><surname>Gesten</surname><given-name>Foster</given-name><initials>F.</initials><afid>60028134</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36088466500</author-url><authid>36088466500</authid><authname>Patterson W.</authname><surname>Patterson</surname><given-name>Wendy</given-name><initials>W.</initials><afid>60028134</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56584290800</author-url><authid>56584290800</authid><authname>Peoples B.</authname><surname>Peoples</surname><given-name>Brittany</given-name><initials>B.</initials><afid>60028134</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:15841425200</author-url><authid>15841425200</authid><authname>Gracia G.</authname><surname>Gracia</surname><given-name>Gerald</given-name><initials>G.</initials><afid>60002053</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56621486500</author-url><authid>56621486500</authid><authname>Yang J.</authname><surname>Yang</surname><given-name>Jie</given-name><initials>J.</initials><afid>60002053</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56271008100</author-url><authid>56271008100</authid><authname>Zhang Q.</authname><surname>Zhang</surname><given-name>Qiao</given-name><initials>Q.</initials><afid>60002053</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56490200800</author-url><authid>56490200800</authid><authname>Altieri M.</authname><surname>Altieri</surname><given-name>Maria</given-name><initials>M.</initials><afid>60002053</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005275451</author-url><authid>7005275451</authid><authname>Pryor A.</authname><surname>Pryor</surname><given-name>Aurora D.</given-name><initials>A.D.</initials><afid>60002053</afid></author><authkeywords>Bariatric surgery | Hospital admission | Long term outcomes | Outcomes | Perioperative outcomes</authkeywords><intid>1785862304</intid><source-id>19196</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926385279"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926385279?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926385279&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926385279&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014480015000726"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926385279</prism:url><dc:identifier>SCOPUS_ID:84926385279</dc:identifier><eid>2-s2.0-84926385279</eid><dc:title>Temporal and spatial rearrangements of a repetitive element array on C57BL/6J mouse genome</dc:title><dc:creator>Lee K.</dc:creator><prism:publicationName>Experimental and Molecular Pathology</prism:publicationName><prism:issn>00144800</prism:issn><prism:eIssn>10960945</prism:eIssn><prism:volume>98</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>439-445</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yexmp.2015.03.037</prism:doi><pii>S0014480015000726</pii><dc:description>© 2015 Elsevier Inc. Repetitive elements (REs) make up the vast majority of the mammalian genomes. We identified species-specific genomic libraries of RE arrays. The non-random configurations of RE arrays suggest their functions. We tested whether RE arrays undergo age- and tissue/cell-specific rearrangements. An RE array of C57BL/6J mice, containing tandem repeats of a mosaic of transposable REs, was selected to examine rearrangements in different ages and tissues. There were marked changes in the array configuration in the genomes of the skin and brain in all mice of six weeks and older, whereas the heart and liver had alterations at 29. weeks. The temporal variations were confirmed by identifying putative rearrangement junctions. Temporal and spatial rearrangements of certain RE arrays may contribute to the acquired characteristics of the genome information system.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014439</affiliation-url><afid>60014439</afid><affilname>UC Davis</affilname><name-variant>University of California</name-variant><affiliation-city>Davis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55541369900</author-url><authid>55541369900</authid><authname>Lee K.</authname><surname>Lee</surname><given-name>Kang Hoon</given-name><initials>K.H.</initials><afid>60014439</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56581487900</author-url><authid>56581487900</authid><authname>Yee L.</authname><surname>Yee</surname><given-name>Lisa</given-name><initials>L.</initials><afid>60014439</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55542384000</author-url><authid>55542384000</authid><authname>Lim D.</authname><surname>Lim</surname><given-name>Debora</given-name><initials>D.</initials><afid>60014439</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35408382700</author-url><authid>35408382700</authid><authname>Greenhalgh D.</authname><surname>Greenhalgh</surname><given-name>David</given-name><initials>D.</initials><afid>60014439</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55541792200</author-url><authid>55541792200</authid><authname>Cho K.</authname><surname>Cho</surname><given-name>Kiho</given-name><initials>K.</initials><afid>60014439</afid></author><authkeywords>Acquired genome characteristics | Dynamic genome | Four-dimensional genome unit | RE array&lt;inf&gt;CHR7.32&lt;/inf&gt; | Spatial rearrangement | Temporal rearrangement</authkeywords><intid>535433806</intid><source-id>13247</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922353903"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922353903?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922353903&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922353903&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0011393X14000307"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922353903</prism:url><dc:identifier>SCOPUS_ID:84922353903</dc:identifier><eid>2-s2.0-84922353903</eid><dc:title>Clinical Pharmacology of Paracetamol in Neonates: A Review</dc:title><dc:creator>Pacifici G.</dc:creator><prism:publicationName>Current Therapeutic Research - Clinical and Experimental</prism:publicationName><prism:issn>0011393X</prism:issn><prism:eIssn>18790313</prism:eIssn><prism:volume>77</prism:volume><prism:pageRange>24-30</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.curtheres.2014.12.001</prism:doi><pii>S0011393X14000307</pii><dc:description>© 2014 The Author. Paracetamol is commonly used to control mild-to-moderate pain or to reduce opioid exposure as part of multimodal analgesia, and is the only compound recommended to treat fever in neonates.Paracetamol clearance is lower in neonates than in children and adults. After metabolic conversion, paracetamol is subsequently eliminated by the renal route. The main metabolic conversions are conjugation with glucuronic acid and with sulphate. In the urine of neonates sulphated paracetamol concentration is higher than the glucuronidated paracetamol level, suggesting that sulfation prevails over glucuronidation in neonates. A loading dose of 20 mg/kg followed by 10 mg/kg every 6 hours of intravenous paracetamol is suggested to achieve a compartment concentration of 11 mg/L in late preterm and term neonates. Aiming for the same target concentration, oral doses are similar with rectal administration of 25 to 30 mg/kg/d in preterm neonates of 30 weeks' gestation, 45 mg/kg/d in preterm infants of 34 weeks' gestation, and 60 mg/kg/d in term neonates are suggested. The above-mentioned paracetamol doses for these indications (pain, fever) are well tolerated in neonates, but do not result in a significant increase in liver enzymes, and do not affect blood pressure and have limited effects on heart rate. In contrast, the higher doses suggested in extreme preterm neonates to induce closure of the patent ductus arteriosus have not yet been sufficiently evaluated regarding efficacy or safety. Moreover, focussed pharmacovigilance to explore the potential causal association between paracetamol exposure during perinatal life and infancy and subsequent atopy is warranted.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028868</affiliation-url><afid>60028868</afid><affilname>Universita di Pisa</affilname><name-variant>University of Pisa</name-variant><affiliation-city>Pisa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031069</affiliation-url><afid>60031069</afid><affilname>University Hospital Leuven</affilname><name-variant>University Hospitals Leuven</name-variant><affiliation-city>Leuven</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006598411</author-url><authid>7006598411</authid><authname>Pacifici G.</authname><surname>Pacifici</surname><given-name>Gian Maria</given-name><initials>G.M.</initials><afid>60028868</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003304865</author-url><authid>7003304865</authid><authname>Allegaert K.</authname><surname>Allegaert</surname><given-name>Karel</given-name><initials>K.</initials><afid>60031069</afid></author><authkeywords>Dosing | Glucuronidation | Metabolism | Neonate | Paracetamol | Sulfation</authkeywords><intid>1034791178</intid><source-id>12328</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928493219"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928493219?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928493219&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928493219&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S221442691530001X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928493219</prism:url><dc:identifier>SCOPUS_ID:84928493219</dc:identifier><eid>2-s2.0-84928493219</eid><dc:title>Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients</dc:title><dc:creator>Parini R.</dc:creator><prism:publicationName>Molecular Genetics and Metabolism Reports</prism:publicationName><prism:eIssn>22144269</prism:eIssn><prism:volume>3</prism:volume><prism:pageRange>65-74</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ymgmr.2015.03.011</prism:doi><pii>S221442691530001X</pii><dc:description>Hunter disease is an X-linked lysosomal storage disorder characterized by progressive storage of glycosaminoglycans (GAGs) and multi-organ impairment. The central nervous system (CNS) is involved in at least 50% of cases. Since 2006, the enzymatic replacement therapy (ERT) is available but with no effect on the cognitive impairment, as the present formulation does not cross the blood-brain barrier. Here we report the outcome of 17 Hunter patients treated in a single center. Most of them (11) started ERT in 2006, 3 had started it earlier in 2004, enrolled in the phase III trial, and 3 after 2006, as soon as the diagnosis was made. The liver and spleen sizes and urinary GAGs significantly decreased and normalized throughout the treatment. Heart parameters improved, in particular the left ventricular mass index/m&lt;sup&gt;2&lt;/sup&gt; decreased significantly. Amelioration of hearing was seen in many patients. Joint range of motion improved in all patients. However, no improvement on respiratory function, eye, skeletal and CNS disease was found. The developmental quotient of patients with a CNS involvement showed a fast decline. These patients were no more testable after 6 years of age and, albeit the benefits drawn from ERT, their quality of life worsened throughout the years. The whole group of patients showed a consistent residual disease burden mainly represented by persistent skeletal disease and frequent need of surgery. This study suggests that early diagnosis and treatment and other different therapies which are able to cross the blood-brain barrier, might in the future improve the MPS II outcome.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015708</affiliation-url><afid>60015708</afid><affilname>Ospedale Niguarda, Milan</affilname><name-variant>Niguarda Ca' Granda Hospital</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012306</affiliation-url><afid>60012306</afid><affilname>Universita degli Studi di Milano - Bicocca</affilname><name-variant>Università di Milano-Bicocca</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014378</affiliation-url><afid>60014378</afid><affilname>Azienda Ospedaliera San Gerardo Monza</affilname><name-variant>Ospedale San Gerardo</name-variant><affiliation-city>Monza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012306</affiliation-url><afid>60012306</afid><affilname>Universita degli Studi di Milano - Bicocca</affilname><name-variant>Università di Milano-Bicocca</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115188025</affiliation-url><afid>115188025</afid><affilname>Azienda Ospedaliera San Carlo</affilname><name-variant>Azienda Ospedaliera San Carlo</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Istituti Clinici Humanitas</affilname><name-variant>Dept of Neuroradiology</name-variant><affiliation-city>Rozzano, Milano</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115188301</affiliation-url><afid>115188301</afid><affilname>Ospedale G. Tatarella Cerignola</affilname><name-variant>Ospedale G. Tatarella Cerignola</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">26</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701709593</author-url><authid>6701709593</authid><authname>Parini R.</authname><surname>Parini</surname><given-name>Rossella</given-name><initials>R.</initials><afid>60014378</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24559172300</author-url><authid>24559172300</authid><authname>Rigoldi M.</authname><surname>Rigoldi</surname><given-name>Miriam</given-name><initials>M.</initials><afid>60014378</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56605974100</author-url><authid>56605974100</authid><authname>Tedesco L.</authname><surname>Tedesco</surname><given-name>Lucia</given-name><initials>L.</initials><afid>60014378</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603682553</author-url><authid>6603682553</authid><authname>Boffi L.</authname><surname>Boffi</surname><given-name>Lucia</given-name><initials>L.</initials><afid>60014378</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56605944000</author-url><authid>56605944000</authid><authname>Brambilla A.</authname><surname>Brambilla</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60014378</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56606306700</author-url><authid>56606306700</authid><authname>Bertoletti S.</authname><surname>Bertoletti</surname><given-name>Sara</given-name><initials>S.</initials><afid>60014378</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:23484374600</author-url><authid>23484374600</authid><authname>Boncimino A.</authname><surname>Boncimino</surname><given-name>Agata</given-name><initials>A.</initials><afid>60014378</afid><afid>115188025</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:23484374600</author-url><authid>23484374600</authid><authname>Boncimino A.</authname><surname>Boncimino</surname><given-name>Agata</given-name><initials>A.</initials><afid>60014378</afid><afid>115188025</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55334435000</author-url><authid>55334435000</authid><authname>Del Longo A.</authname><surname>Del Longo</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60015708</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7801586278</author-url><authid>7801586278</authid><authname>De Lorenzo P.</authname><surname>De Lorenzo</surname><given-name>Paola</given-name><initials>P.</initials><afid>60012306</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701383786</author-url><authid>6701383786</authid><authname>Gaini R.</authname><surname>Gaini</surname><given-name>Renato</given-name><initials>R.</initials><afid>60014378</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6603238923</author-url><authid>6603238923</authid><authname>Gallone D.</authname><surname>Gallone</surname><given-name>Denise</given-name><initials>D.</initials><afid>60014378</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6603951287</author-url><authid>6603951287</authid><authname>Gasperini S.</authname><surname>Gasperini</surname><given-name>Serena</given-name><initials>S.</initials><afid>60014378</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6602588630</author-url><authid>6602588630</authid><authname>Giussani C.</authname><surname>Giussani</surname><given-name>Carlo</given-name><initials>C.</initials><afid>60014378</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7101660446</author-url><authid>7101660446</authid><authname>Grimaldi M.</authname><surname>Grimaldi</surname><given-name>Marco</given-name><initials>M.</initials><afid>60014378</afid><afid/></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7101660446</author-url><authid>7101660446</authid><authname>Grimaldi M.</authname><surname>Grimaldi</surname><given-name>Marco</given-name><initials>M.</initials><afid>60014378</afid><afid/></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6508009624</author-url><authid>6508009624</authid><authname>Grioni D.</authname><surname>Grioni</surname><given-name>Daniele</given-name><initials>D.</initials><afid>60014378</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:36824844700</author-url><authid>36824844700</authid><authname>Meregalli P.</authname><surname>Meregalli</surname><given-name>Pamela</given-name><initials>P.</initials><afid>60014378</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:14037617900</author-url><authid>14037617900</authid><authname>Messinesi G.</authname><surname>Messinesi</surname><given-name>Grazia</given-name><initials>G.</initials><afid>60012306</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:6507214806</author-url><authid>6507214806</authid><authname>Nichelli F.</authname><surname>Nichelli</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60014378</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:25723739200</author-url><authid>25723739200</authid><authname>Romagnoli M.</authname><surname>Romagnoli</surname><given-name>Marco</given-name><initials>M.</initials><afid>60014378</afid></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:36886680900</author-url><authid>36886680900</authid><authname>Russo P.</authname><surname>Russo</surname><given-name>Pierluigi</given-name><initials>P.</initials><afid>60014378</afid><afid>115188301</afid></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:36886680900</author-url><authid>36886680900</authid><authname>Russo P.</authname><surname>Russo</surname><given-name>Pierluigi</given-name><initials>P.</initials><afid>60014378</afid><afid>115188301</afid></author><author seq="21"><author-url>http://api.elsevier.com/content/author/author_id:7004303268</author-url><authid>7004303268</authid><authname>Sganzerla E.</authname><surname>Sganzerla</surname><given-name>Erik</given-name><initials>E.</initials><afid>60014378</afid></author><author seq="22"><author-url>http://api.elsevier.com/content/author/author_id:56605996600</author-url><authid>56605996600</authid><authname>Valsecchi G.</authname><surname>Valsecchi</surname><given-name>Grazia</given-name><initials>G.</initials><afid>60012306</afid></author><author seq="23"><author-url>http://api.elsevier.com/content/author/author_id:17633380800</author-url><authid>17633380800</authid><authname>Biondi A.</authname><surname>Biondi</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60014378</afid></author><authkeywords>Enzymatic replacement therapy | ERT | Hunter disease | Hunter syndrome | Idursulfase | MPS II | Mucopolysaccharidosis type II</authkeywords><intid>1535792754</intid><source-id>21100326555</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924627674"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924627674?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924627674&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924627674&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0161589015000711"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924627674</prism:url><dc:identifier>SCOPUS_ID:84924627674</dc:identifier><eid>2-s2.0-84924627674</eid><dc:title>Molecular characterization of the liver-expressed antimicrobial peptide 2 (LEAP-2) in a teleost fish, Plecoglossus altivelis: Antimicrobial activity and molecular mechanism</dc:title><dc:creator>Li H.</dc:creator><prism:publicationName>Molecular Immunology</prism:publicationName><prism:issn>01615890</prism:issn><prism:eIssn>18729142</prism:eIssn><prism:volume>65</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>406-415</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.molimm.2015.02.022</prism:doi><pii>S0161589015000711</pii><dc:description>© 2015 Elsevier Ltd. Liver-expressed antimicrobial peptide 2 (LEAP-2) is widespread in fish and plays an important role in the host's innate immune system. In this study, full-length cDNA for LEAP-2 (PaLEAP-2) gene was cloned and sequenced from ayu, Plecoglossus altivelis. PaLEAP-2 mRNA was detected in a wide range of tissues, with the highest level of transcripts found in the liver. Upon induction by Vibrio anguillarum, its expression significantly increased in the liver, kidney, spleen, gill, and heart, but decreased in the intestine. The PaLEAP-2 mature peptide was chemically synthesized; it exhibited selective antimicrobial activity against various bacteria in vitro. PaLEAP-2 at high concentration reduced the bacterial load and improved the survival rate of V. anguillarum-infected ayu. Moreover, it inhibited the expression of mRNAs for TNF-α and IL-1β in V. anguillarum-infected ayu, both at high and low concentrations. PaLEAP-2 induced hydrolysis of the pET-22b plasmid DNA and bacterium genomic DNA. These results suggest that PaLEAP-2 plays a role in ayu immune responses against bacterial infection.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031419</affiliation-url><afid>60031419</afid><affilname>Ningbo University</affilname><name-variant>Ningbo University</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031419</affiliation-url><afid>60031419</afid><affilname>Ningbo University</affilname><name-variant>Ningbo University</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><pubmed-id>25749706</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56127232100</author-url><authid>56127232100</authid><authname>Li H.</authname><surname>Li</surname><given-name>He Xiang</given-name><initials>H.X.</initials><afid>60031419</afid><afid>60031419</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56127232100</author-url><authid>56127232100</authid><authname>Li H.</authname><surname>Li</surname><given-name>He Xiang</given-name><initials>H.X.</initials><afid>60031419</afid><afid>60031419</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55613238673</author-url><authid>55613238673</authid><authname>Lu X.</authname><surname>Lu</surname><given-name>Xin Jiang</given-name><initials>X.J.</initials><afid>60031419</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56255826600</author-url><authid>56255826600</authid><authname>Li C.</authname><surname>Li</surname><given-name>Chang Hong</given-name><initials>C.H.</initials><afid>60031419</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55924870000</author-url><authid>55924870000</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jiong</given-name><initials>J.</initials><afid>60031419</afid><afid>60031419</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55924870000</author-url><authid>55924870000</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jiong</given-name><initials>J.</initials><afid>60031419</afid><afid>60031419</afid></author><authkeywords>Antimicrobial activity | Bacterial load | Gene expression | Liver-expressed antimicrobial peptide 2 | Survival rate</authkeywords><intid>1535167445</intid><source-id>14156</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927921227"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927921227?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927921227&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927921227&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1570023215002068"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927921227</prism:url><dc:identifier>SCOPUS_ID:84927921227</dc:identifier><eid>2-s2.0-84927921227</eid><dc:title>Pharmacokinetics and tissue distribution study of Isovitexin in rats by HPLC-MS/MS</dc:title><dc:creator>Li Y.</dc:creator><prism:publicationName>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</prism:publicationName><prism:issn>15700232</prism:issn><prism:eIssn>1873376X</prism:eIssn><prism:volume>991</prism:volume><prism:pageRange>13-20</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jchromb.2015.04.003</prism:doi><pii>S1570023215002068</pii><dc:description>© 2015 Elsevier B.V. A sensitive and credible high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was established and validated for the determination of isovitexin in rat plasma and various tissues (including heart, liver, lung, kidney, stomach, intestine, muscle, brain and cerebellum). The samples were prepared with methanol by liquid-liquid extraction, and puerarin was used as the internal standard. The chromatographic separation was carried out on an Agilent Poroshell 120 EC-C&lt;inf&gt;18&lt;/inf&gt; column (4.6mm×50mm, 2.7μm) with a mobile phase consisting of acetonitrile and 0.1% formic acid (21:79, v/v). The MS analysis was performed by multiple reaction monitoring (MRM) with electronic spray ionization source (ESI&lt;sup&gt;-&lt;/sup&gt;) for quantitative response of isovitexin (431.0→311.0) and puerarin (415.1→295.0). The linearity of isovitexin in all the biosamples was good, with correlation coefficients greater than 0.9912 within the corresponding concentration range. The intra- and inter-day precisions in plasma and various tissues were less than 11.80%, and the accuracy (RE %) ranged from -4.89% to 4.78%. The extraction recoveries were in the range of 72.70%-90.81%. The present method was successfully applied to pharmacokinetics and tissue distribution of isovitexin in rats after tail vein injection with 2.0mg/kg of the compound. The pharmacokinetic parameters were demonstrated as followed: the half-life (t&lt;inf&gt;1/2&lt;/inf&gt;) was 1.05±0.325h, the apparent volume of mean residual time (MRT) was 1.229±0.429h, and the area under the curve (AUC) was 11.39±5.05μg/mL/h. The results of tissue distribution showed that the main tissue depots for isovitexin in rats were kidney, intestine and liver. The results provided a meaningful insight for the further pharmacological investigation of isovitexin.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029368</affiliation-url><afid>60029368</afid><affilname>Tianjin University of Commerce</affilname><name-variant>Tianjin University of Commerce</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106376769</affiliation-url><afid>106376769</afid><affilname>Tianjin Key Laboratory of Food Biotechnology</affilname><name-variant>Tianjin Key Laboratory of Food Biotechnology</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032389</affiliation-url><afid>60032389</afid><affilname>Hebei University of Technology</affilname><name-variant>Hebei University of Technology</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56501146900</author-url><authid>56501146900</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yaxin</given-name><initials>Y.</initials><afid>60029368</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54584602700</author-url><authid>54584602700</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yanqing</given-name><initials>Y.</initials><afid>60029368</afid><afid>106376769</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54584602700</author-url><authid>54584602700</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yanqing</given-name><initials>Y.</initials><afid>60029368</afid><afid>106376769</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56595892300</author-url><authid>56595892300</authid><authname>Yang T.</authname><surname>Yang</surname><given-name>Tan</given-name><initials>T.</initials><afid>60032389</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56595782000</author-url><authid>56595782000</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hui</given-name><initials>H.</initials><afid>60029368</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56595843800</author-url><authid>56595843800</authid><authname>Guo J.</authname><surname>Guo</surname><given-name>Jiang</given-name><initials>J.</initials><afid>60029368</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56595910500</author-url><authid>56595910500</authid><authname>Zhao Q.</authname><surname>Zhao</surname><given-name>Qiqing</given-name><initials>Q.</initials><afid>60029368</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:34977966200</author-url><authid>34977966200</authid><authname>Xie J.</authname><surname>Xie</surname><given-name>Junbo</given-name><initials>J.</initials><afid>60029368</afid><afid>106376769</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:34977966200</author-url><authid>34977966200</authid><authname>Xie J.</authname><surname>Xie</surname><given-name>Junbo</given-name><initials>J.</initials><afid>60029368</afid><afid>106376769</afid></author><authkeywords>HPLC-MS/MS | Isovitexin | Pharmacokinetics | Tissue distribution</authkeywords><intid>2035696658</intid><source-id>24172</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927169005"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927169005?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927169005&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927169005&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002191"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927169005</prism:url><dc:identifier>SCOPUS_ID:84927169005</dc:identifier><eid>2-s2.0-84927169005</eid><dc:title>Secondhand smoke exposure is associated with increased carotid artery intima-media thickness: The Bogalusa Heart Study</dc:title><dc:creator>Chen W.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>374-379</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.002</prism:doi><pii>S0021915015002191</pii><dc:description>© 2015 Elsevier Ireland Ltd. Background: Secondhand smoke (SHS) exposure increases cardiovascular disease risk. The objective of this study was to examine the association of SHS exposure in childhood and adulthood with adult arterial thickness. Methods: The study cohort consisted of 415 nonsmoking adults (301 whites and 114 blacks; ages 26.2-48.0 years) enrolled in 2004-2010. The arterial wall thickness was measured as common, bulb and internal carotid artery intima-media thickness (IMT). SHS exposure data in childhood and adulthood were obtained by a questionnaire survey. Results: Increased adult composite carotid IMT was significantly associated with SHS exposure (regression coefficient, β=53.1μm, p&lt;0.001) after adjusting for race, age, gender, education, income, body mass index, systolic blood pressure, LDL cholesterol and triglycerides/HDL cholesterol ratio, with blacks (β=81.2μm, p=0.005) and whites (β=38.9μm, p=0.017) showing the same direction of the association. Furthermore, the SHS exposure in childhood showed a relatively stronger association with increased carotid IMT than the exposure in adulthood based on standardized βs (0.180 vs 0.106); the same trend in the difference between childhood and adulthood exposure was noted for duration of SHS exposure (0.186 vs 0.145). The covariates-adjusted composite carotid IMT showed a significant increasing trend by the order of exposure status of none, adulthood only, childhood only and both (p for trend &lt; 0.001). Conclusions: If the relationship is causal, the associations observed in this study suggest that more awareness should be raised on the dangers of SHS exposure during childhood so that its effect may be mitigated and controlled early in the cardiovascular disease process.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017672</affiliation-url><afid>60017672</afid><affilname>Tulane University</affilname><name-variant>Tulane University</name-variant><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032275</affiliation-url><afid>60032275</afid><affilname>Minzu University of China</affilname><name-variant>Central University for Nationalities</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008706</affiliation-url><afid>60008706</afid><affilname>Peking Union Medical College</affilname><name-variant>Peking Union Medical College Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017672</affiliation-url><afid>60017672</afid><affilname>Tulane University</affilname><name-variant>Tulane University</name-variant><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56124358100</author-url><authid>56124358100</authid><authname>Chen W.</authname><surname>Chen</surname><given-name>Wei</given-name><initials>W.</initials><afid>60017672</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56123577500</author-url><authid>56123577500</authid><authname>Yun M.</authname><surname>Yun</surname><given-name>Miaoying</given-name><initials>M.</initials><afid>60017672</afid><afid>60032275</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56123577500</author-url><authid>56123577500</authid><authname>Yun M.</authname><surname>Yun</surname><given-name>Miaoying</given-name><initials>M.</initials><afid>60017672</afid><afid>60032275</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36598208800</author-url><authid>36598208800</authid><authname>Fernandez C.</authname><surname>Fernandez</surname><given-name>Camilo</given-name><initials>C.</initials><afid>60017672</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7409244756</author-url><authid>7409244756</authid><authname>Li S.</authname><surname>Li</surname><given-name>Shengxu</given-name><initials>S.</initials><afid>60017672</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56390411300</author-url><authid>56390411300</authid><authname>Sun D.</authname><surname>Sun</surname><given-name>Dianjianyi</given-name><initials>D.</initials><afid>60017672</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56390787500</author-url><authid>56390787500</authid><authname>Lai C.</authname><surname>Lai</surname><given-name>Chin Chih</given-name><initials>C.C.</initials><afid>60017672</afid><afid>60008706</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56390787500</author-url><authid>56390787500</authid><authname>Lai C.</authname><surname>Lai</surname><given-name>Chin Chih</given-name><initials>C.C.</initials><afid>60017672</afid><afid>60008706</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56587381400</author-url><authid>56587381400</authid><authname>Hua Y.</authname><surname>Hua</surname><given-name>Yingxiao</given-name><initials>Y.</initials><afid>60017672</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55561952400</author-url><authid>55561952400</authid><authname>Wang F.</authname><surname>Wang</surname><given-name>Fu</given-name><initials>F.</initials><afid>60017672</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35212776400</author-url><authid>35212776400</authid><authname>Zhang T.</authname><surname>Zhang</surname><given-name>Tao</given-name><initials>T.</initials><afid>60017672</afid><afid>60031031</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35212776400</author-url><authid>35212776400</authid><authname>Zhang T.</authname><surname>Zhang</surname><given-name>Tao</given-name><initials>T.</initials><afid>60017672</afid><afid>60031031</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36049303700</author-url><authid>36049303700</authid><authname>Srinivasan S.</authname><surname>Srinivasan</surname><given-name>Sathanur R.</given-name><initials>S.R.</initials><afid>60017672</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7405668189</author-url><authid>7405668189</authid><authname>Johnson C.</authname><surname>Johnson</surname><given-name>Carolyn C.</given-name><initials>C.C.</initials><afid>60017672</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56346486500</author-url><authid>56346486500</authid><authname>Berenson G.</authname><surname>Berenson</surname><given-name>Gerald S.</given-name><initials>G.S.</initials><afid>60017672</afid></author><authkeywords>Arterial wall thickness | Childhood | Secondhand smoke</authkeywords><intid>1785571389</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207347"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207347?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207347&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207347&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207347</prism:url><dc:identifier>SCOPUS_ID:84930207347</dc:identifier><eid>2-s2.0-84930207347</eid><dc:title>Adult patients with Fabry disease: What does the cardiologist need to know?</dc:title><dc:creator>Hagège A.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>916-918</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2015-307472</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030857</affiliation-url><afid>60030857</afid><affilname>Hopital Europeen Georges-Pompidou</affilname><name-variant>Hôpital Européen Georges Pompidou</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028950</affiliation-url><afid>60028950</afid><affilname>Universite Paris Descartes</affilname><name-variant>Université Paris Descartes</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030857</affiliation-url><afid>60030857</afid><affilname>Hopital Europeen Georges-Pompidou</affilname><name-variant>Hôpital Européen Georges Pompidou</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029937</affiliation-url><afid>60029937</afid><affilname>Universite de Versailles Saint-Quentin-en-Yvelines</affilname><name-variant>Université de Versailles</name-variant><affiliation-city>Versailles</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55793295200</author-url><authid>55793295200</authid><authname>Hagège A.</authname><surname>Hagège</surname><given-name>Albert A.</given-name><initials>A.A.</initials><afid>60030857</afid><afid>60028950</afid><afid>60030857</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55793295200</author-url><authid>55793295200</authid><authname>Hagège A.</authname><surname>Hagège</surname><given-name>Albert A.</given-name><initials>A.A.</initials><afid>60030857</afid><afid>60028950</afid><afid>60030857</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55793295200</author-url><authid>55793295200</authid><authname>Hagège A.</authname><surname>Hagège</surname><given-name>Albert A.</given-name><initials>A.A.</initials><afid>60030857</afid><afid>60028950</afid><afid>60030857</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006706457</author-url><authid>7006706457</authid><authname>Germain D.</authname><surname>Germain</surname><given-name>Dominique P.</given-name><initials>D.P.</initials><afid>60029937</afid></author><intid>1786087519</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928346156"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928346156?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928346156&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928346156&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928346156</prism:url><dc:identifier>SCOPUS_ID:84928346156</dc:identifier><eid>2-s2.0-84928346156</eid><dc:title>Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation</dc:title><dc:creator>Madhavan M.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0598-4</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The number of patients who undergo percutaneous coronary intervention (PCI) and additionally require chronic anticoagulation for a variety of indications is not insignificant. The choice of antithrombotic therapy after PCI in patients with chronic indications for anticoagulation therapy remains a challenge for interventional cardiologists, as the risk of bleeding must be adequately weighed against the benefit of preventing future ischemic events. While these clinical scenarios are encountered in approximately 10 % of patients undergoing PCI, current practice guidelines do not sufficiently guide physicians as to how to best treat these PCI patients requiring chronic anticoagulation. Notwithstanding the clinical difficulties of treating such patients, there are several recent studies and analyses that have assessed optimal antithrombotic strategies in the PCI population, and there are several others that are currently underway. This review evaluates the currently available data and clinical scenarios commonly encountered by treating physicians.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018043</affiliation-url><afid>60018043</afid><affilname>New York Presbyterian Hospital</affilname><name-variant>New York Presbyterian Hospital</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015884</affiliation-url><afid>60015884</afid><affilname>Cardiovascular Research Foundation</affilname><name-variant>Cardiovascular Research Foundation</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55841163900</author-url><authid>55841163900</authid><authname>Madhavan M.</authname><surname>Madhavan</surname><given-name>Mahesh V.</given-name><initials>M.V.</initials><afid>60018043</afid><afid>60015884</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55841163900</author-url><authid>55841163900</authid><authname>Madhavan M.</authname><surname>Madhavan</surname><given-name>Mahesh V.</given-name><initials>M.V.</initials><afid>60018043</afid><afid>60015884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603083771</author-url><authid>6603083771</authid><authname>Kirtane A.</authname><surname>Kirtane</surname><given-name>Ajay J.</given-name><initials>A.J.</initials><afid>60018043</afid><afid>60015884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603083771</author-url><authid>6603083771</authid><authname>Kirtane A.</authname><surname>Kirtane</surname><given-name>Ajay J.</given-name><initials>A.J.</initials><afid>60018043</afid><afid>60015884</afid></author><authkeywords>Anticoagulation | Antiplatelet agents | Bleeding | Ischemia | Post-PCI antithrombotic therapy</authkeywords><intid>1035762574</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929154434"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929154434?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929154434&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929154434&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929154434</prism:url><dc:identifier>SCOPUS_ID:84929154434</dc:identifier><eid>2-s2.0-84929154434</eid><dc:title>Thymic derived iPs cells can be differentiated into cardiomyocytes</dc:title><dc:creator>Li J.</dc:creator><prism:publicationName>Frontiers in Bioscience - Landmark</prism:publicationName><prism:issn>10939946</prism:issn><prism:eIssn>10934715</prism:eIssn><prism:volume>20</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>964-974</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><dc:description>© 2015, Frontiers in Bioscience. All rights reserved. Ventricular septal defect (VSD) is a common congenital heart malformation. Several factors lead to the development of VSD, including familial causes, exposure to certain drugs, infectious agents, and maternal metabolic disturbances. We hypothesized that induced pluripotent stem (iPS) cells can be obtained from VSD patients to generate cardiomyocytes. Here, we show the generation and cardiomyocyte differentiation of iPS cells from the thymic epithelial cells of a patient with VSD (TECs-VSD) by overexpressing four transcription factors: OCT4, SOX2, NANOG, and LIN28 using lentiviral vectors. The self-renewal capacity and pluripotency of iPS cells was verified in vitro by expression of pluripotency markers and formation of teratoma in vivo. The results show that iPS cells can be derived from patients with VSD and they can be differentiated into cardiomyocytes. These cells can be used for understanding the pathogenesis of defect that causes VSD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009860</affiliation-url><afid>60009860</afid><affilname>Fudan University</affilname><name-variant>Fudan University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114343090</affiliation-url><afid>114343090</afid><affilname>Shanghai Key Laboratory of Birth Defects</affilname><name-variant>Shanghai Key Laboratory of Birth Defects</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60066010</affiliation-url><afid>60066010</afid><affilname>Fudan University Shanghai Medical College</affilname><name-variant>Fudan University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55305828000</author-url><authid>55305828000</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jian</given-name><initials>J.</initials><afid>60009860</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56256533800</author-url><authid>56256533800</authid><authname>Cao Y.</authname><surname>Cao</surname><given-name>Yin Yin</given-name><initials>Y.Y.</initials><afid>60009860</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56565784000</author-url><authid>56565784000</authid><authname>Ma X.</authname><surname>Ma</surname><given-name>Xiao Jing</given-name><initials>X.J.</initials><afid>60009860</afid><afid>114343090</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56565784000</author-url><authid>56565784000</authid><authname>Ma X.</authname><surname>Ma</surname><given-name>Xiao Jing</given-name><initials>X.J.</initials><afid>60009860</afid><afid>114343090</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640100900</author-url><authid>56640100900</authid><authname>Liu F.</authname><surname>Liu</surname><given-name>Fang</given-name><initials>F.</initials><afid>60009860</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640032600</author-url><authid>56640032600</authid><authname>Li S.</authname><surname>Li</surname><given-name>Shuo Lin</given-name><initials>S.L.</initials><afid>60009860</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56116313400</author-url><authid>56116313400</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jing</given-name><initials>J.</initials><afid>60009860</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56640129500</author-url><authid>56640129500</authid><authname>Gao Y.</authname><surname>Gao</surname><given-name>Yan</given-name><initials>Y.</initials><afid>60009860</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56641170700</author-url><authid>56641170700</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Hui Jun</given-name><initials>H.J.</initials><afid>60009860</afid><afid>114343090</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56641170700</author-url><authid>56641170700</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Hui Jun</given-name><initials>H.J.</initials><afid>60009860</afid><afid>114343090</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56640252000</author-url><authid>56640252000</authid><authname>Yuan Y.</authname><surname>Yuan</surname><given-name>Yuan</given-name><initials>Y.</initials><afid>60009860</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:8444245900</author-url><authid>8444245900</authid><authname>Ma D.</authname><surname>Ma</surname><given-name>Duan</given-name><initials>D.</initials><afid>114343090</afid><afid>60066010</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:8444245900</author-url><authid>8444245900</authid><authname>Ma D.</authname><surname>Ma</surname><given-name>Duan</given-name><initials>D.</initials><afid>114343090</afid><afid>60066010</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:13309093700</author-url><authid>13309093700</authid><authname>Huang G.</authname><surname>Huang</surname><given-name>Guo Ying</given-name><initials>G.Y.</initials><afid>60009860</afid><afid>114343090</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:13309093700</author-url><authid>13309093700</authid><authname>Huang G.</authname><surname>Huang</surname><given-name>Guo Ying</given-name><initials>G.Y.</initials><afid>60009860</afid><afid>114343090</afid></author><authkeywords>Cardiomyocyte | Differentiation | Malformations | Pluripotent stem cells | Ventricular septal defect</authkeywords><intid>1535915974</intid><source-id>27974</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930194664"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930194664?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930194664&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930194664&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930194664</prism:url><dc:identifier>SCOPUS_ID:84930194664</dc:identifier><eid>2-s2.0-84930194664</eid><dc:title>Aortic stenosis begets aortic stenosis: Between a rock and a hard place?</dc:title><dc:creator>Dweck M.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>919-920</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2015-307519</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027272</affiliation-url><afid>60027272</afid><affilname>University of Edinburgh</affilname><name-variant>University of Edinburgh</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110426038</affiliation-url><afid>110426038</afid><affilname>Edinburgh Heart Centre</affilname><name-variant>Edinburgh Heart Centre</name-variant><affiliation-city>Edinburgh</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12783691400</author-url><authid>12783691400</authid><authname>Dweck M.</authname><surname>Dweck</surname><given-name>M. R.</given-name><initials>M.R.</initials><afid>60027272</afid><afid>110426038</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:12783691400</author-url><authid>12783691400</authid><authname>Dweck M.</authname><surname>Dweck</surname><given-name>M. R.</given-name><initials>M.R.</initials><afid>60027272</afid><afid>110426038</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56016639100</author-url><authid>56016639100</authid><authname>Pawade T.</authname><surname>Pawade</surname><given-name>T. A.</given-name><initials>T.A.</initials><afid>60027272</afid><afid>110426038</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56016639100</author-url><authid>56016639100</authid><authname>Pawade T.</authname><surname>Pawade</surname><given-name>T. A.</given-name><initials>T.A.</initials><afid>60027272</afid><afid>110426038</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006580760</author-url><authid>7006580760</authid><authname>Newby D.</authname><surname>Newby</surname><given-name>D. E.</given-name><initials>D.E.</initials><afid>60027272</afid><afid>110426038</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006580760</author-url><authid>7006580760</authid><authname>Newby D.</authname><surname>Newby</surname><given-name>D. E.</given-name><initials>D.E.</initials><afid>60027272</afid><afid>110426038</afid></author><intid>1786088352</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930204541"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930204541?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930204541&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930204541&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930204541</prism:url><dc:identifier>SCOPUS_ID:84930204541</dc:identifier><eid>2-s2.0-84930204541</eid><dc:title>Complications of cardiac catheterisation in children</dc:title><dc:creator>Krasemann T.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>915</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2015-307453</prism:doi><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23050631400</author-url><authid>23050631400</authid><authname>Krasemann T.</authname><surname>Krasemann</surname><given-name>Thomas</given-name><initials>T.</initials></author><intid>2036081535</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930227009"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930227009?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930227009&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930227009&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930227009</prism:url><dc:identifier>SCOPUS_ID:84930227009</dc:identifier><eid>2-s2.0-84930227009</eid><dc:title>Public knowledge and confidence in the use of public access defibrillation</dc:title><dc:creator>Brooks B.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>967-971</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2015-307624</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Introduction: Growing numbers of public access defibrillators aim to improve the effectiveness of bystander cardiopulmonary resuscitation prior to ambulance arrival. In the UK, however, public access defibrillators are only deployed successfully in 1.7% of out-of-hospital cardiac arrests. We aimed to understand whether this was due to a lack of devices, lack of awareness of their location or a reflection of lack of public knowledge and confidence to use a defibrillator. Methods: Face-to-face semistructured open quantitative questionnaire delivered in a busy urban shopping centre, to identify public knowledge relating to public access defibrillation. Results: 1004 members of the public aged 9-90 years completed the survey. 61.1% had been first aid trained to a basic life support level. 69.3% claimed to know what an automatic external defibrillator was and 26.1% reported knowing how to use one. Only 5.1% knew where or how to find their nearest public access defibrillator. Only 3.3% of people would attempt to locate a defibrillator in a cardiac arrest situation, and even fewer (2.1%) would actually retrieve and use the device. Conclusions: These findings suggest that a lack of public knowledge, confidence in using a defibrillator and the inability to locate a nearby device may be more important than a lack of defibrillators themselves. Underused public access defibrillation is a missed opportunity to save lives, and improving this link in the chain of survival may require these issues to be addressed ahead of investing more funds in actual defibrillator installation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025225</affiliation-url><afid>60025225</afid><affilname>University of Southampton</affilname><name-variant>University of Southampton</name-variant><affiliation-city>Southampton</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112981416</affiliation-url><afid>112981416</afid><affilname>South Central Ambulance Service</affilname><name-variant>South Central Ambulance Service</name-variant><affiliation-city>Bracknell</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000703</affiliation-url><afid>60000703</afid><affilname>Southampton University Hospitals NHS Trust</affilname><name-variant>Southampton University Hospitals NHS Trust</name-variant><affiliation-city>Southampton</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662741500</author-url><authid>56662741500</authid><authname>Brooks B.</authname><surname>Brooks</surname><given-name>Ben</given-name><initials>B.</initials><afid>60025225</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662629000</author-url><authid>56662629000</authid><authname>Chan S.</authname><surname>Chan</surname><given-name>Stephanie</given-name><initials>S.</initials><afid>60025225</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662864600</author-url><authid>56662864600</authid><authname>Lander P.</authname><surname>Lander</surname><given-name>Peter</given-name><initials>P.</initials><afid>60025225</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662802200</author-url><authid>56662802200</authid><authname>Adamson R.</authname><surname>Adamson</surname><given-name>Robbie</given-name><initials>R.</initials><afid>60025225</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663104200</author-url><authid>56663104200</authid><authname>Hodgetts G.</authname><surname>Hodgetts</surname><given-name>Gillian A.</given-name><initials>G.A.</initials><afid>112981416</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56247724000</author-url><authid>56247724000</authid><authname>Deakin C.</authname><surname>Deakin</surname><given-name>Charles D.</given-name><initials>C.D.</initials><afid>112981416</afid><afid>60000703</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56247724000</author-url><authid>56247724000</authid><authname>Deakin C.</authname><surname>Deakin</surname><given-name>Charles D.</given-name><initials>C.D.</initials><afid>112981416</afid><afid>60000703</afid></author><intid>36086740</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929656730"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929656730?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929656730&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929656730&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S004016251400002X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929656730</prism:url><dc:identifier>SCOPUS_ID:84929656730</dc:identifier><eid>2-s2.0-84929656730</eid><dc:title>Can a CEO's YouTube apology following a service failure win customers' hearts?</dc:title><dc:creator>Manika D.</dc:creator><prism:publicationName>Technological Forecasting and Social Change</prism:publicationName><prism:issn>00401625</prism:issn><prism:volume>95</prism:volume><prism:pageRange>87-95</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.techfore.2013.12.021</prism:doi><pii>S004016251400002X</pii><dc:description>© 2014 Elsevier Inc. This study examines how CEO YouTube apologies affect satisfaction with the company after an apology. A self-administered online Internet survey was developed and pre-tested in order to examine a proposed theoretical model, which identifies consumer and message related factors that might affect satisfaction with the company after an apology. A total of 278 USA consumer panel members completed the survey, and a structural equation modelling approach was used to analyse associations among constructs. Results suggest that incident familiarity before exposure to the YouTube apology, involvement with the apology, perceived persuasiveness of the apology, and attitude towards the CEO after the apology are all significantly associated with satisfaction with the company after the apology. This study provides timely and essential insights regarding the effects of a CEO YouTube service failure apology on customer satisfaction, and highlights many interesting future research directions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022109</affiliation-url><afid>60022109</afid><affilname>Queen Mary, University of London</affilname><name-variant>Queen Mary University of London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006222</affiliation-url><afid>60006222</afid><affilname>Newcastle University, United Kingdom</affilname><name-variant>University of Newcastle upon Tyne</name-variant><affiliation-city>Newcastle</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004407</affiliation-url><afid>60004407</afid><affilname>Cranfield University</affilname><name-variant>Cranfield University</name-variant><affiliation-city>Cranfield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55115748100</author-url><authid>55115748100</authid><authname>Manika D.</authname><surname>Manika</surname><given-name>Danae</given-name><initials>D.</initials><afid>60022109</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8848778400</author-url><authid>8848778400</authid><authname>Papagiannidis S.</authname><surname>Papagiannidis</surname><given-name>Savvas</given-name><initials>S.</initials><afid>60006222</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506844873</author-url><authid>6506844873</authid><authname>Bourlakis M.</authname><surname>Bourlakis</surname><given-name>Michael</given-name><initials>M.</initials><afid>60004407</afid></author><authkeywords>Apology | CEO | Satisfaction | Service failure | Social media | Video</authkeywords><intid>1035986238</intid><source-id>14704</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209737"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209737?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209737&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209737&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209737</prism:url><dc:identifier>SCOPUS_ID:84930209737</dc:identifier><eid>2-s2.0-84930209737</eid><dc:title>Incidence and predictors of cardiac catheterisation-related arterial thrombosis in children</dc:title><dc:creator>Brotschi B.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>948-953</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-306713</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Objective: Arterial thrombosis is one of the most reported complications of cardiac catheterisation (CC) in children. The aim of the study was to evaluate the incidence and predictors of arterial thrombosis in children with cardiac diseases (CDs). Methods: During 12 consecutive months, all children aged 0-19 years undergoing CC of the femoral arteries were included in this observational study. After CC, clinical evaluation of impaired limb perfusion was performed according to local guidelines. Doppler ultrasonography was performed when decreased limb perfusion was suspected. Results: 123 children (30% aged &lt;12 months, 70% aged &gt;12 months) underwent CC. Arterial thrombosis occurred in 14 of the 123 children (11.4%). Twelve cases (12/14=86%) of arterial thrombosis occurred in infants aged &lt;12 months and 2 (2/14=14%) in older children. Overall younger age (p&lt;0.01, OR (95% CI) 0.49 (0.28 to 0.86)) and low body weight (p&lt;0.004, OR (95% CI) 0.78 (0.65 to 0.92)) were significantly associated with an increased risk of arterial thrombosis. Cyanotic CD (p=0.07, OR (95% CI) 2.87 (0.90 to 9.15)) showed a trend towards increased thrombotic risk. Conclusions: Arterial thrombosis is a common complication of CC in infants. Diagnosis of CC-related arterial thrombosis remains a challenge. Well-defined clinical monitoring protocols may be valuable methods for timely detection and treatment of arterial thrombosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002695</affiliation-url><afid>60002695</afid><affilname>Kinderspital Zurich</affilname><name-variant>University Children's Hospital</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002695</affiliation-url><afid>60002695</afid><affilname>Kinderspital Zurich</affilname><name-variant>University Children's Hospital</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002695</affiliation-url><afid>60002695</afid><affilname>Kinderspital Zurich</affilname><name-variant>University Children's Hospital</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030319</affiliation-url><afid>60030319</afid><affilname>Hospital for Sick Children University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35323924900</author-url><authid>35323924900</authid><authname>Brotschi B.</authname><surname>Brotschi</surname><given-name>Barbara</given-name><initials>B.</initials><afid>60002695</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35619433500</author-url><authid>35619433500</authid><authname>Hug M.</authname><surname>Hug</surname><given-name>Maja I.</given-name><initials>M.I.</initials><afid>60002695</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:10040087300</author-url><authid>10040087300</authid><authname>Kretschmar O.</authname><surname>Kretschmar</surname><given-name>Oliver</given-name><initials>O.</initials><afid>60002695</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:22956675200</author-url><authid>22956675200</authid><authname>Rizzi M.</authname><surname>Rizzi</surname><given-name>Mattia</given-name><initials>M.</initials><afid>60002695</afid><afid>60030319</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:22956675200</author-url><authid>22956675200</authid><authname>Rizzi M.</authname><surname>Rizzi</surname><given-name>Mattia</given-name><initials>M.</initials><afid>60002695</afid><afid>60030319</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6601963369</author-url><authid>6601963369</authid><authname>Albisetti M.</authname><surname>Albisetti</surname><given-name>Manuela</given-name><initials>M.</initials><afid>60002695</afid></author><intid>36086733</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927722528"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927722528?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927722528&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927722528&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S002191501500218X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927722528</prism:url><dc:identifier>SCOPUS_ID:84927722528</dc:identifier><eid>2-s2.0-84927722528</eid><dc:title>Left ventricular size as a predictor of vascular events</dc:title><dc:creator>Raggi P.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>398-399</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.001</prism:doi><pii>S002191501500218X</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030835</affiliation-url><afid>60030835</afid><affilname>University of Alberta</affilname><name-variant>University of Alberta</name-variant><affiliation-city>Edmonton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>no</subtype><subtypeDescription>Note</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55794079300</author-url><authid>55794079300</authid><authname>Raggi P.</authname><surname>Raggi</surname><given-name>Paolo</given-name><initials>P.</initials><afid>60030835</afid></author><authkeywords>Coronary artery calcium | Coronary artery disease | Hypertrophy | Left ventricular size | Stroke</authkeywords><intid>35665691</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929092363"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929092363?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929092363&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929092363&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929092363</prism:url><dc:identifier>SCOPUS_ID:84929092363</dc:identifier><eid>2-s2.0-84929092363</eid><dc:title>A multi-center assessment of the temporal trends in myocardial perfusion imaging</dc:title><dc:creator>Duvall W.</dc:creator><prism:publicationName>Journal of Nuclear Cardiology</prism:publicationName><prism:issn>10713581</prism:issn><prism:eIssn>15326551</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>539-551</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12350-014-0051-x</prism:doi><dc:description>© 2015, American Society of Nuclear Cardiology. Background: Recent literature suggests that the frequency of abnormal SPECT myocardial perfusion imaging (MPI) has decreased over the past two decades despite an increase in the prevalence of many cardiac risk factors. This study examined the trends in the prevalence of obstructive coronary artery disease (CAD) by abnormal and ischemic MPI and invasive angiography. Methods: We analyzed all patients who underwent stress MPI or invasive angiography at two academic centers between January 1996 and December 2012, for their demographic data and study results. Results: A total of 108,654 MPI studies were performed. Over time, the percentage of patients with hypertension, hyperlipidemia, diabetes, and a history of smoking increased. There was a decline in the prevalence of abnormal MPI studies in all patients as well as in those with and without known CAD (from 47.2%, 71.8%, and 31.4% in 1996 to 33.9%, 64.8%, and 18.8% in 2012, respectively, all P &lt; .0001). Similarly, there was a decline in the prevalence of ischemic MPI studies in all patients as well as in those with and without known CAD. A total of 142,924 invasive angiograms were performed. There was a decline in the prevalence of one-vessel and multi-vessel coronary disease (from 29.1% and 53.6% in 1996 to 22.4% and 35.9% in 2012, respectively, all P &lt; .0001). Conclusions: There has been a temporal decline in the prevalence of abnormal and ischemic MPI studies as well as the frequency and extent of obstructive CAD on angiography. However, this decline was not to the same extent as previously reported, and the overall 34% abnormal MPI rate, with 19% in patients with no known CAD and 65% in patients with known CAD, remains a clinically relevant percentage of patients tested.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018395</affiliation-url><afid>60018395</afid><affilname>Hartford Hospital</affilname><name-variant>Hartford Hospital</name-variant><affiliation-city>Hartford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018395</affiliation-url><afid>60018395</afid><affilname>Hartford Hospital</affilname><name-variant>Hartford Hospital</name-variant><affiliation-city>Hartford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000764</affiliation-url><afid>60000764</afid><affilname>The Mount Sinai Medical Center</affilname><name-variant>Mount Sinai Medical Center</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602135286</author-url><authid>6602135286</authid><authname>Duvall W.</authname><surname>Duvall</surname><given-name>W. Lane</given-name><initials>W.L.</initials><afid>60018395</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:39561437100</author-url><authid>39561437100</authid><authname>Rai M.</authname><surname>Rai</surname><given-name>Mridula</given-name><initials>M.</initials><afid>60018395</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005565693</author-url><authid>7005565693</authid><authname>Ahlberg A.</authname><surname>Ahlberg</surname><given-name>Alan W.</given-name><initials>A.W.</initials><afid>60018395</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56638426200</author-url><authid>56638426200</authid><authname>O’Sullivan D.</authname><surname>O’Sullivan</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60018395</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701511818</author-url><authid>6701511818</authid><authname>Henzlova M.</authname><surname>Henzlova</surname><given-name>Milena J.</given-name><initials>M.J.</initials><afid>60000764</afid></author><authkeywords>coronary artery disease | Myocardial perfusion imaging | PET | SPECT | trends</authkeywords><intid>35901412</intid><source-id>17229</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929089922"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929089922?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929089922&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929089922&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929089922</prism:url><dc:identifier>SCOPUS_ID:84929089922</dc:identifier><eid>2-s2.0-84929089922</eid><dc:title>Heterogeneity of Mitral Leaflet Matrix Composition and Turnover Correlates with Regional Leaflet Strain</dc:title><dc:creator>Stephens E.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>141-150</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-015-0214-1</prism:doi><dc:description>© 2015, Biomedical Engineering Society. To determine how extracellular matrix and contractile valvular cells contribute to the heterogeneous motion and strain across the mitral valve (MV) during the cardiac cycle, regional MV material properties, matrix composition, matrix turnover, and cell phenotype were related to regional leaflet strain. Radiopaque markers were implanted into 14 sheep to delineate the septal (SEPT), lateral (LAT), and anterior and posterior commissural leaflets (ANT-C, POST-C). Videofluoroscopy imaging was used to calculate radial and circumferential strains. Mechanical properties were assessed using uniaxial tensile testing and micropipette aspiration. Matrix composition and cell phenotypes were immunohistochemically evaluated within each leaflet region [basal leaflet (BL), mid-leaflet (ML), and free edge]. SEPT-BL segments were stiffer and stronger than other valve tissues, while LAT segments demonstrated more extensibility and strain. Collagens I and III in SEPT were greater than in LAT, although LAT showed greater collagen turnover [matrix metalloprotease (MMP)-13, lysyl oxidase] and cell activation [smooth muscle alpha-actin (SMaA), and non-muscle myosin (NMM)]. MMP13, NMM, and SMaA were strongly correlated with each other, as well as with radial and circumferential strains in both SEPT and LAT. SMaA and MMP13 in POST-C ML was greater than ANT-C, corresponding to greater radial strains in POST-C. This work directly relates leaflet strain, material properties, and matrix turnover, and suggests a role for myofibroblasts in the heterogeneity of leaflet composition and strain. New approaches to MV repair techniques and ring design should preserve this normal coupling between leaflet composition and motion.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027565</affiliation-url><afid>60027565</afid><affilname>Columbia University Medical Center</affilname><name-variant>Columbia University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Spectrum Health</affilname><name-variant>Department of Cardiothoracic Surgery</name-variant><name-variant>Meijer Heart and Vascular Institute</name-variant><affiliation-city>Grand Rapids</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032838</affiliation-url><afid>60032838</afid><affilname>Stanford University School of Medicine</affilname><name-variant>Stanford University School of Medicine</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031633</affiliation-url><afid>60031633</afid><affilname>Palo Alto Medical Foundation</affilname><name-variant>Palo Alto Medical Clinic</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16686780800</author-url><authid>16686780800</authid><authname>Stephens E.</authname><surname>Stephens</surname><given-name>Elizabeth H.</given-name><initials>E.H.</initials><afid>60027565</afid><afid>60005286</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16686780800</author-url><authid>16686780800</authid><authname>Stephens E.</authname><surname>Stephens</surname><given-name>Elizabeth H.</given-name><initials>E.H.</initials><afid>60027565</afid><afid>60005286</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56638770200</author-url><authid>56638770200</authid><authname>Connell P.</authname><surname>Connell</surname><given-name>Patrick S.</given-name><initials>P.S.</initials><afid>60005286</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37023079400</author-url><authid>37023079400</authid><authname>Fahrenholtz M.</authname><surname>Fahrenholtz</surname><given-name>Monica M.</given-name><initials>M.M.</initials><afid>60005286</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004507309</author-url><authid>7004507309</authid><authname>Timek T.</authname><surname>Timek</surname><given-name>Tomasz A.</given-name><initials>T.A.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006570201</author-url><authid>7006570201</authid><authname>Daughters G.</authname><surname>Daughters</surname><given-name>George T.</given-name><initials>G.T.</initials><afid>60032838</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35102446500</author-url><authid>35102446500</authid><authname>Kuo J.</authname><surname>Kuo</surname><given-name>Joyce J.</given-name><initials>J.J.</initials><afid>60005286</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35103313700</author-url><authid>35103313700</authid><authname>Patton A.</authname><surname>Patton</surname><given-name>Aaron M.</given-name><initials>A.M.</initials><afid>60005286</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006382451</author-url><authid>7006382451</authid><authname>Ingels N.</authname><surname>Ingels</surname><given-name>Neil B.</given-name><initials>N.B.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006382451</author-url><authid>7006382451</authid><authname>Ingels N.</authname><surname>Ingels</surname><given-name>Neil B.</given-name><initials>N.B.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55930086800</author-url><authid>55930086800</authid><authname>Craig Miller D.</authname><surname>Craig Miller</surname><given-name>D.</given-name><initials>D.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55930086800</author-url><authid>55930086800</authid><authname>Craig Miller D.</authname><surname>Craig Miller</surname><given-name>D.</given-name><initials>D.</initials><afid>60032838</afid><afid>60031633</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56638604400</author-url><authid>56638604400</authid><authname>Jane Grande-Allen K.</authname><surname>Jane Grande-Allen</surname><given-name>K.</given-name><initials>K.</initials><afid>60005286</afid><afid>60005286</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56638604400</author-url><authid>56638604400</authid><authname>Jane Grande-Allen K.</authname><surname>Jane Grande-Allen</surname><given-name>K.</given-name><initials>K.</initials><afid>60005286</afid><afid>60005286</afid></author><authkeywords>Collagen | Extracellular matrix | Leaflet strain | Matrix metalloproteases | Mitral valve</authkeywords><intid>1535901613</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928321636"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928321636?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928321636&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928321636&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928321636</prism:url><dc:identifier>SCOPUS_ID:84928321636</dc:identifier><eid>2-s2.0-84928321636</eid><dc:title>Impact of Functional Foods on Prevention of Cardiovascular Disease and Diabetes</dc:title><dc:creator>Sikand G.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0593-9</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. A healthy dietary pattern is a cornerstone for the prevention and treatment of cardiovascular disease (CVD) and type 2 diabetes (T2DM). Compelling scientific evidence has shown many health effects of individual foods (including herbs and spices), beverages, and their constituent nutrients and bioactive components on risk of chronic disease and associated risk factors. The focus of functional foods research that is reviewed herein has been on assessing the health effects and underlying mechanisms of action of fruits and vegetables, whole grains, dairy products including fermented products, legumes, nuts, green tea, spices, olive oil, seafood, red wine, herbs, and spices. The unique health benefits of these functional foods have been the basis for recommending their inclusion in a healthy dietary pattern. A better understanding of strategies for optimally including functional foods in a healthy dietary pattern will confer greater benefits on the prevention and treatment of CVD and T2DM.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007278</affiliation-url><afid>60007278</afid><affilname>UC Irvine</affilname><name-variant>University of California, Irvine</name-variant><affiliation-city>Irvine</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001439</affiliation-url><afid>60001439</afid><affilname>Pennsylvania State University</affilname><name-variant>Pennsylvania State University</name-variant><affiliation-city>State College</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007278</affiliation-url><afid>60007278</afid><affilname>UC Irvine</affilname><name-variant>University of California, Irvine</name-variant><affiliation-city>Irvine</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602561882</author-url><authid>6602561882</authid><authname>Sikand G.</authname><surname>Sikand</surname><given-name>Geeta</given-name><initials>G.</initials><afid>60007278</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36852738600</author-url><authid>36852738600</authid><authname>Kris-Etherton P.</authname><surname>Kris-Etherton</surname><given-name>Penny</given-name><initials>P.</initials><afid>60001439</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56604063300</author-url><authid>56604063300</authid><authname>Boulos N.</authname><surname>Boulos</surname><given-name>Nancy Mariam</given-name><initials>N.M.</initials><afid>60007278</afid></author><authkeywords>Cardiovascular disease prevention | Functional foods | Type 2 diabetes prevention</authkeywords><intid>2035762504</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193862"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193862?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193862&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193862&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193862</prism:url><dc:identifier>SCOPUS_ID:84930193862</dc:identifier><eid>2-s2.0-84930193862</eid><dc:title>Chest pain, dyspnoea and hypotension in a 61-year-old woman</dc:title><dc:creator>Myszka W.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>960 and 987</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-307211</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100797676</affiliation-url><afid>100797676</afid><affilname>HCP Medical Center</affilname><name-variant>HCP Medical Centre</name-variant><affiliation-city>Poznan</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069010</affiliation-url><afid>60069010</afid><affilname>Poznan University of Medical Sciences</affilname><name-variant>University of Medical Sciences</name-variant><affiliation-city>Poznan</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506260677</author-url><authid>6506260677</authid><authname>Myszka W.</authname><surname>Myszka</surname><given-name>Waldemar</given-name><initials>W.</initials><afid>100797676</afid><afid>60069010</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506260677</author-url><authid>6506260677</authid><authname>Myszka W.</authname><surname>Myszka</surname><given-name>Waldemar</given-name><initials>W.</initials><afid>100797676</afid><afid>60069010</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662749400</author-url><authid>56662749400</authid><authname>Nowak A.</authname><surname>Nowak</surname><given-name>Agata</given-name><initials>A.</initials><afid>100797676</afid><afid>60069010</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662749400</author-url><authid>56662749400</authid><authname>Nowak A.</authname><surname>Nowak</surname><given-name>Agata</given-name><initials>A.</initials><afid>100797676</afid><afid>60069010</afid></author><intid>36085261</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929640981"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929640981?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929640981&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929640981&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929640981</prism:url><dc:identifier>SCOPUS_ID:84929640981</dc:identifier><eid>2-s2.0-84929640981</eid><dc:title>Long-term outcome after transcatheter aortic valve implantation</dc:title><dc:creator>Bouleti C.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>936-942</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2014-306694</prism:doi><dc:description>© 2015, BMJ Publishing Group. All rights reserved. Objective: To assess late outcome after transcatheter aortic valve implantation (TAVI) up to 6 years and to analyse its predictive factors with a particular emphasis on functional status. Very few data exist on the longterm results of TAVI, and these data are crucial for decision making. Methods: Between October 2006 and December 2009, 123 consecutive patients were discharged alive after TAVI in our institution. Mean age was 82±8 years, and 88% of patients were highly symptomatic in New York Heart Association (NYHA) class III-IV. Results: Follow-up was complete in 122 patients (99%). The overall 6-year survival rate was 31%±5%, the majority of deaths being non-cardiac. Predictive factors of late mortality were the presence of lower limb arteritis (p=0.009), a higher Charlson comorbidity index (p=0.03) and post-TAVI paraprosthetic aortic regurgitation ≥2/4 (p=0.01). Late outcomes according to Valve Academic Research Consortium-2 criteria were analysed, and the 5-year event-free survival rate was 28%±4%. Finally, the rate of good functional results, defined as survival in NYHA class I or II, was 32%±5% at 5-year follow-up. In the survivors, the EQ-5D questionnaire further confirmed the benefit in terms of quality of life. Conclusions: About one-third of patients discharged alive after TAVI were alive at 6-year follow-up, and the survivors exhibited good functional results assessed by NYHA class and quality-of-life standardised evaluation.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005711</affiliation-url><afid>60005711</afid><affilname>Universite Paris 7- Denis Diderot</affilname><name-variant>Université Paris 7</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022785</affiliation-url><afid>60022785</afid><affilname>Hopital Bichat-Claude-Bernard AP-HP</affilname><name-variant>Hopital Bichat</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">22</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36917910800</author-url><authid>36917910800</authid><authname>Bouleti C.</authname><surname>Bouleti</surname><given-name>Claire</given-name><initials>C.</initials><afid>60022785</afid><afid>60005711</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36917910800</author-url><authid>36917910800</authid><authname>Bouleti C.</authname><surname>Bouleti</surname><given-name>Claire</given-name><initials>C.</initials><afid>60022785</afid><afid>60005711</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55079971500</author-url><authid>55079971500</authid><authname>Himbert D.</authname><surname>Himbert</surname><given-name>Dominique</given-name><initials>D.</initials><afid>60022785</afid><afid>60022785</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55079971500</author-url><authid>55079971500</authid><authname>Himbert D.</authname><surname>Himbert</surname><given-name>Dominique</given-name><initials>D.</initials><afid>60022785</afid><afid>60022785</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55785385300</author-url><authid>55785385300</authid><authname>Iung B.</authname><surname>Iung</surname><given-name>Bernard</given-name><initials>B.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55785385300</author-url><authid>55785385300</authid><authname>Iung B.</authname><surname>Iung</surname><given-name>Bernard</given-name><initials>B.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55785385300</author-url><authid>55785385300</authid><authname>Iung B.</authname><surname>Iung</surname><given-name>Bernard</given-name><initials>B.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663226700</author-url><authid>56663226700</authid><authname>Alos B.</authname><surname>Alos</surname><given-name>Benjamin</given-name><initials>B.</initials><afid>60022785</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663161100</author-url><authid>56663161100</authid><authname>Kerneis C.</authname><surname>Kerneis</surname><given-name>Caroline</given-name><initials>C.</initials><afid>60022785</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23008091100</author-url><authid>23008091100</authid><authname>Ghodbane W.</authname><surname>Ghodbane</surname><given-name>Walid</given-name><initials>W.</initials><afid>60022785</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603661401</author-url><authid>6603661401</authid><authname>Messika-Zeitoun D.</authname><surname>Messika-Zeitoun</surname><given-name>David</given-name><initials>D.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603661401</author-url><authid>6603661401</authid><authname>Messika-Zeitoun D.</authname><surname>Messika-Zeitoun</surname><given-name>David</given-name><initials>D.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603661401</author-url><authid>6603661401</authid><authname>Messika-Zeitoun D.</authname><surname>Messika-Zeitoun</surname><given-name>David</given-name><initials>D.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003670849</author-url><authid>7003670849</authid><authname>Brochet E.</authname><surname>Brochet</surname><given-name>Eric</given-name><initials>E.</initials><afid>60022785</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:9632885300</author-url><authid>9632885300</authid><authname>Fassa A.</authname><surname>Fassa</surname><given-name>Amir Ali</given-name><initials>A.A.</initials><afid>60022785</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701570804</author-url><authid>6701570804</authid><authname>Depoix J.</authname><surname>Depoix</surname><given-name>Jean Pol</given-name><initials>J.P.</initials><afid>60022785</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56472493500</author-url><authid>56472493500</authid><authname>Ou P.</authname><surname>Ou</surname><given-name>Phalla</given-name><initials>P.</initials><afid>60022785</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004795910</author-url><authid>7004795910</authid><authname>Nataf P.</authname><surname>Nataf</surname><given-name>Patrick</given-name><initials>P.</initials><afid>60022785</afid><afid>60005711</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004795910</author-url><authid>7004795910</authid><authname>Nataf P.</authname><surname>Nataf</surname><given-name>Patrick</given-name><initials>P.</initials><afid>60022785</afid><afid>60005711</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:16158858700</author-url><authid>16158858700</authid><authname>Vahanian A.</authname><surname>Vahanian</surname><given-name>Alec</given-name><initials>A.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:16158858700</author-url><authid>16158858700</authid><authname>Vahanian A.</authname><surname>Vahanian</surname><given-name>Alec</given-name><initials>A.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:16158858700</author-url><authid>16158858700</authid><authname>Vahanian A.</authname><surname>Vahanian</surname><given-name>Alec</given-name><initials>A.</initials><afid>60022785</afid><afid>60005711</afid><afid>60022785</afid></author><intid>1785986817</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928803831"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928803831?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928803831&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928803831&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928803831</prism:url><dc:identifier>SCOPUS_ID:84928803831</dc:identifier><eid>2-s2.0-84928803831</eid><dc:title>Management of Coronary Artery Calcium and Coronary CTA Findings</dc:title><dc:creator>Thomas D.</dc:creator><prism:publicationName>Current Cardiovascular Imaging Reports</prism:publicationName><prism:issn>19419066</prism:issn><prism:eIssn>19419074</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12410-015-9334-0</prism:doi><dc:description>© 2015, The Author(s). Coronary artery calcium (CAC) testing and coronary computed tomography angiography (CTA) have significant data supporting their ability to identify coronary artery disease (CAD) and classify patient risk for atherosclerotic cardiovascular disease (ASCVD). Evidence regarding CAC use for screening has established an excellent prognosis in patients with no detectable CAC, and the ability to risk re-classify the majority of asymptomatic patients considered intermediate risk by traditional risk scores. While data regarding the ideal management of CAC findings are limited, evidence supports statin consideration in patients with CAC &gt; 0 and individualized aspirin therapy accounting for CAD risk factors, CAC severity, and factors which increase a patient’s risk of bleeding. In patients with stable or acute symptoms undergoing coronary CTA, a normal CTA predicts excellent prognosis, allowing reassurance and disposition without further testing. When CTA identifies nonobstructive CAD (&lt;50 % stenosis), observational data support consideration of statin use/intensification in patients with extensive plaque (at least four coronary segments involved) and patients with high-risk plaque features. In patients with both nonobstructive and obstructive CAD, multiple studies have now demonstrated an ability of CTA to guide management and improve CAD risk factor control. Still, significant under-treatment of cardiovascular risk factors and high-risk image findings remain, among concerns that CTA may increase invasive angiography and revascularization. To fully realize the impact of atherosclerosis imaging for ASCVD prevention, patient engagement in lifestyle changes and the modification of ASCVD risk factors remain the foundation of care. This review provides an overview of available data and recommendations in the management of CAC and CTA findings.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092465</affiliation-url><afid>60092465</afid><affilname>San Antonio Military Medical Center, Texas</affilname><name-variant>San Antonio Military Medical Center</name-variant><affiliation-city>Fort Sam Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008634</affiliation-url><afid>60008634</afid><affilname>Brigham and Women's Hospital and Harvard Medical School</affilname><name-variant>Brigham and Women's Hospital and Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006130</affiliation-url><afid>60006130</afid><affilname>Walter Reed National Military Medical Center</affilname><name-variant>Walter Reed Army Med. Cent.</name-variant><affiliation-city>Bethesda MD</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113020270</affiliation-url><afid>113020270</afid><affilname>Center for Prevention and Wellness Research</affilname><name-variant>Center for Prevention and Wellness Research</name-variant><affiliation-city>Miami Beach</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56387939100</author-url><authid>56387939100</authid><authname>Thomas D.</authname><surname>Thomas</surname><given-name>Dustin M.</given-name><initials>D.M.</initials><afid>60092465</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56166985900</author-url><authid>56166985900</authid><authname>Divakaran S.</authname><surname>Divakaran</surname><given-name>Sanjay</given-name><initials>S.</initials><afid>60008634</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506399752</author-url><authid>6506399752</authid><authname>Villines T.</authname><surname>Villines</surname><given-name>Todd C.</given-name><initials>T.C.</initials><afid>60006130</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701774452</author-url><authid>6701774452</authid><authname>Nasir K.</authname><surname>Nasir</surname><given-name>Khurram</given-name><initials>K.</initials><afid>113020270</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56612692700</author-url><authid>56612692700</authid><authname>Shah N.</authname><surname>Shah</surname><given-name>Nishant R.</given-name><initials>N.R.</initials><afid>60016782</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23091871800</author-url><authid>23091871800</authid><authname>Slim A.</authname><surname>Slim</surname><given-name>Ahmad M.</given-name><initials>A.M.</initials><afid>60092465</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24722711900</author-url><authid>24722711900</authid><authname>Blankstein R.</authname><surname>Blankstein</surname><given-name>Ron</given-name><initials>R.</initials><afid>60016782</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35740039600</author-url><authid>35740039600</authid><authname>Cheezum M.</authname><surname>Cheezum</surname><given-name>Michael K.</given-name><initials>M.K.</initials><afid>60016782</afid><afid>60016782</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35740039600</author-url><authid>35740039600</authid><authname>Cheezum M.</authname><surname>Cheezum</surname><given-name>Michael K.</given-name><initials>M.K.</initials><afid>60016782</afid><afid>60016782</afid></author><authkeywords>Acute coronary syndrome | atherosclerosis | Cardiovascular disease | Chest pain | Coronary artery calcium | Coronary CTA | High risk plaque | Ischemic heart disease | Major adverse cardiac events | Management | Prognosis</authkeywords><intid>1535849966</intid><source-id>19600157307</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928330007"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928330007?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928330007&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928330007&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928330007</prism:url><dc:identifier>SCOPUS_ID:84928330007</dc:identifier><eid>2-s2.0-84928330007</eid><dc:title>The Evolution of Temporary Percutaneous Mechanical Circulatory Support Devices: a Review of the Options and Evidence in Cardiogenic Shock</dc:title><dc:creator>Abnousi F.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0594-8</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Temporary percutaneous mechanical circulatory support (MCS) devices were introduced in the 1960s and have developed into a diverse portfolio of options currently available for left, right, and biventricular support. Patients undergoing high-risk percutaneous coronary interventions (PCI), patients with acute myocardial infarction (AMI), and patients with cardiogenic shock in particular may benefit from these options. In this review, we will discuss the currently available devices and the evidence supporting their use in cardiogenic shock.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015615</affiliation-url><afid>60015615</afid><affilname>Stanford University Medical Center</affilname><name-variant>Stanford University Medical Center</name-variant><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23468713900</author-url><authid>23468713900</authid><authname>Abnousi F.</authname><surname>Abnousi</surname><given-name>Freddy</given-name><initials>F.</initials><afid>60015615</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56603737700</author-url><authid>56603737700</authid><authname>Yong C.</authname><surname>Yong</surname><given-name>Celina Mei</given-name><initials>C.M.</initials><afid>60015615</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003425177</author-url><authid>7003425177</authid><authname>Fearon W.</authname><surname>Fearon</surname><given-name>William</given-name><initials>W.</initials><afid>60015615</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56603670800</author-url><authid>56603670800</authid><authname>Banerjee D.</authname><surname>Banerjee</surname><given-name>Dipanjan</given-name><initials>D.</initials><afid>60015615</afid></author><authkeywords>Percutaneous mechanical circulatory support | Ventricular assist device</authkeywords><intid>35767778</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928808051"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928808051?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928808051&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928808051&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928808051</prism:url><dc:identifier>SCOPUS_ID:84928808051</dc:identifier><eid>2-s2.0-84928808051</eid><dc:title>Stenting of Coronary Bifurcation Lesions: a Literature and Technical Review</dc:title><dc:creator>Lee J.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0595-7</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Newer generation drug-eluting stents have improved outcomes in various subsets of coronary lesions including bifurcation lesions. This article reviews the current literature on various issues in bifurcation percutaneous coronary intervention (PCI). Generally, the provisional approach of placing one stent in the main vessel is the preferred first-line treatment for most bifurcation lesions. However, some lesions require 2-stenting. It is unknown whether 2nd-generation DES have improved outcomes with 2-stenting. The use of fractional flow reserve (FFR) for the assessment of functional significance of the jailed side branch can help avoid unnecessary stenting in complex lesions. Skilled techniques in every step of the 2-stenting process and meticulous use of imaging techniques including IVUS or OCT are warranted to obtain optimal angiographic and clinical results. Dedicated bifurcation stents are feasible treatment options and may change future concepts in bifurcation PCI, although larger trials with control groups are required in order to widely apply these techniques into daily routine practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021119</affiliation-url><afid>60021119</afid><affilname>Seoul National University Hospital</affilname><name-variant>Seoul National University Hospital</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013682</affiliation-url><afid>60013682</afid><affilname>Seoul National University</affilname><name-variant>Seoul National University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56428711300</author-url><authid>56428711300</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Joo Myung</given-name><initials>J.M.</initials><afid>60021119</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35300576900</author-url><authid>35300576900</authid><authname>Park K.</authname><surname>Park</surname><given-name>Kyung Woo</given-name><initials>K.W.</initials><afid>60021119</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35285769200</author-url><authid>35285769200</authid><authname>Koo B.</authname><surname>Koo</surname><given-name>Bon Kwon</given-name><initials>B.K.</initials><afid>60021119</afid><afid>60013682</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35285769200</author-url><authid>35285769200</authid><authname>Koo B.</authname><surname>Koo</surname><given-name>Bon Kwon</given-name><initials>B.K.</initials><afid>60021119</afid><afid>60013682</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:33567809200</author-url><authid>33567809200</authid><authname>Kim H.</authname><surname>Kim</surname><given-name>Hyo Soo</given-name><initials>H.S.</initials><afid>60021119</afid></author><authkeywords>Bifurcation | Coronary bifurcation | Drug-eluting stent | Fractional flow reserve | Percutaneous coronary intervention | Provisional stenting | Systemic 2-stenting</authkeywords><intid>1785851941</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929009051"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929009051?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929009051&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929009051&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929009051</prism:url><dc:identifier>SCOPUS_ID:84929009051</dc:identifier><eid>2-s2.0-84929009051</eid><dc:title>PAD in Women: the Ischemic Continuum</dc:title><dc:creator>Pollak A.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0513-x</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Lower extremity peripheral arterial disease (PAD) is part of the ischemic continuum of atherosclerotic vascular disease and is associated with an increased risk of myocardial infarction, stroke, and cardiovascular death. Compared to men, women with PAD are more likely to have asymptomatic disease or atypical symptoms. PAD in women is associated with decreased exercise capacity, reduced quality of life, increased risk of depression, as well as a greater risk of acute cardiovascular events and cardiovascular mortality than male counterparts. Ensuring an appropriate diagnosis of women with PAD offers an opportunity to begin risk factor modification therapy, improve walking capacity and make a timely referral for revascularization if needed. It is critical to highlight the sex-based disparities in lower extremity PAD so that we may work to improve outcomes for women with PAD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002333</affiliation-url><afid>60002333</afid><affilname>Mayo Clinic in Jacksonville, Florida</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Jacksonville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56625617100</author-url><authid>56625617100</authid><authname>Pollak A.</authname><surname>Pollak</surname><given-name>Amy West</given-name><initials>A.W.</initials><afid>60002333</afid></author><authkeywords>Cardiovascular disease | Peripheral arterial disease | Women</authkeywords><intid>1785885813</intid><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209842"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209842?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209842&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209842&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209842</prism:url><dc:identifier>SCOPUS_ID:84930209842</dc:identifier><eid>2-s2.0-84930209842</eid><dc:title>Heartbeat: Highlights from this issue</dc:title><dc:creator>Otto C.</dc:creator><prism:publicationName>Heart</prism:publicationName><prism:issn>13556037</prism:issn><prism:eIssn>1468201X</prism:eIssn><prism:volume>101</prism:volume><prism:issueIdentifier>12</prism:issueIdentifier><prism:pageRange>911-912</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1136/heartjnl-2015-308114</prism:doi><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202696525</author-url><authid>7202696525</authid><authname>Otto C.</authname><surname>Otto</surname><given-name>Catherine M.</given-name><initials>C.M.</initials></author><intid>536087975</intid><source-id>23217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929090294"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929090294?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929090294&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929090294&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929090294</prism:url><dc:identifier>SCOPUS_ID:84929090294</dc:identifier><eid>2-s2.0-84929090294</eid><dc:title>Simultaneous in- and out-of-plane Mitral Valve Annular Force Measurements</dc:title><dc:creator>Skov S.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>185-192</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-015-0227-9</prism:doi><dc:description>© 2015, Biomedical Engineering Society. Mitral valve repair with annuloplasty is often favoured over total valve replacement. In order to develop and optimize new annuloplasty ring designs, it is important to study the complex biomechanical behaviour of the valve annulus and the subvalvular apparatus with simultaneous in- and out-of-plane restraining force measurements. A new flat D-shaped mitral valve annular force transducer was developed. The transducer was mounted with strain gauges to measure strain and calibrated to provide simultaneous restraining forces in- and out of the mitral annular plane. The force transducer was implanted and evaluated in an 80 kg porcine experimental model. Accumulation of out-of-plane restraining forces, creating strain in the anterior segment were 0.7 ± 0.0 N (towards apex) and an average force accumulation of 1.5 ± 0.3 N, creating strain in the commissural segments (away from apex). The accumulations of in-plane restraining forces, creating strain on the inner side of the ring were 1.7 ± 0.2 N (away from ring center). A new mitral annular force transducer was successfully developed and evaluated in vivo. The transducer was able to measure forces simultaneously in different planes. Initial indications point towards overall agreement with previous individual force measurements in- and out-of the mitral annular plane. This can provide more detailed insight into the annular force distribution, and could potentially improve the level of evidence based mitral valve repair and support the development of future mitral annuloplasty devices.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023882</affiliation-url><afid>60023882</afid><affilname>Arhus Universitetshospital</affilname><name-variant>Aarhus University Hospital</name-variant><affiliation-city>Arhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029616</affiliation-url><afid>60029616</afid><affilname>Aarhus Universitet</affilname><name-variant>University of Aarhus</name-variant><affiliation-city>Aarhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56638075000</author-url><authid>56638075000</authid><authname>Skov S.</authname><surname>Skov</surname><given-name>Søren N.</given-name><initials>S.N.</initials><afid>60023882</afid><afid>60029616</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56638075000</author-url><authid>56638075000</authid><authname>Skov S.</authname><surname>Skov</surname><given-name>Søren N.</given-name><initials>S.N.</initials><afid>60023882</afid><afid>60029616</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15849758200</author-url><authid>15849758200</authid><authname>Røpcke D.</authname><surname>Røpcke</surname><given-name>Diana M.</given-name><initials>D.M.</initials><afid>60023882</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56638439600</author-url><authid>56638439600</authid><authname>Telling K.</authname><surname>Telling</surname><given-name>Kristine</given-name><initials>K.</initials><afid>60023882</afid><afid>60029616</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56638439600</author-url><authid>56638439600</authid><authname>Telling K.</authname><surname>Telling</surname><given-name>Kristine</given-name><initials>K.</initials><afid>60023882</afid><afid>60029616</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56638663600</author-url><authid>56638663600</authid><authname>Ilkjær C.</authname><surname>Ilkjær</surname><given-name>Christine</given-name><initials>C.</initials><afid>60023882</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56638456100</author-url><authid>56638456100</authid><authname>Tjørnild M.</authname><surname>Tjørnild</surname><given-name>Marcell J.</given-name><initials>M.J.</initials><afid>60023882</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:39161704700</author-url><authid>39161704700</authid><authname>Nygaard H.</authname><surname>Nygaard</surname><given-name>Hans</given-name><initials>H.</initials><afid>60023882</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35547623500</author-url><authid>35547623500</authid><authname>Nielsen S.</authname><surname>Nielsen</surname><given-name>Sten L.</given-name><initials>S.L.</initials><afid>60023882</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:25622456300</author-url><authid>25622456300</authid><authname>Jensen M.</authname><surname>Jensen</surname><given-name>Morten O.</given-name><initials>M.O.</initials><afid>60023882</afid><afid>60029616</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:25622456300</author-url><authid>25622456300</authid><authname>Jensen M.</authname><surname>Jensen</surname><given-name>Morten O.</given-name><initials>M.O.</initials><afid>60023882</afid><afid>60029616</afid></author><authkeywords>Biomechanics | Mitral valve | Mitral valve annuloplasty | Reconstruction surgery | Strain gauge</authkeywords><intid>1535901432</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929154410"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929154410?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929154410&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929154410&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2213576615000482"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929154410</prism:url><dc:identifier>SCOPUS_ID:84929154410</dc:identifier><eid>2-s2.0-84929154410</eid><dc:title>Coincidence of congenital left-sided diaphragmatic hernia and ductus venosus agenesis: Relation between altered hemodynamic flow and lung-to-head-ratio?</dc:title><dc:creator>Klein T.</dc:creator><prism:publicationName>Journal of Pediatric Surgery Case Reports</prism:publicationName><prism:eIssn>22135766</prism:eIssn><prism:volume>3</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>245-248</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.epsc.2015.04.002</prism:doi><pii>S2213576615000482</pii><dc:description>© 2015 The Authors. All rights reserved. Left-sided diaphragmatic hernia (CDH) as well as ductus venosus agenesis (ADV) are rare complex congenital malformations. We present a case of coincidence of these malformations and an abnormally high lung-head-ratio (LHR). The left-sided liver-up CDH and the ADV were diagnosed in prenatal ultrasound examination. In CDH cases lung volume is decreased due to the herniation of abdominal organs into the thorax. With 1.4 the LHR of our patient exceeded the normal ratio in liver-up CDH cases considerably. One explanation for this unusually high LHR might be an altered blood flow due to the coinciding ADV. In ADV cases less blood bypasses the lung through the foramen ovale. Consecutively pulmonary circulation is improved which may constitute as an advantage in CDH cases. Diagnosis, prognostic factors, physiology, and therapy strategy are discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027540</affiliation-url><afid>60027540</afid><affilname>Kliniken der Stadt Koln gGmbH</affilname><name-variant>Kliniken der Stadt Köln GGmbH</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027540</affiliation-url><afid>60027540</afid><affilname>Kliniken der Stadt Koln gGmbH</affilname><name-variant>Kliniken der Stadt Köln GGmbH</name-variant><affiliation-city>Koln</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Praxis für Pränatalmedizin und Genetik Cologne</affilname><affiliation-city/><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56447960600</author-url><authid>56447960600</authid><authname>Klein T.</authname><surname>Klein</surname><given-name>T.</given-name><initials>T.</initials><afid>60027540</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56448938100</author-url><authid>56448938100</authid><authname>Semaan A.</authname><surname>Semaan</surname><given-name>A.</given-name><initials>A.</initials><afid>60027540</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56640969300</author-url><authid>56640969300</authid><authname>Kellner M.</authname><surname>Kellner</surname><given-name>M.</given-name><initials>M.</initials><afid>60027540</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55335245800</author-url><authid>55335245800</authid><authname>Ritgen J.</authname><surname>Ritgen</surname><given-name>J.</given-name><initials>J.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55915514600</author-url><authid>55915514600</authid><authname>Boemers T.</authname><surname>Boemers</surname><given-name>T. M.</given-name><initials>T.M.</initials><afid>60027540</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56061348500</author-url><authid>56061348500</authid><authname>Stressig R.</authname><surname>Stressig</surname><given-name>R.</given-name><initials>R.</initials><afid/></author><authkeywords>Absence of ductus venosus | Ductus venosus agenesis | Left-sided diaphragmatic hernia</authkeywords><intid>2035912902</intid><source-id>21100255429</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928319160"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928319160?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928319160&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928319160&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0041008X15001209"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928319160</prism:url><dc:identifier>SCOPUS_ID:84928319160</dc:identifier><eid>2-s2.0-84928319160</eid><dc:title>Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice</dc:title><dc:creator>Conklin D.</dc:creator><prism:publicationName>Toxicology and Applied Pharmacology</prism:publicationName><prism:issn>0041008X</prism:issn><prism:eIssn>10960333</prism:eIssn><prism:volume>285</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>136-148</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.taap.2015.03.029</prism:doi><pii>S0041008X15001209</pii><dc:description>© 2015 Elsevier Inc. High-dose chemotherapy regimens using cyclophosphamide (CY) are frequently associated with cardiotoxicity that could lead to myocyte damage and congestive heart failure. However, the mechanisms regulating the cardiotoxic effects of CY remain unclear. Because CY is converted to an unsaturated aldehyde acrolein, a toxic, reactive CY metabolite that induces extensive protein modification and myocardial injury, we examined the role of glutathione S-transferase P (GSTP), an acrolein-metabolizing enzyme, in CY cardiotoxicity in wild-type (WT) and GSTP-null mice. Treatment with CY (100-300. mg/kg) increased plasma levels of creatine kinase-MB isoform (CK·MB) and heart-to-body weight ratio to a significantly greater extent in GSTP-null than WT mice. In addition to modest yet significant echocardiographic changes following acute CY-treatment, GSTP insufficiency was associated with greater phosphorylation of c-Jun and p38 as well as greater accumulation of albumin and protein-acrolein adducts in the heart. Mass spectrometric analysis revealed likely prominent modification of albumin, kallikrein-1-related peptidase, myoglobin and transgelin-2 by acrolein in the hearts of CY-treated mice. Treatment with acrolein (low dose, 1-5. mg/kg) also led to increased heart-to-body weight ratio and myocardial contractility changes. Acrolein induced similar hypotension in GSTP-null and WT mice. GSTP-null mice also were more susceptible than WT mice to mortality associated with high-dose acrolein (10-20. mg/kg). Collectively, these results suggest that CY cardiotoxicity is regulated, in part, by GSTP, which prevents CY toxicity by detoxifying acrolein. Thus, humans with low cardiac GSTP levels or polymorphic forms of GSTP with low acrolein-metabolizing capacity may be more sensitive to CY toxicity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020633</affiliation-url><afid>60020633</afid><affilname>University of Louisville</affilname><name-variant>University of Louisville</name-variant><affiliation-city>Louisville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020633</affiliation-url><afid>60020633</afid><affilname>University of Louisville</affilname><name-variant>University of Louisville</name-variant><affiliation-city>Louisville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020633</affiliation-url><afid>60020633</afid><affilname>University of Louisville</affilname><name-variant>University of Louisville</name-variant><affiliation-city>Louisville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020633</affiliation-url><afid>60020633</afid><affilname>University of Louisville</affilname><name-variant>University of Louisville</name-variant><affiliation-city>Louisville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025152</affiliation-url><afid>60025152</afid><affilname>University of Cincinnati</affilname><name-variant>University of Cincinnati</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006967898</author-url><authid>7006967898</authid><authname>Conklin D.</authname><surname>Conklin</surname><given-name>Daniel J.</given-name><initials>D.J.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006967898</author-url><authid>7006967898</authid><authname>Conklin D.</authname><surname>Conklin</surname><given-name>Daniel J.</given-name><initials>D.J.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637171500</author-url><authid>56637171500</authid><authname>Haberzettl P.</authname><surname>Haberzettl</surname><given-name>Petra</given-name><initials>P.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637171500</author-url><authid>56637171500</authid><authname>Haberzettl P.</authname><surname>Haberzettl</surname><given-name>Petra</given-name><initials>P.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56604096200</author-url><authid>56604096200</authid><authname>Jagatheesan G.</authname><surname>Jagatheesan</surname><given-name>Ganapathy</given-name><initials>G.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56604096200</author-url><authid>56604096200</authid><authname>Jagatheesan G.</authname><surname>Jagatheesan</surname><given-name>Ganapathy</given-name><initials>G.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56603639900</author-url><authid>56603639900</authid><authname>Baba S.</authname><surname>Baba</surname><given-name>Shahid</given-name><initials>S.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56603639900</author-url><authid>56603639900</authid><authname>Baba S.</authname><surname>Baba</surname><given-name>Shahid</given-name><initials>S.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8581420600</author-url><authid>8581420600</authid><authname>Merchant M.</authname><surname>Merchant</surname><given-name>Michael L.</given-name><initials>M.L.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8581420600</author-url><authid>8581420600</authid><authname>Merchant M.</authname><surname>Merchant</surname><given-name>Michael L.</given-name><initials>M.L.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005555537</author-url><authid>7005555537</authid><authname>Prough R.</authname><surname>Prough</surname><given-name>Russell A.</given-name><initials>R.A.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005555537</author-url><authid>7005555537</authid><authname>Prough R.</authname><surname>Prough</surname><given-name>Russell A.</given-name><initials>R.A.</initials><afid>60020633</afid><afid>60020633</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56603453200</author-url><authid>56603453200</authid><authname>Williams J.</authname><surname>Williams</surname><given-name>Jessica D.</given-name><initials>J.D.</initials><afid>60025152</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101753861</author-url><authid>7101753861</authid><authname>Prabhu S.</authname><surname>Prabhu</surname><given-name>Sumanth D.</given-name><initials>S.D.</initials><afid>60027086</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202474550</author-url><authid>7202474550</authid><authname>Bhatnagar A.</authname><surname>Bhatnagar</surname><given-name>Aruni</given-name><initials>A.</initials><afid>60020633</afid><afid>60020633</afid><afid>60020633</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202474550</author-url><authid>7202474550</authid><authname>Bhatnagar A.</authname><surname>Bhatnagar</surname><given-name>Aruni</given-name><initials>A.</initials><afid>60020633</afid><afid>60020633</afid><afid>60020633</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202474550</author-url><authid>7202474550</authid><authname>Bhatnagar A.</authname><surname>Bhatnagar</surname><given-name>Aruni</given-name><initials>A.</initials><afid>60020633</afid><afid>60020633</afid><afid>60020633</afid></author><authkeywords>Acrolein | Apoptosis | Cardiotoxicity | Cytoxan | GSTP1 | JNK/c-Jun</authkeywords><intid>2035762478</intid><source-id>25222</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928991305"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928991305?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928991305&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928991305&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928991305</prism:url><dc:identifier>SCOPUS_ID:84928991305</dc:identifier><eid>2-s2.0-84928991305</eid><dc:title>Closure of mitochondrial potassium channels favors opening of the Tl&lt;sup&gt;+&lt;/sup&gt;-induced permeability transition pore in Ca&lt;sup&gt;2+&lt;/sup&gt;-loaded rat liver mitochondria</dc:title><dc:creator>Korotkov S.</dc:creator><prism:publicationName>Journal of Bioenergetics and Biomembranes</prism:publicationName><prism:issn>0145479X</prism:issn><prism:eIssn>15736881</prism:eIssn><prism:volume>47</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>243-254</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10863-015-9611-2</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. It is known that a closure of ATP sensitive (mitoK&lt;inf&gt;ATP&lt;/inf&gt;) or BK-type Ca&lt;sup&gt;2+&lt;/sup&gt; activated (mitoK&lt;inf&gt;Ca&lt;/inf&gt;) potassium channels triggers opening of the mitochondrial permeability transition pore (MPTP) in cells and isolated mitochondria. We found earlier that the Tl&lt;sup&gt;+&lt;/sup&gt;-induced MPTP opening in Ca&lt;sup&gt;2+&lt;/sup&gt;-loaded rat liver mitochondria was accompanied by a decrease of 2,4-dinitrophenol-uncoupled respiration and increase of mitochondrial swelling and ΔΨ&lt;inf&gt;mito&lt;/inf&gt; dissipation in the medium containing TlNO&lt;inf&gt;3&lt;/inf&gt; and KNO&lt;inf&gt;3&lt;/inf&gt;. On the other hand, our study showed that the mitoK&lt;inf&gt;ATP&lt;/inf&gt; inhibitor, 5-hydroxydecanoate favored the Tl&lt;sup&gt;+&lt;/sup&gt;-induced MPTP opening in the inner membrane of Ca&lt;sup&gt;2+&lt;/sup&gt;-loaded rat heart mitochondria (Korotkov et al. 2013). Here we showed that 5-hydroxydecanoate increased the Tl&lt;sup&gt;+&lt;/sup&gt;-induced MPTP opening in the membrane of rat liver mitochondria regardless of the presence of mitoK&lt;inf&gt;ATP&lt;/inf&gt; modulators (diazoxide and pinacidil). This manifested in more pronounced decrease in the uncoupled respiration and acceleration of both the swelling and the ΔΨ&lt;inf&gt;mito&lt;/inf&gt; dissipation in isolated rat liver mitochondria, incubated in the medium containing TlNO&lt;inf&gt;3&lt;/inf&gt;, KNO&lt;inf&gt;3&lt;/inf&gt;, and Ca&lt;sup&gt;2+&lt;/sup&gt;. A slight delay in Ca&lt;sup&gt;2+&lt;/sup&gt;-induced swelling of the mitochondria exposed to diazoxide could be result of an inhibition of succinate oxidation by the mitoK&lt;inf&gt;ATP&lt;/inf&gt; modulator. Mitochondrial calcium retention capacity (CRC) was markedly decreased in the presence of the mitoK&lt;inf&gt;ATP&lt;/inf&gt; inhibitor (5-hydroxydecanoate) or the mitoK&lt;inf&gt;Ca&lt;/inf&gt; inhibitor (paxilline). We suggest that the closure of mitoK&lt;inf&gt;ATP&lt;/inf&gt; or mitoK&lt;inf&gt;Ca&lt;/inf&gt; in calcium loaded mitochondria favors opening of the Tl&lt;sup&gt;+&lt;/sup&gt;-induced MPTP in the inner mitochondrial membrane.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021331</affiliation-url><afid>60021331</afid><affilname>Russian Academy of Sciences</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113941965</affiliation-url><afid>113941965</afid><affilname>Aurora Research Institute</affilname><name-variant>Aurora Research Institute</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005303300</author-url><authid>7005303300</authid><authname>Korotkov S.</authname><surname>Korotkov</surname><given-name>Sergey M.</given-name><initials>S.M.</initials><afid>60021331</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602890468</author-url><authid>6602890468</authid><authname>Brailovskaya I.</authname><surname>Brailovskaya</surname><given-name>Irina V.</given-name><initials>I.V.</initials><afid>60021331</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56625738000</author-url><authid>56625738000</authid><authname>Shumakov A.</authname><surname>Shumakov</surname><given-name>Anton R.</given-name><initials>A.R.</initials><afid>60021331</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15122027200</author-url><authid>15122027200</authid><authname>Emelyanova L.</authname><surname>Emelyanova</surname><given-name>Larisa V.</given-name><initials>L.V.</initials><afid>60021331</afid><afid>113941965</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15122027200</author-url><authid>15122027200</authid><authname>Emelyanova L.</authname><surname>Emelyanova</surname><given-name>Larisa V.</given-name><initials>L.V.</initials><afid>60021331</afid><afid>113941965</afid></author><authkeywords>Ca&lt;sup&gt;2+&lt;/sup&gt; | Mitochondrial K&lt;inf&gt;ATP&lt;/inf&gt; channel | Mitochondrial K&lt;inf&gt;Ca&lt;/inf&gt; channel | Mitochondrial permeability transition | Rat liver mitochondria | Tl&lt;sup&gt;+&lt;/sup&gt;</authkeywords><intid>1535884594</intid><source-id>17590</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929992024"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929992024?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929992024&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929992024&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929992024</prism:url><dc:identifier>SCOPUS_ID:84929992024</dc:identifier><eid>2-s2.0-84929992024</eid><dc:title>Pharmacokinetics of serelaxin in patients with hepatic impairment: A single-dose, open-label, parallel group study</dc:title><dc:creator>Kobalava Z.</dc:creator><prism:publicationName>British Journal of Clinical Pharmacology</prism:publicationName><prism:issn>03065251</prism:issn><prism:eIssn>13652125</prism:eIssn><prism:volume>79</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>937-945</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bcp.12572</prism:doi><dc:description>© 2014 The British Pharmacological Society. Aims Serelaxin is a recombinant form of human relaxin-2 in development for treatment of acute heart failure. This study aimed to evaluate the pharmacokinetics (PK) of serelaxin in patients with hepatic impairment. Secondary objectives included evaluation of immunogenicity, safety and tolerability of serelaxin. Methods This was an open-label, parallel group study (NCT01433458) comparing the PK of serelaxin following a single 24 h intravenous (i.v.) infusion (30 μg kg&lt;sup&gt;-1&lt;/sup&gt; day&lt;sup&gt;-1&lt;/sup&gt;) between patients with mild, moderate or severe hepatic impairment (Child-Pugh class A, B, C) and healthy matched controls. Blood sampling and standard safety assessments were conducted. Primary non-compartmental PK parameters [including area under the serum concentration-time curve AUC(0-48 h) and AUC(0-∞) and serum concentration at 24 h post-dose (C&lt;inf&gt;24h&lt;/inf&gt;)] were compared between each hepatic impairment group and healthy controls. Results A total of 49 subjects (including 25 patients with hepatic impairment) were enrolled, of which 48 subjects completed the study. In all groups, the serum concentration of serelaxin increased over the first few hours of infusion, reached steady-state at 12-24 h and then declined following completion of infusion, with a mean terminal half-life of 7-8 h. All PK parameter estimates were comparable between each group of patients with hepatic impairment and healthy controls. No serious adverse events, discontinuations due to adverse events or deaths were reported. No serelaxin treatment-related antibodies developed during this study. Conclusions The PK and safety profile of serelaxin were not affected by hepatic impairment. No dose adjustment is needed for serelaxin treatment of 48 h i.v. infusion in patients with hepatic impairment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015024</affiliation-url><afid>60015024</afid><affilname>Peoples’ Friendship University of Russia</affilname><name-variant>Peoples' Friendship University of Russia</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112584628</affiliation-url><afid>112584628</afid><affilname>Gastroenterologisch-Hepatologisches Zentrum Kiel</affilname><name-variant>Gastroenterologisch-Hepatologisches Zentrum Kiel</name-variant><affiliation-city>Kiel</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105763075</affiliation-url><afid>105763075</afid><affilname>Clinical Research Services</affilname><name-variant>CRS-Kiel GmbH</name-variant><affiliation-city>Kiel</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009968</affiliation-url><afid>60009968</afid><affilname>Novartis</affilname><name-variant>Novartis Pharma AG</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006840</affiliation-url><afid>60006840</afid><affilname>Novartis Institutes for Biomedical Research</affilname><name-variant>Novartis Institutes for Biomedical Research</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115281237</affiliation-url><afid>115281237</afid><affilname>KinDyn Consulting Ltd</affilname><name-variant>KinDyn Consulting Ltd</name-variant><affiliation-city>Horsham</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8674573200</author-url><authid>8674573200</authid><authname>Kobalava Z.</authname><surname>Kobalava</surname><given-name>Zhanna</given-name><initials>Z.</initials><afid>60015024</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8947426100</author-url><authid>8947426100</authid><authname>Villevalde S.</authname><surname>Villevalde</surname><given-name>Svetlana</given-name><initials>S.</initials><afid>60015024</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8674572900</author-url><authid>8674572900</authid><authname>Kotovskaya Y.</authname><surname>Kotovskaya</surname><given-name>Yulia</given-name><initials>Y.</initials><afid>60015024</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55818210200</author-url><authid>55818210200</authid><authname>Hinrichsen H.</authname><surname>Hinrichsen</surname><given-name>Holger</given-name><initials>H.</initials><afid>112584628</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56190358800</author-url><authid>56190358800</authid><authname>Petersen-Sylla M.</authname><surname>Petersen-Sylla</surname><given-name>Marc</given-name><initials>M.</initials><afid>105763075</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56658717300</author-url><authid>56658717300</authid><authname>Zaehringer A.</authname><surname>Zaehringer</surname><given-name>Andreas</given-name><initials>A.</initials><afid>60009968</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56511027000</author-url><authid>56511027000</authid><authname>Pang Y.</authname><surname>Pang</surname><given-name>Yinuo</given-name><initials>Y.</initials><afid>60006840</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56127684700</author-url><authid>56127684700</authid><authname>Rajman I.</authname><surname>Rajman</surname><given-name>Iris</given-name><initials>I.</initials><afid>60009968</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6506107169</author-url><authid>6506107169</authid><authname>Canadi J.</authname><surname>Canadi</surname><given-name>Jasna</given-name><initials>J.</initials><afid>60009968</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:39061364700</author-url><authid>39061364700</authid><authname>Dahlke M.</authname><surname>Dahlke</surname><given-name>Marion</given-name><initials>M.</initials><afid>60009968</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:26642964800</author-url><authid>26642964800</authid><authname>Lloyd P.</authname><surname>Lloyd</surname><given-name>Peter</given-name><initials>P.</initials><afid>115281237</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7003902511</author-url><authid>7003902511</authid><authname>Halabi A.</authname><surname>Halabi</surname><given-name>Atef</given-name><initials>A.</initials><afid>105763075</afid></author><authkeywords>cardiovascular disease | healthy subjects | hepatic | pharmacokinetics | therapeutics</authkeywords><intid>1036045182</intid><source-id>20082</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930009729"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930009729?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930009729&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930009729&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930009729</prism:url><dc:identifier>SCOPUS_ID:84930009729</dc:identifier><eid>2-s2.0-84930009729</eid><dc:title>The pathophysiology of the chronic cardiorenal syndrome: a magnetic resonance imaging study</dc:title><dc:creator>Breidthardt T.</dc:creator><prism:publicationName>European Radiology</prism:publicationName><prism:issn>09387994</prism:issn><prism:eIssn>14321084</prism:eIssn><prism:volume>25</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1684-1691</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00330-014-3571-5</prism:doi><dc:description>© 2015, European Society of Radiology. Objective: To study the association of renal function with renal perfusion and renal parenchymal structure (T&lt;inf&gt;1&lt;/inf&gt; relaxation) in patients with chronic heart failure (HF). Methods: After IRB approval, 40 participants were enrolled according to HF and renal function status [10 healthy volunteers &lt; 40 years; 10 healthy age-matched volunteers; 10 HF patients eGFR &gt; 60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;; 10 HF patients eGFR &lt; 60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;] and assessed by MRI. To be eligible for enrolment all HF patients with renal dysfunction (RD) needed to be diagnosed as having chronic cardiorenal syndrome based on current guidelines. Patients with primary kidney disease were excluded. Results: Renal cortical perfusion correlated with eGFR values (r = 0.52;p &lt; 0.01) and was similar between HF patients with and without RD (p = 0.27). T&lt;inf&gt;1&lt;/inf&gt; relaxation correlated negatively with eGFR values (r = -0.41;p &gt; 0.01) and was higher in HF patients compared to volunteers (1121 ± 102 ms vs. 1054 ± 65 ms;p = 0.03). T&lt;inf&gt;1&lt;/inf&gt; relaxation was selectively prolonged in HF patients with RD (1169 ms ± 100 vs. HF without RD 1067 ms ± 79;p = 0.047). In linear regression analyses coronary artery disease (p = 0.01), hypertension (p = 0.04), and diabetes mellitus (p &lt; 0.01) were associated with T&lt;inf&gt;1&lt;/inf&gt; relaxation. Conclusion: RD in HF is not primarily mediated by decreased renal perfusion. Instead, chronic reno-parenchymal damage, as indicated by prolonged T&lt;inf&gt;1&lt;/inf&gt; relaxation, appears to underly chronic cardiorenal syndrome. Key points: • The pathophysiology underlying chronic cardiorenal syndrome is not completely understood. • Chronic cardiorenal syndrome is independent of cardiac output or renal perfusion. • Renal T&lt;inf&gt;1&lt;/inf&gt;relaxation appears to be prolonged in HF with renal impairment. • Renal T&lt;inf&gt;1&lt;/inf&gt;relaxation is associated with classic cardiovascular risk factors. • Association of renal T&lt;inf&gt;1&lt;/inf&gt;relaxation with parenchymal damage should be validated further.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028287</affiliation-url><afid>60028287</afid><affilname>Universitatsspital Basel</affilname><name-variant>University Hospital Basel</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015138</affiliation-url><afid>60015138</afid><affilname>University of Nottingham</affilname><name-variant>University of Nottingham</name-variant><affiliation-city>Nottingham</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033125</affiliation-url><afid>60033125</afid><affilname>University of Leicester</affilname><name-variant>University of Leicester</name-variant><affiliation-city>Leicester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110271285</affiliation-url><afid>110271285</afid><affilname>Royal Derby Hospital</affilname><name-variant>Royal Derby Hospital</name-variant><affiliation-city>Derby</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010884</affiliation-url><afid>60010884</afid><affilname>Western University</affilname><name-variant>University of Western Ontario</name-variant><affiliation-city>London</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15047385600</author-url><authid>15047385600</authid><authname>Breidthardt T.</authname><surname>Breidthardt</surname><given-name>Tobias</given-name><initials>T.</initials><afid>60028287</afid><afid>110271285</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15047385600</author-url><authid>15047385600</authid><authname>Breidthardt T.</authname><surname>Breidthardt</surname><given-name>Tobias</given-name><initials>T.</initials><afid>60028287</afid><afid>110271285</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:17134261300</author-url><authid>17134261300</authid><authname>Cox E.</authname><surname>Cox</surname><given-name>Eleanor F.</given-name><initials>E.F.</initials><afid>60015138</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56044003200</author-url><authid>56044003200</authid><authname>Squire I.</authname><surname>Squire</surname><given-name>Iain</given-name><initials>I.</initials><afid>60033125</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35269508500</author-url><authid>35269508500</authid><authname>Odudu A.</authname><surname>Odudu</surname><given-name>Aghogho</given-name><initials>A.</initials><afid>110271285</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56658379100</author-url><authid>56658379100</authid><authname>Omar N.</authname><surname>Omar</surname><given-name>Nur Farhayu</given-name><initials>N.F.</initials><afid>60015138</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35268578900</author-url><authid>35268578900</authid><authname>Eldehni M.</authname><surname>Eldehni</surname><given-name>Mohamed Tarek</given-name><initials>M.T.</initials><afid>110271285</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7103159005</author-url><authid>7103159005</authid><authname>Francis S.</authname><surname>Francis</surname><given-name>Susan T.</given-name><initials>S.T.</initials><afid>60015138</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23482225400</author-url><authid>23482225400</authid><authname>McIntyre C.</authname><surname>McIntyre</surname><given-name>Christopher W.</given-name><initials>C.W.</initials><afid>110271285</afid><afid>60010884</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23482225400</author-url><authid>23482225400</authid><authname>McIntyre C.</authname><surname>McIntyre</surname><given-name>Christopher W.</given-name><initials>C.W.</initials><afid>110271285</afid><afid>60010884</afid></author><authkeywords>Cardiac function | Cardiorenal syndrome | Magnetic resonance imaging | Renal function | Renal perfusion</authkeywords><intid>36048367</intid><source-id>16687</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930201745"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930201745?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930201745&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930201745&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930201745</prism:url><dc:identifier>SCOPUS_ID:84930201745</dc:identifier><eid>2-s2.0-84930201745</eid><dc:title>Current achievements and future perspectives in whole-organ bioengineering Rocky Tuan; Timothy O'Brien</dc:title><dc:creator>Peloso A.</dc:creator><prism:publicationName>Stem Cell Research and Therapy</prism:publicationName><prism:eIssn>17576512</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1186/s13287-015-0089-y</prism:doi><dc:description>© 2015 Peloso et al.; licensee BioMed Central. Irreversible end-stage organ failure represents one of the leading causes of death, and organ transplantation is currently the only curative solution. Donor organ shortage and adverse effects of immunosuppressive regimens are the major limiting factors for this definitive practice. Recent developments in bioengineering and regenerative medicine could provide a solid base for the future creation of implantable, bioengineered organs. Whole-organ detergent-perfusion protocols permit clinicians to gently remove all the cells and at the same time preserve the natural three-dimensional framework of the native organ. Several decellularized organs, including liver, kidney, and pancreas, have been created as a platform for further successful seeding. These scaffolds are composed of organ-specific extracellular matrix that contains growth factors important for cellular growth and function. Macro- and microvascular tree is entirely maintained and can be incorporated in the recipient's vascular system after the implant. This review will emphasize recent achievements in the whole-organ scaffolds and at the same time underline complications that the scientific community has to resolve before reaching a functional bioengineered organ.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>Università di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003837</affiliation-url><afid>60003837</afid><affilname>Forest Institute</affilname><name-variant>Forest Institute</name-variant><affiliation-city>Huntsville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021783</affiliation-url><afid>60021783</afid><affilname>Nantong University</affilname><name-variant>Affiliated Hospital of Nantong University</name-variant><affiliation-city>Nantong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031437</affiliation-url><afid>60031437</afid><affilname>Wake Forest University School of Medicine</affilname><name-variant>Wake Forest Univ. School of Medicine</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55599187400</author-url><authid>55599187400</authid><authname>Peloso A.</authname><surname>Peloso</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60015197</afid><afid>60003837</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55599187400</author-url><authid>55599187400</authid><authname>Peloso A.</authname><surname>Peloso</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60015197</afid><afid>60003837</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56032972200</author-url><authid>56032972200</authid><authname>Dhal A.</authname><surname>Dhal</surname><given-name>Abritee</given-name><initials>A.</initials><afid>60003837</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8959697100</author-url><authid>8959697100</authid><authname>Zambon J.</authname><surname>Zambon</surname><given-name>Joao P.</given-name><initials>J.P.</initials><afid>60003837</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660100600</author-url><authid>56660100600</authid><authname>Li P.</authname><surname>Li</surname><given-name>Peng</given-name><initials>P.</initials><afid>60003837</afid><afid>60021783</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660100600</author-url><authid>56660100600</authid><authname>Li P.</authname><surname>Li</surname><given-name>Peng</given-name><initials>P.</initials><afid>60003837</afid><afid>60021783</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8852328200</author-url><authid>8852328200</authid><authname>Orlando G.</authname><surname>Orlando</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60003837</afid><afid>60031437</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8852328200</author-url><authid>8852328200</authid><authname>Orlando G.</authname><surname>Orlando</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60003837</afid><afid>60031437</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35403955200</author-url><authid>35403955200</authid><authname>Atala A.</authname><surname>Atala</surname><given-name>Anthony</given-name><initials>A.</initials><afid>60003837</afid><afid>60031437</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35403955200</author-url><authid>35403955200</authid><authname>Atala A.</authname><surname>Atala</surname><given-name>Anthony</given-name><initials>A.</initials><afid>60003837</afid><afid>60031437</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004208883</author-url><authid>7004208883</authid><authname>Soker S.</authname><surname>Soker</surname><given-name>Shay</given-name><initials>S.</initials><afid>60003837</afid></author><intid>1786088025</intid><article-number>107</article-number><source-id>19700201524</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928346266"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928346266?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928346266&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928346266&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928346266</prism:url><dc:identifier>SCOPUS_ID:84928346266</dc:identifier><eid>2-s2.0-84928346266</eid><dc:title>A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk</dc:title><dc:creator>Fergus I.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0592-x</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Cardiometabolic risk describes a collection of risk factors, with a likely underlying pathophysiology, resulting in accelerated atherosclerosis and the terminal cardiovascular events of myocardial infarction and stroke. Beta-blockers, which are divided as vasodilators or non-vasodilators, are used in the treatment of hypertension and other cardiovascular diseases. Vasodilators have been shown to be of particular benefit in both blood pressure control and other cardiometabolic components with limited disturbance in metabolic parameters. Nebivolol, a third-generation beta-blocker (BB), acts by increasing nitric oxide (NO) bioavailability. This property may be especially important in NO-deficient population, such as black people, in regulating both blood pressure control and glucose homeostasis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072122</affiliation-url><afid>60072122</afid><affilname>The University of the West Indies at Cave Hill</affilname><name-variant>University of the West Indies</name-variant><affiliation-city>Bridgetown</affiliation-city><affiliation-country>Barbados</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015112</affiliation-url><afid>60015112</afid><affilname>Tulane University School of Medicine</affilname><name-variant>Tulane Univ. Sch. Med.</name-variant><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602763386</author-url><authid>6602763386</authid><authname>Fergus I.</authname><surname>Fergus</surname><given-name>Icilma V.</given-name><initials>I.V.</initials><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56603905100</author-url><authid>56603905100</authid><authname>Connell K.</authname><surname>Connell</surname><given-name>Kenneth L.</given-name><initials>K.L.</initials><afid>60072122</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36912480700</author-url><authid>36912480700</authid><authname>Ferdinand K.</authname><surname>Ferdinand</surname><given-name>Keith C.</given-name><initials>K.C.</initials><afid>60015112</afid></author><authkeywords>Beta-blockers | Cardiometabolic risk | Nitric oxide | Vasodilators</authkeywords><intid>1035762404</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928625600"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928625600?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928625600&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928625600&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928625600</prism:url><dc:identifier>SCOPUS_ID:84928625600</dc:identifier><eid>2-s2.0-84928625600</eid><dc:title>Stress Echocardiography: What Is New and How Does It Compare with Myocardial Perfusion Imaging and Other Modalities?</dc:title><dc:creator>Tweet M.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0600-1</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Cardiovascular disease is a leading cause of morbidity and mortality, and noninvasive strategies to diagnose and risk stratify patients remain paramount in the evaluative process. Stress echocardiography is a well-established, versatile, real-time imaging modality with advantages including lack of radiation exposure, portability, and affordability. Innovative techniques in stress echocardiography include myocardial contrast echocardiography, deformation imaging, three-dimensional (3D) echocardiography, and assessment of coronary flow reserve. Myocardial perfusion imaging with single-photon emission computed tomography (SPECT) or positron emission tomography (PET) are imaging alternatives, and stress cardiac magnetic resonance imaging and coronary computed tomography (CT) angiography, including CT perfusion imaging, are emerging as newer approaches. This review will discuss recent and upcoming developments in the field of stress testing, with an emphasis on stress echocardiography while highlighting comparisons with other modalities.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36675678900</author-url><authid>36675678900</authid><authname>Tweet M.</authname><surname>Tweet</surname><given-name>Marysia S.</given-name><initials>M.S.</initials><afid>60005558</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506472111</author-url><authid>6506472111</authid><authname>Arruda-Olson A.</authname><surname>Arruda-Olson</surname><given-name>Adelaide M.</given-name><initials>A.M.</initials><afid>60005558</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8628486200</author-url><authid>8628486200</authid><authname>Anavekar N.</authname><surname>Anavekar</surname><given-name>Nandan S.</given-name><initials>N.S.</initials><afid>60005558</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007042258</author-url><authid>7007042258</authid><authname>Pellikka P.</authname><surname>Pellikka</surname><given-name>Patricia A.</given-name><initials>P.A.</initials><afid>60005558</afid></author><authkeywords>Cardiac magnetic resonance imaging | Coronary computed tomography angiography | Dobutamine echocardiography | Exercise echocardiography | Myocardial perfusion imaging | Positron emission tomography | Single-photon emission computed tomography | Stress testing</authkeywords><intid>535814035</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925642518"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925642518?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925642518&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925642518&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0959437X15000209"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925642518</prism:url><dc:identifier>SCOPUS_ID:84925642518</dc:identifier><eid>2-s2.0-84925642518</eid><dc:title>Regulation and evolution of cardiopharyngeal cell identity and behavior: Insights from simple chordates</dc:title><dc:creator>Kaplan N.</dc:creator><prism:publicationName>Current Opinion in Genetics and Development</prism:publicationName><prism:issn>0959437X</prism:issn><prism:eIssn>18790380</prism:eIssn><prism:volume>32</prism:volume><prism:pageRange>119-128</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.gde.2015.02.008</prism:doi><pii>S0959437X15000209</pii><dc:description>© 2015 Elsevier Ltd. The vertebrate heart arises from distinct first and second heart fields. The latter also share a common origin with branchiomeric muscles in the pharyngeal mesoderm and transcription regulators, such as Nkx2-5, Tbx1 and Islet1. Despite significant progress, the complexity of vertebrate embryos has hindered the identification of multipotent cardiopharyngeal progenitors. Here, we summarize recent insights in cardiopharyngeal development gained from ascidian models, among the closest relatives to vertebrates. In a simplified cellular context, progressive fate specification of the ascidian cardiopharyngeal precursors presents striking similarities with their vertebrate counterparts. Multipotent cardiopharyngeal progenitors are primed to activate both the early cardiac and pharyngeal muscles programs, which segregate following asymmetric cells divisions as a result of regulatory cross-antagonisms involving Tbx1 and Nkx2-5 homologs. Activation of Ebf in pharyngeal muscle founder cells triggers both Myogenic Regulatory Factor-associated differentiation and Notch-mediated maintenance of an undifferentiated state in distinct precursors. Cross-species comparisons revealed the deep conservation of the cardiopharyngeal developmental sequence in spite of extreme genome sequence divergence, gene network rewiring and specific morphogenetic differences. Finally, analyses are beginning to uncover the influence of surrounding tissues in determining cardiopharyngeal cell identity and behavior. Thus, ascidian embryos offer a unique opportunity to study gene regulation and cell behaviors at the cellular level throughout cardiopharyngeal morphogenesis and evolution.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021784</affiliation-url><afid>60021784</afid><affilname>New York University</affilname><name-variant>New York University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35230033200</author-url><authid>35230033200</authid><authname>Kaplan N.</authname><surname>Kaplan</surname><given-name>Nicole</given-name><initials>N.</initials><afid>60021784</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55228661100</author-url><authid>55228661100</authid><authname>Razy-Krajka F.</authname><surname>Razy-Krajka</surname><given-name>Florian</given-name><initials>F.</initials><afid>60021784</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506245571</author-url><authid>6506245571</authid><authname>Christiaen L.</authname><surname>Christiaen</surname><given-name>Lionel</given-name><initials>L.</initials><afid>60021784</afid></author><intid>1035324732</intid><source-id>22080</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923337303"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923337303?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923337303&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923337303&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0957417415000664"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923337303</prism:url><dc:identifier>SCOPUS_ID:84923337303</dc:identifier><eid>2-s2.0-84923337303</eid><dc:title>Application of empirical mode decomposition for analysis of normal and diabetic RR-interval signals</dc:title><dc:creator>Pachori R.</dc:creator><prism:publicationName>Expert Systems with Applications</prism:publicationName><prism:issn>09574174</prism:issn><prism:volume>42</prism:volume><prism:issueIdentifier>9</prism:issueIdentifier><prism:pageRange>4567-4581</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.eswa.2015.01.051</prism:doi><pii>S0957417415000664</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Large number of people are affected by Diabetes Mellitus (DM) which is difficult to cure due to its chronic nature and genetic link. The uncontrolled diabetes may lead to heart related problems. Therefore, the diagnosis and monitoring of diabetes is of great importance. The automatic detection of diabetes can be performed using RR-interval signals. The RR-interval signals are nonlinear and non-stationary in nature. Hence linear methods may not be able to capture the hidden information present in the signal. In this paper, a new nonlinear method based on empirical mode decomposition (EMD) is proposed to discriminate between diabetic and normal RR-interval signals. The mean frequency parameter using Fourier-Bessel series expansion (MFFB) and the two bandwidth parameters namely, amplitude modulation bandwidth (BAM) and frequency modulation bandwidth (BFM) extracted from the intrinsic mode functions (IMFs) obtained from the EMD of RR-interval signals are used to discriminate the two groups. Unique representations such as analytic signal representation (ASR) and second order difference plot (SODP) for IMFs of RR-interval signals are also proposed to differentiate the two groups. The area parameters are computed from ASR and SODP of IMFs of RR-interval signals. Area computed from these representation as area corresponding to the 95% central tendency measure (CTM) of ASR of IMFs (AASR) and 95% confidence ellipse area of SODP of IMF (ASODP) are also proposed to discriminate diabetic and normal RR-interval signals. Overall, five features are extracted from IMFs of RR-interval signals namely MFFB,BAM,BFM,AASR and ASODP. Kruskal-Wallis statistical test is used to measure the discrimination ability of the proposed features for detection of diabetic RR-interval signals. Results obtained from proposed methodology indicate that these features provide the statistically significant difference between diabetic and normal classes.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104350</affiliation-url><afid>60104350</afid><affilname>Indian Institute of Technology Indore</affilname><name-variant>Indian Institute of Technology Indore</name-variant><affiliation-city>Indore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012607</affiliation-url><afid>60012607</afid><affilname>Ngee Ann Polytechnic</affilname><name-variant>Ngee Ann Polytechnic</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14632337000</author-url><authid>14632337000</authid><authname>Pachori R.</authname><surname>Pachori</surname><given-name>Ram Bilas</given-name><initials>R.B.</initials><afid>60104350</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56527164400</author-url><authid>56527164400</authid><authname>Avinash P.</authname><surname>Avinash</surname><given-name>Pakala</given-name><initials>P.</initials><afid>60104350</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56527202500</author-url><authid>56527202500</authid><authname>Shashank K.</authname><surname>Shashank</surname><given-name>Kora</given-name><initials>K.</initials><afid>60104350</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7407245303</author-url><authid>7407245303</authid><authname>Sharma R.</authname><surname>Sharma</surname><given-name>Rajeev</given-name><initials>R.</initials><afid>60104350</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004510847</author-url><authid>7004510847</authid><authname>Acharya U.</authname><surname>Acharya</surname><given-name>U. Rajendra</given-name><initials>U.R.</initials><afid>60012607</afid></author><authkeywords>Diabetes | EMD | IMF | Nonlinear | RR signal</authkeywords><intid>1034956648</intid><source-id>24201</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926165839"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926165839?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926165839&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926165839&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091743515000845"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926165839</prism:url><dc:identifier>SCOPUS_ID:84926165839</dc:identifier><eid>2-s2.0-84926165839</eid><dc:title>Does marital status contribute to the explanation of the hypercholesterolemia paradox in relation to long term mortality in myocardial infarction? Findings from the MONICA/KORA Myocardial Infarction Registry</dc:title><dc:creator>Quinones P.</dc:creator><prism:publicationName>Preventive Medicine</prism:publicationName><prism:issn>00917435</prism:issn><prism:eIssn>10960260</prism:eIssn><prism:volume>75</prism:volume><prism:pageRange>25-31</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ypmed.2015.03.013</prism:doi><pii>S0091743515000845</pii><dc:description>© 2015 Elsevier Inc. Objective: A recent study found long-term mortality after first acute myocardial infarction (AMI) to be particularly reduced among married individuals with hypercholesterolemia. This study explores, whether statin treatments during the last week prior to AMI offer an explanation to this phenomenon. Methods: Data were retrieved 2000-2008 from the population-based KORA myocardial infarction registry, located in Bavaria, Germany. The sample included 3162 individuals, alive 28. days after first AMI, who received statins both in hospital and at discharge. Associations with long-term mortality were examined via multivariable Cox regression. Among patients with hypercholesterolemia, individuals with and without prior statin treatment were each tested against the reference group "neither (hypercholesterolemia nor statin)" and tested for interaction with "marital status". Results: Among patients with and without prior statins, hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.46-0.93 and HR 0.72, 95% CI 0.55-0.94, were observed, respectively. Mortality reductions diminished after introduction of the following interaction terms with marital status: HR 0.49, p 0.042 for patients with and HR 0.77, p 0.370, for patients without prior statins. Conclusions: Prior statin treatments appear to be an underlying factor for long-term mortality reduction in married AMI-survivors with hypercholesterolemia. Confirmation of our results in further studies is warranted.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024007</affiliation-url><afid>60024007</afid><affilname>Helmholtz Center Munich German Research Center for Environmental Health</affilname><affiliation-city>Neuherberg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003067</affiliation-url><afid>60003067</afid><affilname>Klinikum Augsburg</affilname><name-variant>Klinikum Augsburg</name-variant><affiliation-city>Augsburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003067</affiliation-url><afid>60003067</afid><affilname>Klinikum Augsburg</affilname><name-variant>Klinikum Augsburg</name-variant><affiliation-city>Augsburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113227579</affiliation-url><afid>113227579</afid><affilname>Hospital of Nördlingen</affilname><name-variant>Hospital of Nördlingen</name-variant><affiliation-city>Nordlingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56021078800</author-url><authid>56021078800</authid><authname>Quinones P.</authname><surname>Quinones</surname><given-name>Philip Andrew</given-name><initials>P.A.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56021078800</author-url><authid>56021078800</authid><authname>Quinones P.</authname><surname>Quinones</surname><given-name>Philip Andrew</given-name><initials>P.A.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643576100</author-url><authid>26643576100</authid><authname>Kirchberger I.</authname><surname>Kirchberger</surname><given-name>Inge</given-name><initials>I.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643576100</author-url><authid>26643576100</authid><authname>Kirchberger I.</authname><surname>Kirchberger</surname><given-name>Inge</given-name><initials>I.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602734606</author-url><authid>6602734606</authid><authname>Amann U.</authname><surname>Amann</surname><given-name>Ute</given-name><initials>U.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602734606</author-url><authid>6602734606</authid><authname>Amann U.</authname><surname>Amann</surname><given-name>Ute</given-name><initials>U.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701522355</author-url><authid>6701522355</authid><authname>Heier M.</authname><surname>Heier</surname><given-name>Margit</given-name><initials>M.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701522355</author-url><authid>6701522355</authid><authname>Heier M.</authname><surname>Heier</surname><given-name>Margit</given-name><initials>M.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8661143000</author-url><authid>8661143000</authid><authname>Kuch B.</authname><surname>Kuch</surname><given-name>Bernhard</given-name><initials>B.</initials><afid>60003067</afid><afid>113227579</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8661143000</author-url><authid>8661143000</authid><authname>Kuch B.</authname><surname>Kuch</surname><given-name>Bernhard</given-name><initials>B.</initials><afid>60003067</afid><afid>113227579</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005433999</author-url><authid>7005433999</authid><authname>von Scheidt W.</authname><surname>von Scheidt</surname><given-name>Wolfgang</given-name><initials>W.</initials><afid>60003067</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35242861500</author-url><authid>35242861500</authid><authname>Meisinger C.</authname><surname>Meisinger</surname><given-name>Christa</given-name><initials>C.</initials><afid>60024007</afid><afid>60003067</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35242861500</author-url><authid>35242861500</authid><authname>Meisinger C.</authname><surname>Meisinger</surname><given-name>Christa</given-name><initials>C.</initials><afid>60024007</afid><afid>60003067</afid></author><authkeywords>Epidemiology | Follow-up studies | Hypercholesterolemia | Marital status | Mortality | Myocardial infarction | Statin treatment</authkeywords><intid>535683080</intid><source-id>17665</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929963340"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929963340?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929963340&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929963340&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009912015000570"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929963340</prism:url><dc:identifier>SCOPUS_ID:84929963340</dc:identifier><eid>2-s2.0-84929963340</eid><dc:title>Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases</dc:title><dc:creator>Berezin A.</dc:creator><prism:publicationName>Clinical Biochemistry</prism:publicationName><prism:issn>00099120</prism:issn><prism:eIssn>18732933</prism:eIssn><prism:volume>48</prism:volume><prism:issueIdentifier>9</prism:issueIdentifier><prism:pageRange>562-568</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.clinbiochem.2015.02.003</prism:doi><pii>S0009912015000570</pii><dc:description>© 2015 The Canadian Society of Clinical Chemists. Endothelial-derived microparticles (EMPs) are a novel biological marker of endothelium injury and vasomotion disorders that are involved in pathogenesis of cardiovascular, metabolic, and inflammatory diseases. Circulating levels of EMPs are thought to reflect a balance between cell stimulation, proliferation, apoptosis, and cell death. Increased EMPs may be defined in several cardiovascular diseases, such as stable and unstable coronary artery disease, acute and chronic heart failure, hypertension, arrhythmias, thromboembolism, asymptomatic atherosclerosis as well as renal failure, metabolic disorders (including type two diabetes mellitus, abdominal obesity, metabolic syndrome, insulin resistance) and dyslipidemia. This review highlights the controversial opinions regarding impact of circulating EMPs in major cardiovascular and metabolic diseases and summarizes the perspective implementation of the EMPs in risk stratification models.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011630</affiliation-url><afid>60011630</afid><affilname>Zaporozhye State Medical University</affilname><name-variant>Zaporozhe State Medical University</name-variant><affiliation-city>Zaporizhia</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006234</affiliation-url><afid>60006234</afid><affilname>Victoria University Melbourne</affilname><name-variant>Victoria University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000050</affiliation-url><afid>60000050</afid><affilname>Royal College of Surgeons in Ireland</affilname><name-variant>Royal College of Surgeons</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021802</affiliation-url><afid>60021802</afid><affilname>University of Ljubljana Faculty of Medicine</affilname><name-variant>University of Ljubljana</name-variant><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068899</affiliation-url><afid>60068899</afid><affilname>St. Anne's University Hospital Brno</affilname><name-variant>St. Anne's University Hospital Brno</name-variant><affiliation-city>Brno</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56564942300</author-url><authid>56564942300</authid><authname>Berezin A.</authname><surname>Berezin</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60011630</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603539924</author-url><authid>6603539924</authid><authname>Zulli A.</authname><surname>Zulli</surname><given-name>Anthony</given-name><initials>A.</initials><afid>60006234</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56565082100</author-url><authid>56565082100</authid><authname>Kerrigan S.</authname><surname>Kerrigan</surname><given-name>Steve</given-name><initials>S.</initials><afid>60000050</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56494328800</author-url><authid>56494328800</authid><authname>Petrovic D.</authname><surname>Petrovic</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60021802</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35731716000</author-url><authid>35731716000</authid><authname>Kruzliak P.</authname><surname>Kruzliak</surname><given-name>Peter</given-name><initials>P.</initials><afid>60068899</afid></author><authkeywords>Cardiovascular diseases | Endothelial-derived microparticles | Metabolic diseases | Risk stratification</authkeywords><intid>36041519</intid><source-id>16954</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928618220"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928618220?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928618220&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928618220&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928618220</prism:url><dc:identifier>SCOPUS_ID:84928618220</dc:identifier><eid>2-s2.0-84928618220</eid><dc:title>Understanding Air Pollution and Cardiovascular Diseases: Is It Preventable?</dc:title><dc:creator>Morishita M.</dc:creator><prism:publicationName>Current Cardiovascular Risk Reports</prism:publicationName><prism:issn>19329520</prism:issn><prism:eIssn>19329563</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12170-015-0458-1</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Fine particulate matter (&lt;2.5 μm, PM&lt;inf&gt;2.5&lt;/inf&gt;) air pollution is a leading risk factor for morbidity and mortality worldwide. The largest portion of adverse health effects is from cardiovascular diseases. In North America, PM&lt;inf&gt;2.5&lt;/inf&gt; concentrations have shown a steady decline over the past several decades; however, the opposite trend has occurred throughout much of the developing world whereby daily concentrations commonly reach extraordinarily high levels. While air quality regulations can reduce air pollution at a societal level, what individuals can do to reduce their personal exposures remains an active field of investigation. Here, we review the emerging evidence that several interventions (e.g., air filters) and/or behavioral changes can lower PM pollution exposure and as such, may be capable of mitigating the ensuing adverse cardiovascular health consequences. Air pollution remains a worldwide epidemic and a multi-tiered prevention strategy is required in order to optimally protect global public health.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016660</affiliation-url><afid>60016660</afid><affilname>University of Michigan School of Public Health</affilname><name-variant>University of Michigan School of Public Health</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56608763800</author-url><authid>56608763800</authid><authname>Morishita M.</authname><surname>Morishita</surname><given-name>Masako</given-name><initials>M.</initials><afid>60016660</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56608609800</author-url><authid>56608609800</authid><authname>Thompson K.</authname><surname>Thompson</surname><given-name>Kathryn C.</given-name><initials>K.C.</initials><afid>60016660</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202129401</author-url><authid>7202129401</authid><authname>Brook R.</authname><surname>Brook</surname><given-name>Robert D.</given-name><initials>R.D.</initials><afid>60025778</afid></author><authkeywords>Air pollution | Cardiovascular disease risks | Interventions</authkeywords><intid>1035810383</intid><source-id>19500157062</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929081749"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929081749?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929081749&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929081749&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929081749</prism:url><dc:identifier>SCOPUS_ID:84929081749</dc:identifier><eid>2-s2.0-84929081749</eid><dc:title>Human Cardiac Function Simulator for the Optimal Design of a Novel Annuloplasty Ring with a Sub-valvular Element for Correction of Ischemic Mitral Regurgitation</dc:title><dc:creator>Baillargeon B.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>105-116</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-015-0216-z</prism:doi><dc:description>© 2015, The Author(s). Ischemic mitral regurgitation is associated with substantial risk of death. We sought to: (1) detail significant recent improvements to the Dassault Systèmes human cardiac function simulator (HCFS); (2) use the HCFS to simulate normal cardiac function as well as pathologic function in the setting of posterior left ventricular (LV) papillary muscle infarction; and (3) debut our novel device for correction of ischemic mitral regurgitation. We synthesized two recent studies of human myocardial mechanics. The first study presented the robust and integrative finite element HCFS. Its primary limitation was its poor diastolic performance with an LV ejection fraction below 20% caused by overly stiff ex vivo porcine tissue parameters. The second study derived improved diastolic myocardial material parameters using in vivo MRI data from five normal human subjects. We combined these models to simulate ischemic mitral regurgitation by computationally infarcting an LV region including the posterior papillary muscle. Contact between our novel device and the mitral valve apparatus was simulated using Dassault Systèmes SIMULIA software. Incorporating improved cardiac geometry and diastolic myocardial material properties in the HCFS resulted in a realistic LV ejection fraction of 55%. Simulating infarction of posterior papillary muscle caused regurgitant mitral valve mechanics. Implementation of our novel device corrected valve dysfunction. Improvements in the current study to the HCFS permit increasingly accurate study of myocardial mechanics. The first application of this simulator to abnormal human cardiac function suggests that our novel annuloplasty ring with a sub-valvular element will correct ischemic mitral regurgitation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115228569</affiliation-url><afid>115228569</afid><affilname>Dassault Systèmes Simulia Corporation</affilname><name-variant>Dassault Systèmes Simulia Corporation</name-variant><affiliation-city>Fremont</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024989</affiliation-url><afid>60024989</afid><affilname>Universidade de Brasilia</affilname><name-variant>University of Brasilia</name-variant><affiliation-city>Brasilia</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023691</affiliation-url><afid>60023691</afid><affilname>University of California, San Francisco</affilname><name-variant>University of California, San Francisco</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031707</affiliation-url><afid>60031707</afid><affilname>Michigan State University</affilname><name-variant>Michigan State University</name-variant><affiliation-city>East Lansing</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025858</affiliation-url><afid>60025858</afid><affilname>Eidgenossische Technische Hochschule Zurich</affilname><name-variant>ETH Zurich</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023691</affiliation-url><afid>60023691</afid><affilname>University of California, San Francisco</affilname><name-variant>University of California, San Francisco</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015941</affiliation-url><afid>60015941</afid><affilname>University of Kentucky</affilname><name-variant>University of Kentucky</name-variant><affiliation-city>Lexington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012708</affiliation-url><afid>60012708</afid><affilname>Stanford University</affilname><name-variant>Stanford University</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031970</affiliation-url><afid>60031970</afid><affilname>UCSF School of Medicine</affilname><name-variant>University of California School of Medicine</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8300165800</author-url><authid>8300165800</authid><authname>Baillargeon B.</authname><surname>Baillargeon</surname><given-name>Brian</given-name><initials>B.</initials><afid>115228569</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637861600</author-url><authid>56637861600</authid><authname>Costa I.</authname><surname>Costa</surname><given-name>Ivan</given-name><initials>I.</initials><afid>60024989</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:34872509200</author-url><authid>34872509200</authid><authname>Leach J.</authname><surname>Leach</surname><given-name>Joseph R.</given-name><initials>J.R.</initials><afid>60023691</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56637447700</author-url><authid>56637447700</authid><authname>Lee L.</authname><surname>Lee</surname><given-name>Lik Chuan</given-name><initials>L.C.</initials><afid>60031707</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24604950600</author-url><authid>24604950600</authid><authname>Genet M.</authname><surname>Genet</surname><given-name>Martin</given-name><initials>M.</initials><afid>60025858</afid><afid>60023691</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24604950600</author-url><authid>24604950600</authid><authname>Genet M.</authname><surname>Genet</surname><given-name>Martin</given-name><initials>M.</initials><afid>60025858</afid><afid>60023691</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56638020600</author-url><authid>56638020600</authid><authname>Toutain A.</authname><surname>Toutain</surname><given-name>Arnaud</given-name><initials>A.</initials><afid>60023691</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56638753200</author-url><authid>56638753200</authid><authname>Wenk J.</authname><surname>Wenk</surname><given-name>Jonathan F.</given-name><initials>J.F.</initials><afid>60015941</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36656450800</author-url><authid>36656450800</authid><authname>Rausch M.</authname><surname>Rausch</surname><given-name>Manuel K.</given-name><initials>M.K.</initials><afid>60012708</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6701680898</author-url><authid>6701680898</authid><authname>Rebelo N.</authname><surname>Rebelo</surname><given-name>Nuno</given-name><initials>N.</initials><afid>115228569</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:13410089900</author-url><authid>13410089900</authid><authname>Acevedo-Bolton G.</authname><surname>Acevedo-Bolton</surname><given-name>Gabriel</given-name><initials>G.</initials><afid>60023691</afid><afid>60023691</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:13410089900</author-url><authid>13410089900</authid><authname>Acevedo-Bolton G.</authname><surname>Acevedo-Bolton</surname><given-name>Gabriel</given-name><initials>G.</initials><afid>60023691</afid><afid>60023691</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7004398913</author-url><authid>7004398913</authid><authname>Kuhl E.</authname><surname>Kuhl</surname><given-name>Ellen</given-name><initials>E.</initials><afid>60012708</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7006313887</author-url><authid>7006313887</authid><authname>Navia J.</authname><surname>Navia</surname><given-name>Jose L.</given-name><initials>J.L.</initials><afid>60021160</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7004591594</author-url><authid>7004591594</authid><authname>Guccione J.</authname><surname>Guccione</surname><given-name>Julius M.</given-name><initials>J.M.</initials><afid>60023691</afid><afid>60031970</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7004591594</author-url><authid>7004591594</authid><authname>Guccione J.</authname><surname>Guccione</surname><given-name>Julius M.</given-name><initials>J.M.</initials><afid>60023691</afid><afid>60031970</afid></author><authkeywords>Finite element method | Ischemic mitral regurgitation | Mitral annuloplasty | Myocardial infarction | Realistic simulation | Ventricular function</authkeywords><intid>35900571</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928797676"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928797676?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928797676&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928797676&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928797676</prism:url><dc:identifier>SCOPUS_ID:84928797676</dc:identifier><eid>2-s2.0-84928797676</eid><dc:title>Advances in CMR of Post-ablation Atrial Injury</dc:title><dc:creator>Harrison J.</dc:creator><prism:publicationName>Current Cardiovascular Imaging Reports</prism:publicationName><prism:issn>19419066</prism:issn><prism:eIssn>19419074</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12410-015-9336-y</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Technical advancements in cardiac magnetic resonance (CMR) imaging over the past two decades have allowed clinically useful imaging of the thin atrial wall for the first time. During this period, there has been a parallel increase in the use of catheter ablation to treat atrial fibrillation (AF). These developments have led to new indications for and increasing use of CMR in the assessment of pre- and post-ablation atrial structure and function and their potential link to arrhythmia substrate. This review focuses on the role of CMR in the assessment of acute and chronic post-ablation atrial tissue characterisation and its potential use in the treatment of atrial arrhythmias.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011520</affiliation-url><afid>60011520</afid><affilname>King's College London</affilname><name-variant>King's College London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:27169867000</author-url><authid>27169867000</authid><authname>Harrison J.</authname><surname>Harrison</surname><given-name>James L.</given-name><initials>J.L.</initials><afid>60011520</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:10140078000</author-url><authid>10140078000</authid><authname>Whitaker J.</authname><surname>Whitaker</surname><given-name>John</given-name><initials>J.</initials><afid>60011520</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:10540462100</author-url><authid>10540462100</authid><authname>Chubb H.</authname><surname>Chubb</surname><given-name>Henry</given-name><initials>H.</initials><afid>60011520</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55520636500</author-url><authid>55520636500</authid><authname>Williams S.</authname><surname>Williams</surname><given-name>Steven E.</given-name><initials>S.E.</initials><afid>60011520</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401558602</author-url><authid>7401558602</authid><authname>Wright M.</authname><surname>Wright</surname><given-name>Matthew</given-name><initials>M.</initials><afid>60011520</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:13908270000</author-url><authid>13908270000</authid><authname>Razavi R.</authname><surname>Razavi</surname><given-name>Reza S.</given-name><initials>R.S.</initials><afid>60011520</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:12775028900</author-url><authid>12775028900</authid><authname>O’Neill M.</authname><surname>O’Neill</surname><given-name>Mark D.</given-name><initials>M.D.</initials><afid>60011520</afid></author><authkeywords>Ablation | Atrial fibrillation | Cardiac magnetic resonance</authkeywords><intid>535851595</intid><source-id>19600157307</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926455477"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926455477?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926455477&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926455477&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015001823"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926455477</prism:url><dc:identifier>SCOPUS_ID:84926455477</dc:identifier><eid>2-s2.0-84926455477</eid><dc:title>A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 danish individuals</dc:title><dc:creator>Krarup N.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>305-310</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.022</prism:doi><pii>S0021915015001823</pii><dc:description>© 2015 Elsevier Ireland Ltd. Background: In Europeans, 45 genetic risk variants for coronary artery disease (CAD) have been identified in genome-wide association studies. We constructed a genetic risk score (GRS) of these variants to estimate the effect on incidence and clinical predictability of myocardial infarction (MI) and CAD. Methods: Genotype was available from 6041 Danes. An unweighted GRS was constructed by making a summated score of the 45 known genetic CAD risk variants. Registries provided information (mean follow-up=11.6 years) on CAD (n=374) and MI (n=124) events. Cox proportional hazard estimates with age as time scale was adjusted for sex, BMI, type 2 diabetes mellitus and smoking status. Analyses were also stratified either by sex or median age (below or above 45 years of age). We estimated GRS contribution to MI prediction by assessing net reclassification index (NRI) and integrated discrimination improvement (IDI) added to the European SCORE for 10-year MI risk prediction. Results: The GRS associated significantly with risk of incident MI (allele-dependent hazard ratio (95%CI): 1.06 (1.02-1.11), p=0.01) but not with CAD (p=0.39). Stratification revealed association of GRS with MI in men (1.06 (1.01-1.12), p=0.02) and in individuals above the median of 45.11 years of age (1.06 (1.00-1.12), p=0.03). There was no interaction between GRS and gender (p=0.90) or age (p=0.83). The GRS improved neither NRI nor IDI. Conclusion: The GRS of 45 GWAS identified risk variants increase the risk of MI in a Danish cohort. The GRS did not improve NRI or IDI beyond the performance of conventional European SCORE risk factors.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004829</affiliation-url><afid>60004829</afid><affilname>Amtssygehuset i Glostrup</affilname><name-variant>Glostrup University Hospital</name-variant><affiliation-city>Glostrup</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022134</affiliation-url><afid>60022134</afid><affilname>Aalborg Universitet</affilname><name-variant>Aalborg University</name-variant><affiliation-city>Aalborg</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011350</affiliation-url><afid>60011350</afid><affilname>Faculty of Health Sciences, University of Southern Denmark</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25029730400</author-url><authid>25029730400</authid><authname>Krarup N.</authname><surname>Krarup</surname><given-name>N. T.</given-name><initials>N.T.</initials><afid>60030840</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36155272000</author-url><authid>36155272000</authid><authname>Borglykke A.</authname><surname>Borglykke</surname><given-name>A.</given-name><initials>A.</initials><afid>60004829</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24777951500</author-url><authid>24777951500</authid><authname>Allin K.</authname><surname>Allin</surname><given-name>K. H.</given-name><initials>K.H.</initials><afid>60030840</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36146192100</author-url><authid>36146192100</authid><authname>Sandholt C.</authname><surname>Sandholt</surname><given-name>C. H.</given-name><initials>C.H.</initials><afid>60030840</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36801720500</author-url><authid>36801720500</authid><authname>Justesen J.</authname><surname>Justesen</surname><given-name>J. M.</given-name><initials>J.M.</initials><afid>60030840</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23033268200</author-url><authid>23033268200</authid><authname>Andersson E.</authname><surname>Andersson</surname><given-name>E. A.</given-name><initials>E.A.</initials><afid>60030840</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15759864800</author-url><authid>15759864800</authid><authname>Grarup N.</authname><surname>Grarup</surname><given-name>N.</given-name><initials>N.</initials><afid>60030840</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55503137200</author-url><authid>55503137200</authid><authname>Jørgensen T.</authname><surname>Jørgensen</surname><given-name>T.</given-name><initials>T.</initials><afid>60004829</afid><afid>60030840</afid><afid>60022134</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55503137200</author-url><authid>55503137200</authid><authname>Jørgensen T.</authname><surname>Jørgensen</surname><given-name>T.</given-name><initials>T.</initials><afid>60004829</afid><afid>60030840</afid><afid>60022134</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55503137200</author-url><authid>55503137200</authid><authname>Jørgensen T.</authname><surname>Jørgensen</surname><given-name>T.</given-name><initials>T.</initials><afid>60004829</afid><afid>60030840</afid><afid>60022134</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55800246900</author-url><authid>55800246900</authid><authname>Pedersen O.</authname><surname>Pedersen</surname><given-name>O.</given-name><initials>O.</initials><afid>60030840</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56016225800</author-url><authid>56016225800</authid><authname>Hansen T.</authname><surname>Hansen</surname><given-name>T.</given-name><initials>T.</initials><afid>60030840</afid><afid>60011350</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56016225800</author-url><authid>56016225800</authid><authname>Hansen T.</authname><surname>Hansen</surname><given-name>T.</given-name><initials>T.</initials><afid>60030840</afid><afid>60011350</afid></author><authkeywords>Coronary artery disease | Genetic risk score | Myocardial infarction | Single-nucleotide polymorphism</authkeywords><intid>1035449985</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929074912"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929074912?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929074912&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929074912&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929074912</prism:url><dc:identifier>SCOPUS_ID:84929074912</dc:identifier><eid>2-s2.0-84929074912</eid><dc:title>Asymptotic Model of Fluid–Tissue Interaction for Mitral Valve Dynamics</dc:title><dc:creator>Domenichini F.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>95-104</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-014-0201-y</prism:doi><dc:description>© 2014, Biomedical Engineering Society. The vortex formation process inside the left ventricle is intrinsically connected to the dynamics of the mitral leaflets while they interact with the flow crossing the valve during diastole. The description of the dynamics of a natural mitral valve still represents a challenging issue, especially because its material properties are not measurable in vivo. Medical imaging can provide some indications about the geometry of the valve, but not about its mechanical properties. In this work, we introduce a parametric model of the mitral valve geometry, whose motion is described in the asymptotic limit under the assumption that it moves with the flow, without any additional resistance other than that given by its shape, and without the need to specify its material properties. The mitral valve model is coupled with a simple description of the left ventricle geometry, and their dynamics is solved numerically together with the equations ruling the blood flow. The intra-ventricular flow is analyzed in its relationship with the valvular motion. It is found that the initial valve opening anticipates the peak velocity of the Early filling wave with little influence of the specific geometry; while subsequent closure and re-opening are more dependent on the intraventricular vortex dynamics and thus on the leaflets’ geometry itself. The limitations and potential applications of the proposed model are discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021859</affiliation-url><afid>60021859</afid><affilname>Universita degli Studi di Firenze</affilname><name-variant>Università di Firenze</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018363</affiliation-url><afid>60018363</afid><affilname>Universita degli Studi di Trieste</affilname><name-variant>Università di Trieste</name-variant><affiliation-city>Trieste</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602088384</author-url><authid>6602088384</authid><authname>Domenichini F.</authname><surname>Domenichini</surname><given-name>Federico</given-name><initials>F.</initials><afid>60021859</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003630390</author-url><authid>7003630390</authid><authname>Pedrizzetti G.</authname><surname>Pedrizzetti</surname><given-name>Gianni</given-name><initials>G.</initials><afid>60018363</afid></author><authkeywords>Cardiovascular fluid dynamics | Left ventricle | Mitral valve | Vortex formation</authkeywords><intid>535903353</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928591699"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928591699?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928591699&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928591699&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928591699</prism:url><dc:identifier>SCOPUS_ID:84928591699</dc:identifier><eid>2-s2.0-84928591699</eid><dc:title>Achieving Safe Femoral Arterial Access</dc:title><dc:creator>Lee M.</dc:creator><prism:publicationName>Current Cardiology Reports</prism:publicationName><prism:issn>15233782</prism:issn><prism:eIssn>15343170</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11886-015-0596-6</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Percutaneous coronary intervention can lead to vascular access complications that prolong patient hospital stay and costs as well as increase patient morbidity and mortality. Given its ease of use and familiarity, transfemoral access is still the preferred method of approach by many operators. The transfemoral approach is used when large bore access is required or if transradial access is not feasible due to variations in the anatomy of the upper extremity artery. The use of fluoroscopy, ultrasonography, and femoral angiography can help the operator obtain proper arteriotomy of the common femoral artery. Measures to decrease vascular access complications include proper technique, optimal pharmacotherapy, and avoiding the use of arterial sheaths &gt;6 Fr. Optimal pharmacotherapy includes the use of bivalirudin and weight-based unfractionated heparin to avoid supratherapeutic activated clotting times, and to avoid glycoprotein IIb/IIIa inhibitors. When used appropriately, vascular closure devices can decrease the risk of bleeding complications. Randomized trials are needed to confirm these recommendations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032023</affiliation-url><afid>60032023</afid><affilname>UCLA Medical Center</affilname><name-variant>UCLA Medical Center</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55547117617</author-url><authid>55547117617</authid><authname>Lee M.</authname><surname>Lee</surname><given-name>Michael S.</given-name><initials>M.S.</initials><afid>60032023</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56608597800</author-url><authid>56608597800</authid><authname>Kong J.</authname><surname>Kong</surname><given-name>Jeremy</given-name><initials>J.</initials><afid>60032023</afid></author><authkeywords>Bleeding | Vascular access | Vascular complications</authkeywords><intid>1785814753</intid><source-id>23118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927537766"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927537766?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927537766&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927537766&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002245"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927537766</prism:url><dc:identifier>SCOPUS_ID:84927537766</dc:identifier><eid>2-s2.0-84927537766</eid><dc:title>How to save six million people per year</dc:title><dc:creator>Agewall S.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>387-388</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.006</prism:doi><pii>S0021915015002245</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068729</affiliation-url><afid>60068729</afid><affilname>Ulleval University Hospital</affilname><name-variant>Ullevaal University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>no</subtype><subtypeDescription>Note</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006435302</author-url><authid>7006435302</authid><authname>Agewall S.</authname><surname>Agewall</surname><given-name>S.</given-name><initials>S.</initials><afid>60068729</afid></author><authkeywords>Cardiovascular risk score | Risk factors | Sick leave | Smoking</authkeywords><intid>1785634467</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930003888"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930003888?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930003888&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930003888&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930003888</prism:url><dc:identifier>SCOPUS_ID:84930003888</dc:identifier><eid>2-s2.0-84930003888</eid><dc:title>Sepsis in the Severely Immunocompromised Patient</dc:title><dc:creator>Kalil A.</dc:creator><prism:publicationName>Current Infectious Disease Reports</prism:publicationName><prism:issn>15233847</prism:issn><prism:eIssn>15343146</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11908-015-0487-4</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. The prevention and treatment of sepsis in the immunocompromised host present a challenging array of diagnostic and management issues. The neutropenic patient has a primary defect in innate immune responses and is susceptible to conventional and opportunistic pathogens. The solid organ transplant patient has a primary defect in adaptive immunity and is susceptible to a myriad of pathogens that require an effective cellular immune response. Risk for infections in organ transplant recipients is further complicated by mechanical, vascular, and rejection of the transplanted organ itself. The immune suppressed state can modify the cardinal signs of inflammation, making accurate and rapid diagnosis of infection and sepsis difficult. Empiric antimicrobial agents can be lifesaving in these patients, but managing therapy in an era of progressive antibiotic resistance has become a real issue. This review discusses the challenges faced when treating severe infections in these high-risk patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016261</affiliation-url><afid>60016261</afid><affilname>University of Nebraska Medical Center</affilname><name-variant>University of Nebraska Medical Center</name-variant><affiliation-city>Omaha</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011460</affiliation-url><afid>60011460</afid><affilname>Brown University</affilname><name-variant>Brown University</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004226167</author-url><authid>7004226167</authid><authname>Kalil A.</authname><surname>Kalil</surname><given-name>Andre C.</given-name><initials>A.C.</initials><afid>60016261</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7401979686</author-url><authid>7401979686</authid><authname>Opal S.</authname><surname>Opal</surname><given-name>Steven M.</given-name><initials>S.M.</initials><afid>60011460</afid></author><authkeywords>Immunocompromised host | Neutropenia | Neutropenic fever | Sepsis | Septic shock | Solid organ transplant infections</authkeywords><intid>1036044965</intid><source-id>20760</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928485461"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928485461?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928485461&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928485461&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0005272815000638"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928485461</prism:url><dc:identifier>SCOPUS_ID:84928485461</dc:identifier><eid>2-s2.0-84928485461</eid><dc:title>Computational modeling analysis of mitochondrial superoxide production under varying substrate conditions and upon inhibition of different segments of the electron transport chain</dc:title><dc:creator>Markevich N.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Bioenergetics</prism:publicationName><prism:issn>00052728</prism:issn><prism:eIssn>18792650</prism:eIssn><prism:volume>1847</prism:volume><prism:issueIdentifier>6-7</prism:issueIdentifier><prism:pageRange>656-679</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbabio.2015.04.005</prism:doi><pii>S0005272815000638</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. A computational mechanistic model of superoxide (O&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;•-&lt;/sup&gt;) formation in the mitochondrial electron transport chain (ETC) was developed to facilitate the quantitative analysis of factors controlling mitochondrial O&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;•-&lt;/sup&gt; production and assist in the interpretation of experimental studies. The model takes into account all individual electron transfer reactions in Complexes I and III. The model accounts for multiple, often seemingly contradictory observations on the effects of ΔΨ and ΔpH, and for the effects of multiple substrate and inhibitor conditions, including differential effects of Complex III inhibitors antimycin A, myxothiazol and stigmatellin. Simulation results confirm that, in addition to O&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;•-&lt;/sup&gt; formation in Complex III and at the flavin site of Complex I, the quinone binding site of Complex I is an additional superoxide generating site that accounts for experimental observations on O&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;•-&lt;/sup&gt; production during reverse electron transfer. However, our simulation results predict that, when cytochrome c oxidase is inhibited during oxidation of succinate, ROS production at this site is eliminated and almost all superoxide in Complex I is generated by reduced FMN, even when the redox pressure for reverse electron transfer from succinate is strong. In addition, the model indicates that conflicting literature data on the kinetics of electron transfer in Complex III involving the iron-sulfur protein-cytochrome bL complex can be resolved in favor of a dissociation of the protein only after electron transfer to cytochrome bH. The model predictions can be helpful in understanding factors driving mitochondrial superoxide formation in intact cells and tissues.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015277</affiliation-url><afid>60015277</afid><affilname>Thomas Jefferson University</affilname><name-variant>Thomas Jefferson University</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021331</affiliation-url><afid>60021331</afid><affilname>Russian Academy of Sciences</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003514357</author-url><authid>7003514357</authid><authname>Markevich N.</authname><surname>Markevich</surname><given-name>Nikolai I.</given-name><initials>N.I.</initials><afid>60015277</afid><afid>60021331</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003514357</author-url><authid>7003514357</authid><authname>Markevich N.</authname><surname>Markevich</surname><given-name>Nikolai I.</given-name><initials>N.I.</initials><afid>60015277</afid><afid>60021331</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35876499300</author-url><authid>35876499300</authid><authname>Hoek J.</authname><surname>Hoek</surname><given-name>Jan B.</given-name><initials>J.B.</initials><afid>60015277</afid></author><authkeywords>Computational model | Inhibitory analysis | Membrane potential | Respiratory chain | Semiquinone | Superoxide</authkeywords><intid>535794254</intid><source-id>16791</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929224425"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929224425?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929224425&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929224425&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929224425</prism:url><dc:identifier>SCOPUS_ID:84929224425</dc:identifier><eid>2-s2.0-84929224425</eid><dc:title>Short-term variability in QT interval and ventricular arrhythmias induced by dofetilide are dependent on high-frequency autonomic oscillations</dc:title><dc:creator>Champeroux P.</dc:creator><prism:publicationName>British Journal of Pharmacology</prism:publicationName><prism:issn>00071188</prism:issn><prism:eIssn>14765381</prism:eIssn><prism:volume>172</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:pageRange>2878-2891</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bph.13093</prism:doi><dc:description>© 2015 The British Pharmacological Society. Background and Purpose The present study was undertaken to investigate an effect of dofetilide, a potent arrhythmic blocker of the voltage-gated K&lt;sup&gt;+&lt;/sup&gt; channel, hERG, on cardiac autonomic control. Combined with effects on ardiomyocytes, these properties could influence its arrhythmic potency. Experimental Approach The short-term variability of beat-to-beat QT interval (STV&lt;inf&gt;QT&lt;/inf&gt;), induced by dofetilide is a strong surrogate of Torsades de pointes liability. Involvement of autonomic modulation in STV&lt;inf&gt;QT&lt;/inf&gt; was investigated in healthy cynomolgus monkeys and beagle dogs by power spectral analysis under conditions of autonomic blockade with hexamethonium. Key Results Increase in STV&lt;inf&gt;QT&lt;/inf&gt; induced by dofetilide in monkeys and dogs was closely associated with an enhancement of endogenous heart rate and QT interval high-frequency (HF) oscillations. These effects were fully suppressed under conditions of autonomic blockade with hexamethonium. Ventricular arrhythmias, including Torsades de pointes in monkeys, were prevented in both species when HF oscillations were suppressed by autonomic blockade. Similar enhancements of heart rate HF oscillations were found in dogs with other hERG blockers described as causing Torsades de pointes in humans. Conclusions and Implications These results demonstrate for the first time that beat-to-beat ventricular repolarization variability and ventricular arrhythmias induced by dofetilide are dependent on endogenous HF autonomic oscillations in heart rate. When combined with evidence of hERG-blocking properties, enhancement of endogenous HF oscillations in heart rate could constitute an earlier and more sensitive biomarker than STV&lt;inf&gt;QT&lt;/inf&gt; for Torsades de pointes liability, applicable to preclinical regulatory studies conducted in healthy animals.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100432918</affiliation-url><afid>100432918</afid><affilname>CERB</affilname><name-variant>CERB</name-variant><affiliation-city>Baugy</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000905</affiliation-url><afid>60000905</afid><affilname>Inserm</affilname><name-variant>INSERM</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601943621</author-url><authid>6601943621</authid><authname>Champeroux P.</authname><surname>Champeroux</surname><given-name>P.</given-name><initials>P.</initials><afid>100432918</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23096044600</author-url><authid>23096044600</authid><authname>Thireau J.</authname><surname>Thireau</surname><given-name>J.</given-name><initials>J.</initials><afid>100432918</afid><afid>60000905</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23096044600</author-url><authid>23096044600</authid><authname>Thireau J.</authname><surname>Thireau</surname><given-name>J.</given-name><initials>J.</initials><afid>100432918</afid><afid>60000905</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:9640081200</author-url><authid>9640081200</authid><authname>Judé S.</authname><surname>Judé</surname><given-name>S.</given-name><initials>S.</initials><afid>100432918</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56641705100</author-url><authid>56641705100</authid><authname>Laigot-Barbé C.</authname><surname>Laigot-Barbé</surname><given-name>C.</given-name><initials>C.</initials><afid>100432918</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36926890400</author-url><authid>36926890400</authid><authname>Maurin A.</authname><surname>Maurin</surname><given-name>A.</given-name><initials>A.</initials><afid>100432918</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:25960396400</author-url><authid>25960396400</authid><authname>Sola M.</authname><surname>Sola</surname><given-name>M. L.</given-name><initials>M.L.</initials><afid>100432918</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7402370797</author-url><authid>7402370797</authid><authname>Fowler J.</authname><surname>Fowler</surname><given-name>J. S L</given-name><initials>J.S.L.</initials><afid>100432918</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102035558</author-url><authid>7102035558</authid><authname>Richard S.</authname><surname>Richard</surname><given-name>S.</given-name><initials>S.</initials><afid>100432918</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004522046</author-url><authid>7004522046</authid><authname>Le Guennec J.</authname><surname>Le Guennec</surname><given-name>J. Y.</given-name><initials>J.Y.</initials><afid>100432918</afid><afid>60000905</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004522046</author-url><authid>7004522046</authid><authname>Le Guennec J.</authname><surname>Le Guennec</surname><given-name>J. Y.</given-name><initials>J.Y.</initials><afid>100432918</afid><afid>60000905</afid></author><intid>35917947</intid><source-id>20084</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929208385"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929208385?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929208385&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929208385&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929208385</prism:url><dc:identifier>SCOPUS_ID:84929208385</dc:identifier><eid>2-s2.0-84929208385</eid><dc:title>The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1</dc:title><dc:creator>Feng X.</dc:creator><prism:publicationName>British Journal of Pharmacology</prism:publicationName><prism:issn>00071188</prism:issn><prism:eIssn>14765381</prism:eIssn><prism:volume>172</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:pageRange>2852-2863</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bph.13091</prism:doi><dc:description>© 2015 The British Pharmacological Society. Background and Purpose The orphan nuclear receptor NOR1 belongs to the NR4A subfamily of the nuclear hormone receptor superfamily, and is involved in glucose and fat metabolism. However, its potential contribution to cardiovascular diseases remains to be assessed. Here, the roles of NOR1 in cardiac hypertrophy induced by isoprenaline and the underlying molecular mechanisms were investigated. Experimental Approach NOR1 was expressed in cardiomyocytes treated with isoprenaline. After NOR1 overexpression or knockdown in neonatal rat cardiomyocytes, cellular hypertrophy was monitored by measuring cell surface area and the mRNA of hypertrophic biomarkers. Interactions between NOR1 and PARP-1 were investigated by co-immunoprecipitation. NOR1 expression and PARP-1 activity were measured in rats with cardiac hypertrophy induced by isoprenaline. Key Results Treatment with isoprenaline significantly up-regulated NOR1 expression and PARP-1 activity both in vivo and in vitro. Specific gene silencing of NOR1 attenuated isoprenaline-induced cardiomyocyte hypertrophy, whereas NOR1 overexpression exacerbated cardiac hypertrophy. We identified a physical interaction between NOR1 and PARP-1, which was enhanced by NOR1 transfection and thereby led to PARP-1 activation. Overexpression of NOR1, but not C293Y, a NOR1 mutant lacking the PARP-1 binding activity, increased cellular surface area and the mRNA levels of atrial natriuretic factor and brain natriuretic polypeptide, effects blocked by the PARP-1 inhibitor 3-aminobenzamide or siRNA for PARP-1. Conclusions and Implications This is the first evidence that NOR1 was involved in isoprenaline-induced cardiac hypertrophy. The pro-hypertrophic effect of NOR1 can be partly attributed to its regulation of PARP-1 enzymic activity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021182</affiliation-url><afid>60021182</afid><affilname>Sun Yat-Sen University</affilname><name-variant>Sun Yat-Sen University</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033142</affiliation-url><afid>60033142</afid><affilname>Jishou University</affilname><name-variant>Jishou University</name-variant><affiliation-city>Jishou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112630784</affiliation-url><afid>112630784</afid><affilname>Chengdu Fifth People's Hospital</affilname><name-variant>Chengdu Fifth People's Hospital</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:44061128800</author-url><authid>44061128800</authid><authname>Feng X.</authname><surname>Feng</surname><given-name>Xiao Jun</given-name><initials>X.J.</initials><afid>60021182</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37029493300</author-url><authid>37029493300</authid><authname>Gao H.</authname><surname>Gao</surname><given-name>Hui</given-name><initials>H.</initials><afid>60021182</afid><afid>60033142</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37029493300</author-url><authid>37029493300</authid><authname>Gao H.</authname><surname>Gao</surname><given-name>Hui</given-name><initials>H.</initials><afid>60021182</afid><afid>60033142</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36970471400</author-url><authid>36970471400</authid><authname>Gao S.</authname><surname>Gao</surname><given-name>Si</given-name><initials>S.</initials><afid>60021182</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56016187100</author-url><authid>56016187100</authid><authname>Li Z.</authname><surname>Li</surname><given-name>Zhuoming</given-name><initials>Z.</initials><afid>60021182</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26643344800</author-url><authid>26643344800</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hong</given-name><initials>H.</initials><afid>60021182</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7601564090</author-url><authid>7601564090</authid><authname>Lu J.</authname><surname>Lu</surname><given-name>Jing</given-name><initials>J.</initials><afid>60021182</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56024427600</author-url><authid>56024427600</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jiao Jiao</given-name><initials>J.J.</initials><afid>60021182</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56651170700</author-url><authid>56651170700</authid><authname>Huang X.</authname><surname>Huang</surname><given-name>Xiao Yang</given-name><initials>X.Y.</initials><afid>60021182</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:36014577200</author-url><authid>36014577200</authid><authname>Liu M.</authname><surname>Liu</surname><given-name>Min</given-name><initials>M.</initials><afid>60021182</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7401551804</author-url><authid>7401551804</authid><authname>Zou J.</authname><surname>Zou</surname><given-name>Jian</given-name><initials>J.</initials><afid>112630784</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7403237664</author-url><authid>7403237664</authid><authname>Ye J.</authname><surname>Ye</surname><given-name>Jian Tao</given-name><initials>J.T.</initials><afid>60021182</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55510070300</author-url><authid>55510070300</authid><authname>Liu P.</authname><surname>Liu</surname><given-name>Pei Qing</given-name><initials>P.Q.</initials><afid>60021182</afid></author><intid>1035912067</intid><source-id>20084</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926452273"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926452273?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926452273&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926452273&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0891584915000763"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926452273</prism:url><dc:identifier>SCOPUS_ID:84926452273</dc:identifier><eid>2-s2.0-84926452273</eid><dc:title>A novel function of nuclear nonmuscle myosin regulatory light chain in promotion of xanthine oxidase transcription after myocardial ischemia/reperfusion</dc:title><dc:creator>Zhang Y.</dc:creator><prism:publicationName>Free Radical Biology and Medicine</prism:publicationName><prism:issn>08915849</prism:issn><prism:eIssn>18734596</prism:eIssn><prism:volume>83</prism:volume><prism:pageRange>115-128</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.freeradbiomed.2015.02.013</prism:doi><pii>S0891584915000763</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Nuclear myosin regulates gene transcription and this novel function might be modulated through phosphorylation of the myosin regulatory light chain (p-MLC&lt;inf&gt;20&lt;/inf&gt;). Nonmuscle MLC&lt;inf&gt;20&lt;/inf&gt; (nmMLC&lt;inf&gt;20&lt;/inf&gt;) is also present in the nuclei of cardiomyocytes and a potential nmMLC&lt;inf&gt;20&lt;/inf&gt; binding sequence has been identified in the promoter of the xanthine oxidase (XO) gene. Thus, we investigated its function in the regulation of XO transcription after myocardial ischemia/reperfusion (IR). In a rat model of myocardial IR and a cardiomyocyte model of hypoxia/reoxygenation (HR) injury, the cardiac or cell injury, myosin light chain kinase (MLCK) content, XO expression and activity, XO-derived products, and level of nuclear p-nmMLC&lt;inf&gt;20&lt;/inf&gt; were detected. Coimmunoprecipitation (co-IP), chromatin immunoprecipitation, DNA pull-down, and luciferase reporter gene assays were used to decipher the molecular mechanisms through which nmMLC&lt;inf&gt;20&lt;/inf&gt; promotes XO expression. IR or HR treatment dramatically elevated nuclear p-nmMLC&lt;inf&gt;20&lt;/inf&gt; level, accompanied by increased XO expression, activity, and products (H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; and uric acid), as well as the IR or HR injury; these effects were ameliorated by inhibition of MLCK or knockdown of nmMLC&lt;inf&gt;20&lt;/inf&gt;. Our findings from these experiments demonstrated that nuclear p-nmMLC&lt;inf&gt;20&lt;/inf&gt; binds to the consensus sequence GTCGCC in the XO gene promoter, interacts with RNA polymerase II and transcription factor IIB to form a transcription preinitiation complex, and hence activates XO gene transcription. These results suggest that nuclear p-nmMLC&lt;inf&gt;20&lt;/inf&gt; plays an important role in IR/HR injury by transcriptionally upregulating XO gene expression to increase oxidative stress in myocardium. Our findings demonstrate nuclear nmMLC&lt;inf&gt;20&lt;/inf&gt; as a potential new therapeutic target to combat cardiac IR injury.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017060</affiliation-url><afid>60017060</afid><affilname>Central South University China</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017060</affiliation-url><afid>60017060</afid><affilname>Central South University China</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082821</affiliation-url><afid>60082821</afid><affilname>Xiangya Hospital of Central-south University</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56584127200</author-url><authid>56584127200</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yi Shuai</given-name><initials>Y.S.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56584127200</author-url><authid>56584127200</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yi Shuai</given-name><initials>Y.S.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56437806200</author-url><authid>56437806200</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Bin</given-name><initials>B.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56437806200</author-url><authid>56437806200</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Bin</given-name><initials>B.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56437820600</author-url><authid>56437820600</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xiu Ju</given-name><initials>X.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56437820600</author-url><authid>56437820600</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xiu Ju</given-name><initials>X.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56021338100</author-url><authid>56021338100</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jie Jie</given-name><initials>J.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56021338100</author-url><authid>56021338100</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jie Jie</given-name><initials>J.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56583079700</author-url><authid>56583079700</authid><authname>Li N.</authname><surname>Li</surname><given-name>Nian Sheng</given-name><initials>N.S.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56583079700</author-url><authid>56583079700</authid><authname>Li N.</authname><surname>Li</surname><given-name>Nian Sheng</given-name><initials>N.S.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7402815903</author-url><authid>7402815903</authid><authname>Ma Q.</authname><surname>Ma</surname><given-name>Qi Lin</given-name><initials>Q.L.</initials><afid>60082821</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56216250400</author-url><authid>56216250400</authid><authname>Jiang J.</authname><surname>Jiang</surname><given-name>Jun Lin</given-name><initials>J.L.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56216250400</author-url><authid>56216250400</authid><authname>Jiang J.</authname><surname>Jiang</surname><given-name>Jun Lin</given-name><initials>J.L.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56048894100</author-url><authid>56048894100</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yuan Jian</given-name><initials>Y.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56048894100</author-url><authid>56048894100</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yuan Jian</given-name><initials>Y.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7405861379</author-url><authid>7405861379</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qingjie</given-name><initials>Q.</initials><afid>60014569</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7401958753</author-url><authid>7401958753</authid><authname>Peng J.</authname><surname>Peng</surname><given-name>Jun</given-name><initials>J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7401958753</author-url><authid>7401958753</authid><authname>Peng J.</authname><surname>Peng</surname><given-name>Jun</given-name><initials>J.</initials><afid>60017060</afid><afid>60017060</afid></author><authkeywords>Free radicals | Ischemia | Nonmuscle myosin regulatory light chain | Reperfusion | Transcription | Xanthine oxidase</authkeywords><intid>2035449495</intid><source-id>15095</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359225"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359225?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359225&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359225&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359225</prism:url><dc:identifier>SCOPUS_ID:84929359225</dc:identifier><eid>2-s2.0-84929359225</eid><dc:title>Applied apical torsion for cardiac assist: Design considerations and prototype development</dc:title><dc:creator>Trumble D.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030135</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027950</affiliation-url><afid>60027950</afid><affilname>Carnegie Mellon University</affilname><name-variant>Carnegie-Mellon University</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115242784</affiliation-url><afid>115242784</afid><affilname>Left Field Cardiac, Inc</affilname><name-variant>Left Field Cardiac, Inc</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107874038</affiliation-url><afid>107874038</afid><affilname>Insilicomed, Inc</affilname><name-variant>Insilicomed, Inc</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003677693</author-url><authid>7003677693</authid><authname>Trumble D.</authname><surname>Trumble</surname><given-name>Dennis R.</given-name><initials>D.R.</initials><afid>60027950</afid><afid>115242784</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003677693</author-url><authid>7003677693</authid><authname>Trumble D.</authname><surname>Trumble</surname><given-name>Dennis R.</given-name><initials>D.R.</initials><afid>60027950</afid><afid>115242784</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644781400</author-url><authid>56644781400</authid><authname>Soohoo E.</authname><surname>Soohoo</surname><given-name>Elaine</given-name><initials>E.</initials><afid>60027950</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701688200</author-url><authid>6701688200</authid><authname>Waldman L.</authname><surname>Waldman</surname><given-name>Lewis K.</given-name><initials>L.K.</initials><afid>107874038</afid></author><intid>2035939711</intid><article-number>020923</article-number><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928684118"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928684118?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928684118&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928684118&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015010187"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928684118</prism:url><dc:identifier>SCOPUS_ID:84928684118</dc:identifier><eid>2-s2.0-84928684118</eid><dc:title>Anxiety and depressive symptoms are associated with higher carotid intima-media thickness. Cross-sectional analysis from ELSA-Brasil baseline data</dc:title><dc:creator>Santos I.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>529-534</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.800</prism:doi><pii>S0021915015010187</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. Background: Studies focusing on the association between anxiety/depressive symptoms and accelerated subclinical atherosclerosis have yielded mixed results. Our aim is to examine associations between anxiety/depressive symptoms, common mental disorder (CMD), major depression disorder (MDD) or generalized anxiety disorder (GAD) and carotid intima-media thickness (CIMT) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort baseline. Methods: The ELSA-Brasil baseline assessment included CIMT measurements and the Clinical Interview Schedule - Revised (CIS-R), a validated questionnaire for anxiety/depressive symptoms/diagnoses. We analyzed participants without previous coronary heart disease or stroke, and with high-quality CIMT images. We built regression models to determine whether the CIS-R score, CMD, MDD or GAD were associated with maximal CIMT levels. Results: The study sample comprised 9744 participants. We found that individuals with higher CIS-R scores (Odds ratio for one standard deviation increase [OR]:1.12; 95% confidence interval [95%CI]:1.06-1.19), CMD (OR:1.22; 95%CI:1.07-1.38) and GAD (OR:1.19; 95%CI:1.01-1.41) had significantly higher odds of being classified in the highest age, sex and race-specific CIMT quartile. In the linear models, after adjustment for traditional cardiovascular risk factors, higher CIS-R scores (β:0.005; P=0.010) and GAD (β:0.010; P=0.049) were independently associated with CIMT values. Conclusion: Individuals with more symptoms of anxiety and/or depression, or diagnoses of CMD or GAD, had higher CIMT values, compared to peers of same age, sex and race. CIS-R scores and GAD were independently associated with higher CIMT values. These results suggest an association between anxiety/depressive symptoms (and, most notably, GAD) and accelerated subclinical atherosclerosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54585921500</author-url><authid>54585921500</authid><authname>Santos I.</authname><surname>Santos</surname><given-name>Itamar S.</given-name><initials>I.S.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54585921500</author-url><authid>54585921500</authid><authname>Santos I.</authname><surname>Santos</surname><given-name>Itamar S.</given-name><initials>I.S.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:22937718500</author-url><authid>22937718500</authid><authname>Goulart A.</authname><surname>Goulart</surname><given-name>Alessandra C.</given-name><initials>A.C.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24073048100</author-url><authid>24073048100</authid><authname>Brunoni A.</authname><surname>Brunoni</surname><given-name>André R.</given-name><initials>A.R.</initials><afid>60008088</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202027539</author-url><authid>7202027539</authid><authname>Kemp A.</authname><surname>Kemp</surname><given-name>Andrew H.</given-name><initials>A.H.</initials><afid>60008088</afid><afid>60025709</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202027539</author-url><authid>7202027539</authid><authname>Kemp A.</authname><surname>Kemp</surname><given-name>Andrew H.</given-name><initials>A.H.</initials><afid>60008088</afid><afid>60025709</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003331101</author-url><authid>7003331101</authid><authname>Lotufo P.</authname><surname>Lotufo</surname><given-name>Paulo A.</given-name><initials>P.A.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003331101</author-url><authid>7003331101</authid><authname>Lotufo P.</authname><surname>Lotufo</surname><given-name>Paulo A.</given-name><initials>P.A.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56569991800</author-url><authid>56569991800</authid><authname>Bensenor I.</authname><surname>Bensenor</surname><given-name>Isabela M.</given-name><initials>I.M.</initials><afid>60008088</afid><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56569991800</author-url><authid>56569991800</authid><authname>Bensenor I.</authname><surname>Bensenor</surname><given-name>Isabela M.</given-name><initials>I.M.</initials><afid>60008088</afid><afid>60008088</afid></author><authkeywords>Anxiety | Atherosclerosis | Common mental disorder | Depression | Generalized anxiety disorder | Intima-media thickness</authkeywords><intid>2035819211</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927129629"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927129629?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927129629&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927129629&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S221442691500018X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927129629</prism:url><dc:identifier>SCOPUS_ID:84927129629</dc:identifier><eid>2-s2.0-84927129629</eid><dc:title>An uncommon clinical presentation of relapsing dilated cardiomyopathy with identification of sequence variations in MYNPC3, KCNH2 and mitochondrial tRNA cysteine</dc:title><dc:creator>Guillen Sacoto M.</dc:creator><prism:publicationName>Molecular Genetics and Metabolism Reports</prism:publicationName><prism:eIssn>22144269</prism:eIssn><prism:volume>3</prism:volume><prism:pageRange>47-54</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ymgmr.2015.03.007</prism:doi><pii>S221442691500018X</pii><dc:description>© 2015 The Authors. Published by Elsevier Inc. We describe a young girl with dilated cardiomyopathy, long QT syndrome, and possible energy deficiency. Two major sequence changes were identified by whole exome sequencing (WES) and mitochondrial DNA analysis that were interpreted as potentially causative. Changes were identified in the KCNH2 gene and mitochondrial tRNA for cysteine. A variation was also seen in MYPBC3. Since the launch of WES as a clinically available technology in 2010, there has been concern regarding the identification of variants unrelated to the patient's phenotype. However, in cases where targeted sequencing fails to explain the clinical presentation, the underlying etiology could be more complex than anticipated. In this situation, the extensive reach of this tool helped explain both her phenotype and family history.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013369</affiliation-url><afid>60013369</afid><affilname>National Human Genome Research Institute</affilname><name-variant>National Human Genome Research Institute</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005723</affiliation-url><afid>60005723</afid><affilname>Children's National Medical Center</affilname><name-variant>Children's National Medical Center</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005723</affiliation-url><afid>60005723</afid><affilname>Children's National Medical Center</affilname><name-variant>Children's National Medical Center</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56588048700</author-url><authid>56588048700</authid><authname>Guillen Sacoto M.</authname><surname>Guillen Sacoto</surname><given-name>Maria J.</given-name><initials>M.J.</initials><afid>60013369</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:49863126500</author-url><authid>49863126500</authid><authname>Chapman K.</authname><surname>Chapman</surname><given-name>Kimberly A.</given-name><initials>K.A.</initials><afid>60005723</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35203221300</author-url><authid>35203221300</authid><authname>Heath D.</authname><surname>Heath</surname><given-name>Deneen</given-name><initials>D.</initials><afid>60005723</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56588042900</author-url><authid>56588042900</authid><authname>Seprish M.</authname><surname>Seprish</surname><given-name>Mary Beth</given-name><initials>M.B.</initials><afid>60005723</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602328249</author-url><authid>6602328249</authid><authname>Zand D.</authname><surname>Zand</surname><given-name>Dina J.</given-name><initials>D.J.</initials><afid>60005723</afid></author><authkeywords>Dilated cardiomyopathy | Hearing loss | Long QT | Mitochondrial | Sensorineural hearing loss | Whole exome sequencing</authkeywords><intid>535570710</intid><source-id>21100326555</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929069321"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929069321?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929069321&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929069321&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929069321</prism:url><dc:identifier>SCOPUS_ID:84929069321</dc:identifier><eid>2-s2.0-84929069321</eid><dc:title>Simple method to correct for breast attenuation artifact</dc:title><dc:creator>Farag A.</dc:creator><prism:publicationName>Journal of Nuclear Cardiology</prism:publicationName><prism:issn>10713581</prism:issn><prism:eIssn>15326551</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>583-585</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12350-014-9989-y</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56335209100</author-url><authid>56335209100</authid><authname>Farag A.</authname><surname>Farag</surname><given-name>Ayman A.</given-name><initials>A.A.</initials><afid>60027086</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637657500</author-url><authid>56637657500</authid><authname>Heo J.</authname><surname>Heo</surname><given-name>Jaekyeong</given-name><initials>J.</initials><afid>60027086</afid></author><intid>35901326</intid><source-id>17229</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926512788"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926512788?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926512788&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926512788&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002002"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926512788</prism:url><dc:identifier>SCOPUS_ID:84926512788</dc:identifier><eid>2-s2.0-84926512788</eid><dc:title>High daily insulin exposure in patients with type 2 diabetes isassociated with increased risk of cardiovascular events</dc:title><dc:creator>Stoekenbroek R.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>318-323</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.040</prism:doi><pii>S0021915015002002</pii><dc:description>© 2015 Elsevier Ireland Ltd. Aims: Intensive glucose control, often involving insulin treatment, failed to improve cardiovascular outcomes in several clinical trials. Observational studies reported an association between insulin use and cardiovascular disease (CVD) risk. It has therefore been suggested that insulin adversely affects CVD risk. To investigate the feasibility of this hypothesis, we studied the association between insulin dose and CVD risk in type 2 diabetes. Methods: A case-control study was conducted of new users of oral antidiabetics who were prescribed insulin, using the Dutch Pharmo database. Cases were hospitalized for a cardiovascular event (CVE) and matched 1:2 to patients who were not hospitalized for a CVE, by sex, age, duration of diabetes and type of oral antidiabetic. Patients were divided into tertiles according to mean daily insulin dose. Conditional logistic regression analyses were used to explore the association between insulin exposure and CVE risk. Results: We included 836 patients (517 (62%) male, mean age 66 years). After adjusting for available potential confounders, including HbA1c and triglycerides, insulin exposure was positively related to CVE risk (odds ratios for high (≥53.0 U/day) and intermediate (24.3-52.9 U/day) vs. low exposure (≤24.2 U/day): 3.00 [95% confidence interval (CI) 1.70 to 5.28] and 2.03 [95% CI 1.17 to 3.52]. Conclusion: Our findings are in line with the suggestion that high-dose insulin therapy adversely affects CVD risk, but need to be interpreted with caution due to the observational nature of the study. The role of particularly high-dose insulin in the progression of CVD warrants further investigation.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001157</affiliation-url><afid>60001157</afid><affilname>Academic Medical Centre, University of Amsterdam</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023998</affiliation-url><afid>60023998</afid><affilname>Cardiff University</affilname><name-variant>University of Wales</name-variant><affiliation-city>Cardiff</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55603165100</author-url><authid>55603165100</authid><authname>Stoekenbroek R.</authname><surname>Stoekenbroek</surname><given-name>R. M.</given-name><initials>R.M.</initials><afid>60001157</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:18438395400</author-url><authid>18438395400</authid><authname>Rensing K.</authname><surname>Rensing</surname><given-name>K. L.</given-name><initials>K.L.</initials><afid>60001157</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55757976400</author-url><authid>55757976400</authid><authname>Bernelot Moens S.</authname><surname>Bernelot Moens</surname><given-name>S. J.</given-name><initials>S.J.</initials><afid>60001157</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:22433607700</author-url><authid>22433607700</authid><authname>Nieuwdorp M.</authname><surname>Nieuwdorp</surname><given-name>M.</given-name><initials>M.</initials><afid>60001157</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55666085900</author-url><authid>55666085900</authid><authname>DeVries J.</authname><surname>DeVries</surname><given-name>J. H.</given-name><initials>J.H.</initials><afid>60001157</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55660206600</author-url><authid>55660206600</authid><authname>Zwinderman A.</authname><surname>Zwinderman</surname><given-name>A. H.</given-name><initials>A.H.</initials><afid>60001157</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004092642</author-url><authid>7004092642</authid><authname>Stroes E.</authname><surname>Stroes</surname><given-name>E. S.</given-name><initials>E.S.</initials><afid>60001157</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35236774800</author-url><authid>35236774800</authid><authname>Currie C.</authname><surname>Currie</surname><given-name>C. J.</given-name><initials>C.J.</initials><afid>60023998</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603689339</author-url><authid>6603689339</authid><authname>Hutten B.</authname><surname>Hutten</surname><given-name>B. A.</given-name><initials>B.A.</initials><afid>60001157</afid></author><authkeywords>Cardiovascular disease | Diabetes | Insulin therapy</authkeywords><intid>1785455732</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929162401"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929162401?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929162401&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929162401&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929162401</prism:url><dc:identifier>SCOPUS_ID:84929162401</dc:identifier><eid>2-s2.0-84929162401</eid><dc:title>Safety of bronchoscopy in elderly</dc:title><dc:creator>Hadique S.</dc:creator><prism:publicationName>Current Geriatrics Reports</prism:publicationName><prism:eIssn>21967865</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>154-165</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13670-015-0123-z</prism:doi><dc:description>© 2015 Springer Science+Business Media New York. Flexible bronchoscopy (FB) is a commonly performed procedure for diagnostic and therapeutic interventions of pulmonary disorders. Due to high prevalence of lung diseases especially lung cancer in the aging population, there is an increasing demand for FB in elderly patients. Flexible bronchoscopy is a well-tolerated procedure with low complication rate and mortality while providing valuable diagnostic and staging information. However, due to age-related decline in cardiopulmonary reserves and frequent presence of co-morbid conditions, procedural safety is the most critical issue in any elderly patient undergoing FB. A thorough understanding of these cardiopulmonary limitations and a careful assessment of medical issues, functional status and social support are essential in every elderly patient before performing bronchoscopy. Several studies have shown that age has no major effect on procedure-related complications or tolerance to bronchoscopy even with recent addition of increasingly complex and longer procedures. Advanced age by itself is not a contraindication to bronchoscopy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021143</affiliation-url><afid>60021143</afid><affilname>West Virginia University</affilname><name-variant>West Virginia University</name-variant><affiliation-city>Morgantown</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6504822326</author-url><authid>6504822326</authid><authname>Hadique S.</authname><surname>Hadique</surname><given-name>Sarah</given-name><initials>S.</initials><afid>60021143</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7402520515</author-url><authid>7402520515</authid><authname>Jain P.</authname><surname>Jain</surname><given-name>Prasoon</given-name><initials>P.</initials><afid>60014232</afid></author><authkeywords>Bronchoscopy safety | Elderly | Flexible bronchoscopy | Lung cancer</authkeywords><intid>35917474</intid><source-id>21100358312</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928015933"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928015933?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928015933&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928015933&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002336"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928015933</prism:url><dc:identifier>SCOPUS_ID:84928015933</dc:identifier><eid>2-s2.0-84928015933</eid><dc:title>Efficacy and safety of P2Y&lt;inf&gt;12&lt;/inf&gt; inhibitors according to diabetes, age, gender, body mass index and body weight: Systematic review and meta-analyses of randomized clinical trials</dc:title><dc:creator>Zaccardi F.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>439-445</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.015</prism:doi><pii>S0021915015002336</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objective: The efficacy of antiplatelet drugs may differ in specific patient subgroups. We aimed to assess the efficacy and safety of the P2Y&lt;inf&gt;12&lt;/inf&gt; inhibitors clopidogrel, ticlopidine, prasugrel, ticagrelor, and cangrelor according to diabetes status, age, gender, body mass index, and body weight. Methods: Randomized clinical trials (RCTs) of P2Y&lt;inf&gt;12&lt;/inf&gt; inhibitors reporting information on cardiovascular disease (defined as myocardial infarction, stroke, or cardiovascular death) and bleeding (defined as any bleeding) events among the subgroups diabetes and non-diabetes, age ≥65 and &lt;65 year-old, men and women, body mass index ≥30 and &lt;30kg/m&lt;sup&gt;2&lt;/sup&gt;, and body weight ≥60 and &lt;60kg, were identified in Medline, Embase, Web of Science, and Cochrane Library on August 31st, 2014. For each inhibitor, random-effects meta-analyses were used to estimate the ratio of relative risks (rRR) for cardiovascular and bleeding events among patient subgroups. Results: Twenty distinct RCTs (233285 participants, 21323 cardiovascular and 5183 bleeding events) were identified. Cardiovascular risk reduction with clopidogrel did not significantly differ according to diabetes (rRR: 1.04; 95% CI: 0.95 to 1.13; p=0.395), age (0.98; 0.88 to 1.09; p=0.347), gender (0.97; 0.90 to 1.04; p=0.382), or body mass index (1.11, 0.95 to 1.31; p=0.191). Results for other inhibitors were comparable, although available data were sparse. Limited data on bleeding events were available. Conclusion: Data from RCTs did not show a different cardiovascular efficacy of clopidogrel in diabetes mellitus and other clinically relevant subgroups. Limited information was available on the efficacy and safety of other P2Y&lt;inf&gt;12&lt;/inf&gt; inhibitors in specific subgroups.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029431</affiliation-url><afid>60029431</afid><affilname>Universita Cattolica del Sacro Cuore, Rome, Facolta di Medicina e Chirurgia</affilname><name-variant>Catholic University Medical School</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031101</affiliation-url><afid>60031101</afid><affilname>University of Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103673</affiliation-url><afid>60103673</afid><affilname>Ita-Suomen yliopisto</affilname><name-variant>University of Eastern Finland</name-variant><affiliation-city>Kuopio</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24345862000</author-url><authid>24345862000</authid><authname>Zaccardi F.</authname><surname>Zaccardi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60029431</afid><afid>60031101</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24345862000</author-url><authid>24345862000</authid><authname>Zaccardi F.</authname><surname>Zaccardi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60029431</afid><afid>60031101</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602110238</author-url><authid>6602110238</authid><authname>Pitocco D.</authname><surname>Pitocco</surname><given-name>Dario</given-name><initials>D.</initials><afid>60029431</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35338594600</author-url><authid>35338594600</authid><authname>Willeit P.</authname><surname>Willeit</surname><given-name>Peter</given-name><initials>P.</initials><afid>60031101</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004320420</author-url><authid>7004320420</authid><authname>Laukkanen J.</authname><surname>Laukkanen</surname><given-name>Jari A.</given-name><initials>J.A.</initials><afid>60103673</afid></author><authkeywords>Antiplatelet resistance | Clopidogrel | Diabetes | Meta-analysis | P2Y&lt;inf&gt;12&lt;/inf&gt; inhibitors | Thienopyridines</authkeywords><intid>35716776</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929092878"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929092878?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929092878&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929092878&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929092878</prism:url><dc:identifier>SCOPUS_ID:84929092878</dc:identifier><eid>2-s2.0-84929092878</eid><dc:title>Normal Myocardial Perfusion Gated SPECT and Positive Stress Test: Different Prognoses in Women and Men</dc:title><dc:creator>Romero-Farina G.</dc:creator><prism:publicationName>Journal of Nuclear Cardiology</prism:publicationName><prism:issn>10713581</prism:issn><prism:eIssn>15326551</prism:eIssn><prism:volume>22</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>453-465</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s12350-014-0009-z</prism:doi><dc:description>© 2014, American Society of Nuclear Cardiology. Background: The aim of this study was to analyze different prognoses in women and men with normal myocardial perfusion gated SPECT, according to stress test results. Methods: Differences between women and men in terms of hard events (HE) (non-fatal acute myocardial infarction or cardiac death) and HE plus coronary revascularization (HE + CR) were analyzed in 2,414 consecutive patients (mean age 62.8 ± 13.5 years, 1,438 women) with a normal stress-rest gated SPECT, taking into account their stress test results. Results: Four hundred and seven patients (16.9 %) (15.9 % women and 17.5 % men) had a positive stress test (ST-segment depression ≥1 mm and/or angina). During a follow-up of 5.1 ± 3.4 years, there were more significant HE (6.5 % vs 2.3 %; P = .005) and HE + CR (11.6 % vs 4.8 %, P = .001) in men with a positive stress test than in men with a negative stress test. These differences were not observed in women. In multivariate regression models, HE and HE + CR were also more frequent in men with a positive stress test (HR:3.3 [95 % CI 1.1 % to 9.5 %]; HR:4.2 [95 % CI 1.8 % to 9.9 %]; respectively) vs women with a positive stress test. Conclusions: Although patients with normal gated SPECT studies have a favorable outcome, men with an abnormal stress test have a more adverse prognosis than women.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012486</affiliation-url><afid>60012486</afid><affilname>Hospital Universitari Vall d'Hebron</affilname><name-variant>Hospital Vall d'Hebron</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012486</affiliation-url><afid>60012486</afid><affilname>Hospital Universitari Vall d'Hebron</affilname><name-variant>Hospital Vall d'Hebron</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602367384</author-url><authid>6602367384</authid><authname>Romero-Farina G.</authname><surname>Romero-Farina</surname><given-name>Guillermo</given-name><initials>G.</initials><afid>60012486</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006652765</author-url><authid>7006652765</authid><authname>Candell-Riera J.</authname><surname>Candell-Riera</surname><given-name>Jaume</given-name><initials>J.</initials><afid>60012486</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507637994</author-url><authid>6507637994</authid><authname>Ferreira-González I.</authname><surname>Ferreira-González</surname><given-name>Ignacio</given-name><initials>I.</initials><afid>60012486</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003895815</author-url><authid>7003895815</authid><authname>Aguadé-Bruix S.</authname><surname>Aguadé-Bruix</surname><given-name>Santiago</given-name><initials>S.</initials><afid>60012486</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56497683500</author-url><authid>56497683500</authid><authname>Pizzi N.</authname><surname>Pizzi</surname><given-name>Nazarena</given-name><initials>N.</initials><afid>60012486</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005652216</author-url><authid>7005652216</authid><authname>García-Dorado D.</authname><surname>García-Dorado</surname><given-name>David</given-name><initials>D.</initials><afid>60012486</afid></author><authkeywords>coronary angiography | gender | Normal single photon emission computed tomography | positive stress test | prognosis</authkeywords><intid>1785902409</intid><source-id>17229</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926335310"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926335310?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926335310&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926335310&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014480015000696"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926335310</prism:url><dc:identifier>SCOPUS_ID:84926335310</dc:identifier><eid>2-s2.0-84926335310</eid><dc:title>Mitochondrial dysfunction in skeletal muscle during experimental Chagas disease</dc:title><dc:creator>Báez A.</dc:creator><prism:publicationName>Experimental and Molecular Pathology</prism:publicationName><prism:issn>00144800</prism:issn><prism:eIssn>10960945</prism:eIssn><prism:volume>98</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>467-475</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yexmp.2015.03.034</prism:doi><pii>S0014480015000696</pii><dc:description>© 2015 Elsevier Inc. Trypanosoma cruzi invasion and replication in cardiomyocytes and other tissues induce cellular injuries and cytotoxic reactions, with the production of inflammatory cytokines and nitric oxide, both sources of reactive oxygen species. The myocyte response to oxidative stress involves the progression of cellular changes primarily targeting mitochondria. Similar alterations could be taking place in mitochondria from the skeletal muscle if that is the case, a simple skeletal muscle biopsy would give information about the cardiac energetic production that could be used as a predictor of the chagasic cardiopathy evolution. Therefore, in the present paper we studied skeletal muscle mitochondrial structure and the enzymatic activity of citrate synthase and respiratory chain complexes I to IV (CI-CIV), in Albino Swiss mice infected with T. cruzi, Tulahuen strain and SGO Z12 and Lucky isolates, along the infection. Changes in the mitochondrial structure were detected in 100% of the mitochondria analyzed from the infected groups: they all presented at least 1 significant abnormality such as increase in their matrix or disorganization of their cristae, which are probably related to the enzymatic dysfunction.When we studied the Krebs cycle functionality through the measurement of the specific citrate synthase activity, we found it to be significantly diminished during the acute phase of the infection in Tulahuen and SGO Z12 infected groups with respect to the control one citrate synthase activity from the Lucky group was significantly increased (p. &lt;. 0.05). The activity of this enzyme was reduced in all the infected groups during the chronic asymptomatic phase (p. &lt;. 0.001) and return to normal values (Tulahuen and SGO Z12) or increased its activity (Lucky) by day 365 post-infection (p.i.). When the mitochondrial respiratory chain was analyzed from the acute to the chronic phase of the infection through the measurement of the activity of complexes I to IV, the activity of CI remained similar to control in Tulahuen and Lucky groups, but was significantly augmented in the SGO Z12 one in the acute and chronic phases (p. &lt;. 0.05). CII increased its activity in Tulahuen and Lucky groups by day 75 p.i. and in SGO Z12 by day 365 p.i. (p. &lt;. 0.05). CIII showed a similar behavior in the 3 infected groups, remaining similar to control values in the first two stages of the infection and significantly increasing later on (p. &lt;. 0.0001). CIV showed an increase in its activity in Lucky throughout all stages of infection (p. &lt;. 0.0001) and an increase in Tulahuen by day 365. days p.i. (p. &lt;. 0.0001); SGO Z12 on the other hand, showed a decreased CIV activity at the same time.The structural changes in skeletal muscle mitochondria and their altered enzyme activity began in the acute phase of infection, probably modifying the ability of mitochondria to generate energy; these changes were not compensated in the rest of the phases of the infection. Chagas is a systemic disease, which produces not only heart damage but also permanent skeletal muscle alterations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000658</affiliation-url><afid>60000658</afid><affilname>Universidad Nacional de Cordoba</affilname><name-variant>Universidad Nacional de Cordoba</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016376</affiliation-url><afid>60016376</afid><affilname>Universidad Nacional de Cordoba, Facultad de Ciencias Medicas</affilname><name-variant>Universidad Nacional de Córdoba</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25421341100</author-url><authid>25421341100</authid><authname>Báez A.</authname><surname>Báez</surname><given-name>Alejandra L.</given-name><initials>A.L.</initials><afid>60000658</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56581731800</author-url><authid>56581731800</authid><authname>Reynoso M.</authname><surname>Reynoso</surname><given-name>María N.</given-name><initials>M.N.</initials><afid>60000658</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701650021</author-url><authid>6701650021</authid><authname>Lo Presti M.</authname><surname>Lo Presti</surname><given-name>María S.</given-name><initials>M.S.</initials><afid>60000658</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24328993600</author-url><authid>24328993600</authid><authname>Bazán P.</authname><surname>Bazán</surname><given-name>Paola C.</given-name><initials>P.C.</initials><afid>60000658</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55603177200</author-url><authid>55603177200</authid><authname>Strauss M.</authname><surname>Strauss</surname><given-name>Mariana</given-name><initials>M.</initials><afid>60000658</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56582137400</author-url><authid>56582137400</authid><authname>Miler N.</authname><surname>Miler</surname><given-name>Noemí</given-name><initials>N.</initials><afid>60000658</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005134526</author-url><authid>7005134526</authid><authname>Pons P.</authname><surname>Pons</surname><given-name>Patricia</given-name><initials>P.</initials><afid>60016376</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6602247005</author-url><authid>6602247005</authid><authname>Rivarola H.</authname><surname>Rivarola</surname><given-name>Héctor W.</given-name><initials>H.W.</initials><afid>60000658</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602882497</author-url><authid>6602882497</authid><authname>Paglini-Oliva P.</authname><surname>Paglini-Oliva</surname><given-name>Patricia</given-name><initials>P.</initials><afid>60000658</afid></author><authkeywords>Chagas' disease | Krebs cycle | Mitochondria | Respiratory chain | Skeletal muscle | Trypanosoma cruzi</authkeywords><intid>1035428155</intid><source-id>13247</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926436109"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926436109?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926436109&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926436109&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0005272815000377"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926436109</prism:url><dc:identifier>SCOPUS_ID:84926436109</dc:identifier><eid>2-s2.0-84926436109</eid><dc:title>Increased reactive oxygen species production during reductive stress: The roles of mitochondrial glutathione and thioredoxin reductases</dc:title><dc:creator>Korge P.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Bioenergetics</prism:publicationName><prism:issn>00052728</prism:issn><prism:eIssn>18792650</prism:eIssn><prism:volume>1847</prism:volume><prism:issueIdentifier>6-7</prism:issueIdentifier><prism:pageRange>514-525</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbabio.2015.02.012</prism:doi><pii>S0005272815000377</pii><dc:description>© 2015 Elsevier B.V. Both extremes of redox balance are known to cause cardiac injury, with mounting evidence revealing that the injury induced by both oxidative and reductive stress is oxidative in nature. During reductive stress, when electron acceptors are expected to be mostly reduced, some redox proteins can donate electrons to O&lt;inf&gt;2&lt;/inf&gt; instead, which increases reactive oxygen species (ROS) production. However, the high level of reducing equivalents also concomitantly enhances ROS scavenging systems involving redox couples such as NADPH/NADP&lt;sup&gt;+&lt;/sup&gt; and GSH/GSSG. Here our objective was to explore how reductive stress paradoxically increases net mitochondrial ROS production despite the concomitant enhancement of ROS scavenging systems. Using recombinant enzymes and isolated permeabilized cardiac mitochondria, we show that two normally antioxidant matrix NADPH reductases, glutathione reductase and thioredoxin reductase, generate H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; by leaking electrons from their reduced flavoprotein to O&lt;inf&gt;2&lt;/inf&gt; when electron flow is impaired by inhibitors or because of limited availability of their natural electron acceptors, GSSG and oxidized thioredoxin. The spillover of H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; under these conditions depends on H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; reduction by peroxiredoxin activity, which may regulate redox signaling in response to endogenous or exogenous factors. These findings may explain how ROS production during reductive stress overwhelms ROS scavenging capability, generating the net mitochondrial ROS spillover causing oxidative injury. These enzymes could potentially be targeted to increase cancer cell death or modulate H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;-induced redox signaling to protect the heart against ischemia/reperfusion damage.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005247</affiliation-url><afid>60005247</afid><affilname>David Geffen School of Medicine at UCLA</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005247</affiliation-url><afid>60005247</afid><affilname>David Geffen School of Medicine at UCLA</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005247</affiliation-url><afid>60005247</afid><affilname>David Geffen School of Medicine at UCLA</affilname><name-variant>University of California</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003932210</author-url><authid>7003932210</authid><authname>Korge P.</authname><surname>Korge</surname><given-name>Paavo</given-name><initials>P.</initials><afid>60005247</afid><afid>60005247</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003932210</author-url><authid>7003932210</authid><authname>Korge P.</authname><surname>Korge</surname><given-name>Paavo</given-name><initials>P.</initials><afid>60005247</afid><afid>60005247</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24479679700</author-url><authid>24479679700</authid><authname>Calmettes G.</authname><surname>Calmettes</surname><given-name>Guillaume</given-name><initials>G.</initials><afid>60005247</afid><afid>60005247</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24479679700</author-url><authid>24479679700</authid><authname>Calmettes G.</authname><surname>Calmettes</surname><given-name>Guillaume</given-name><initials>G.</initials><afid>60005247</afid><afid>60005247</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35400314700</author-url><authid>35400314700</authid><authname>Weiss J.</authname><surname>Weiss</surname><given-name>James N.</given-name><initials>J.N.</initials><afid>60005247</afid><afid>60005247</afid><afid>60005247</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35400314700</author-url><authid>35400314700</authid><authname>Weiss J.</authname><surname>Weiss</surname><given-name>James N.</given-name><initials>J.N.</initials><afid>60005247</afid><afid>60005247</afid><afid>60005247</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35400314700</author-url><authid>35400314700</authid><authname>Weiss J.</authname><surname>Weiss</surname><given-name>James N.</given-name><initials>J.N.</initials><afid>60005247</afid><afid>60005247</afid><afid>60005247</afid></author><authkeywords>Mitochondria | Reductive stress | ROS production</authkeywords><intid>35454779</intid><source-id>16791</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929144754"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929144754?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929144754&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929144754&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929144754</prism:url><dc:identifier>SCOPUS_ID:84929144754</dc:identifier><eid>2-s2.0-84929144754</eid><dc:title>Unusual neurological manifestation of severe digitoxin intoxication with bilateral ballism and visual hallucinations</dc:title><dc:creator>Holstein A.</dc:creator><prism:publicationName>Aging Clinical and Experimental Research</prism:publicationName><prism:issn>15940667</prism:issn><prism:eIssn>17208319</prism:eIssn><prism:volume>27</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>391-393</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40520-014-0289-9</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106444691</affiliation-url><afid>106444691</afid><affilname>Lippe-Detmold Hospital</affilname><name-variant>Lippe-Detmold Clinic</name-variant><affiliation-city>Detmold</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100836224</affiliation-url><afid>100836224</afid><affilname>Lippe Hospital Lemgo</affilname><name-variant>Lippe-Lemgo Hospital</name-variant><affiliation-city>Lemgo</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:34975074700</author-url><authid>34975074700</authid><authname>Holstein A.</authname><surname>Holstein</surname><given-name>Andreas</given-name><initials>A.</initials><afid>106444691</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640502400</author-url><authid>56640502400</authid><authname>Hassan A.</authname><surname>Hassan</surname><given-name>Ahmad</given-name><initials>A.</initials><afid>106444691</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36716538700</author-url><authid>36716538700</authid><authname>Patzer O.</authname><surname>Patzer</surname><given-name>Olaf M.</given-name><initials>O.M.</initials><afid>106444691</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640734100</author-url><authid>56640734100</authid><authname>Rohde M.</authname><surname>Rohde</surname><given-name>Matthias</given-name><initials>M.</initials><afid>100836224</afid></author><authkeywords>Ballism | Digitoxin | Hallucinations | Intoxication</authkeywords><intid>1035911734</intid><source-id>28496</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928792272"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928792272?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928792272&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928792272&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928792272</prism:url><dc:identifier>SCOPUS_ID:84928792272</dc:identifier><eid>2-s2.0-84928792272</eid><dc:title>Treatment of Submassive Pulmonary Embolism: Knowing When to be Aggressive and When to be Conservative</dc:title><dc:creator>Ain D.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0385-y</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. A patient who presents with pulmonary embolism (PE) but without hypotension should undergo risk stratification with echocardiography, computed tomography, and serum biomarker assessment. Submassive PE is identified by the findings of right ventricular dysfunction by physical examination or imaging, or by elevations in serum troponin or brain-type natriuretic peptide in the context of acute PE. Evidence of cardiac strain should prompt evaluation by a multidisciplinary team with experience in the management of submassive PE. Consideration of therapies beyond systemic anticoagulation, such as systemic intravenous thrombolysis, catheter-directed thrombolysis, and percutaneous or surgical embolectomy, must be based on the clinical presentation, the risk of adverse outcome, the skill of the operator, and the bleeding risk. Here, we address the current understanding of submassive PE, new insights into how established therapies alter the natural history of the disease process, and recent advances in treatment options.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23767750500</author-url><authid>23767750500</authid><authname>Ain D.</authname><surname>Ain</surname><given-name>David L.</given-name><initials>D.L.</initials><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003664045</author-url><authid>7003664045</authid><authname>Jaff M.</authname><surname>Jaff</surname><given-name>Michael R.</given-name><initials>M.R.</initials><afid>60029929</afid></author><authkeywords>Embolectomy | Hypotension | Pulmonary embolism | Submassive PE | Vascular disease</authkeywords><intid>1035847353</intid><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928986557"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928986557?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928986557&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928986557&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928986557</prism:url><dc:identifier>SCOPUS_ID:84928986557</dc:identifier><eid>2-s2.0-84928986557</eid><dc:title>Trending ability and limitations of transpulmonary thermodilution and pulse contour cardiac output measurement in cats as a model for pediatric patients</dc:title><dc:creator>Kutter A.</dc:creator><prism:publicationName>Journal of Clinical Monitoring and Computing</prism:publicationName><prism:issn>13871307</prism:issn><prism:eIssn>15732614</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>377-383</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10877-014-9615-1</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. The present study evaluated transpulmonary thermodilution (TPTD) and pulse contour cardiac output (PCCO) both measured by the PiCCO Plus™ monitor (Pulsion Medical Systems, Munich, Germany) against pulmonary artery thermodilution (PATD) in cats as a hemodynamic model for small children. A wide range of cardiac outputs (CO) was simultaneously measured. Accuracy and trending abilities were critically evaluated. Three cats were studied under isoflurane anesthesia and 160 CO measurements were performed with 3 mL ice-cold 5 % dextrose with PATD and TPTD. The results were compared with the PCCO measurement before the bolus measurement. Cardiac output was manipulated from 32 to 224 mL/kg/min by dobutamine, dopamine, phenylephrine, medetomidine and increased concentrations of isoflurane. Bland–Altman analysis, concordance and polar plot analysis were performed to assess accuracy and trending ability. TPTD was measuring constantly higher than PATD with a mean bias of 73 mL/kg/min and limits of agreement of 34–112 mL/kg/min, a concordance rate of 94 % and a mean polar angle of −5° with radial limits of agreement (RLOA) of 33°. Concordance rate of the PCCO versus PATD was 82 % with a mean polar angle of −10° and RLOA of 46° and versus TPTD 90 % with a mean polar angle of −6° and RLOA of 46°. Both tested methods constantly overestimated simultaneous PATD measurements. The small size, low flows and the relative short catheter not reaching the abdominal aorta may explain that. However TPTD tracked changes accurately opposed to a poor trending ability of the PCCO measurement.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012614</affiliation-url><afid>60012614</afid><affilname>Universitat Zurich</affilname><name-variant>University of Zurich</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017248</affiliation-url><afid>60017248</afid><affilname>Stadtspital Triemli</affilname><name-variant>City Hospital Triemli</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8865521400</author-url><authid>8865521400</authid><authname>Kutter A.</authname><surname>Kutter</surname><given-name>Annette P N</given-name><initials>A.P.N.</initials><afid>60012614</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:49862731300</author-url><authid>49862731300</authid><authname>Bektas R.</authname><surname>Bektas</surname><given-name>Rima N.</given-name><initials>R.N.</initials><afid>60012614</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005022177</author-url><authid>7005022177</authid><authname>Hofer C.</authname><surname>Hofer</surname><given-name>Christoph K.</given-name><initials>C.K.</initials><afid>60017248</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56626058200</author-url><authid>56626058200</authid><authname>Larenza Menzies M.</authname><surname>Larenza Menzies</surname><given-name>M. Paula</given-name><initials>M.P.</initials><afid>60012614</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701843351</author-url><authid>6701843351</authid><authname>Bettschart-Wolfensberger R.</authname><surname>Bettschart-Wolfensberger</surname><given-name>Regula</given-name><initials>R.</initials><afid>60012614</afid></author><authkeywords>Cardiac output | Hemodynamic | Monitoring | Pediatrics | Thermodilution</authkeywords><intid>535884725</intid><source-id>15872</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926143038"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926143038?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926143038&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926143038&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0273230015000653"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926143038</prism:url><dc:identifier>SCOPUS_ID:84926143038</dc:identifier><eid>2-s2.0-84926143038</eid><dc:title>A novel approach to assess the population health impact of introducing a Modified Risk Tobacco Product</dc:title><dc:creator>Weitkunat R.</dc:creator><prism:publicationName>Regulatory Toxicology and Pharmacology</prism:publicationName><prism:issn>02732300</prism:issn><prism:eIssn>10960295</prism:eIssn><prism:volume>72</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>87-93</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.yrtph.2015.03.011</prism:doi><pii>S0273230015000653</pii><dc:description>© 2015 The Authors. Based on the Food and Drug Administration's Modified Risk Tobacco Product (MRTP) Application draft guideline, Philip Morris International (PMI) has developed a Population Health Impact Model to estimate the reduction in the number of deaths over a period following the introduction of an MRTP. Such a model is necessary to assess the effect that its introduction would have on population health, given the lack of epidemiological data available prior to marketing authorization on any risks from MRTPs. The model is based on publicly available data on smoking prevalence and on the relationships between smoking-related disease-specific mortality and various aspects of the smoking of conventional cigarettes (CCs), together with an estimate of exposure from the MRTP relative to that from CCs, and allows the exploration of possible scenarios regarding the effect of MRTP introduction on the prevalence of CC and MRTP use, individually and in combination. By comparing mortality attributable in a scenario where the MRTP is introduced with one where it is not, the model can estimate the mortality attributable to CCs and the MRTP, as well as the reduction in the deaths attributable to the introduction of the MRTP.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033183</affiliation-url><afid>60033183</afid><affilname>Philip Morris International</affilname><name-variant>Philip Morris International</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101665820</affiliation-url><afid>101665820</afid><affilname>P N Lee Statistics and Computing Ltd</affilname><name-variant>P.N. Lee Statistics and Computing Ltd</name-variant><affiliation-city>Sutton</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56580048600</author-url><authid>56580048600</authid><authname>Weitkunat R.</authname><surname>Weitkunat</surname><given-name>Rolf</given-name><initials>R.</initials><afid>60033183</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56579472600</author-url><authid>56579472600</authid><authname>Lee P.</authname><surname>Lee</surname><given-name>Peter N.</given-name><initials>P.N.</initials><afid>101665820</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56579656000</author-url><authid>56579656000</authid><authname>Baker G.</authname><surname>Baker</surname><given-name>Gizelle</given-name><initials>G.</initials><afid>60033183</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15069679100</author-url><authid>15069679100</authid><authname>Sponsiello-Wang Z.</authname><surname>Sponsiello-Wang</surname><given-name>Zheng</given-name><initials>Z.</initials><afid>60033183</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:14037331400</author-url><authid>14037331400</authid><authname>González-Zuloeta Ladd A.</authname><surname>González-Zuloeta Ladd</surname><given-name>Angela M.</given-name><initials>A.M.</initials><afid>60033183</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603675362</author-url><authid>6603675362</authid><authname>Lüdicke F.</authname><surname>Lüdicke</surname><given-name>Frank</given-name><initials>F.</initials><afid>60033183</afid></author><authkeywords>Attributable risk | Harm reduction | Modeling | Modified Risk Tobacco Product | Smoking</authkeywords><intid>2035399201</intid><source-id>25176</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928567650"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928567650?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928567650&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928567650&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928567650</prism:url><dc:identifier>SCOPUS_ID:84928567650</dc:identifier><eid>2-s2.0-84928567650</eid><dc:title>Effect of grape and other berries on cardiovascular health</dc:title><dc:creator>Wightman J.</dc:creator><prism:publicationName>Journal of the Science of Food and Agriculture</prism:publicationName><prism:issn>00225142</prism:issn><prism:eIssn>10970010</prism:eIssn><prism:volume>95</prism:volume><prism:issueIdentifier>8</prism:issueIdentifier><prism:pageRange>1584-1597</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1002/jsfa.6890</prism:doi><dc:description>© 2014 Society of Chemical Industry. Cardiovascular disease is a leading cause of death globally. Many cardiovascular risk factors can be modified through lifestyle modification, including dietary patterns that emphasize daily consumption of a variety of fruits and vegetables. Recent observational and clinical studies suggest that flavonoids, especially those abundant in grapes and other berries, may be associated with health benefits, particularly cardiovascular benefits. Human clinical data support cardioprotective benefits of grapes through inhibition of platelet aggregation, decreased low-density lipoprotein (LDL) oxidation, reduction in oxidative stress and improvements in endothelial function. Emerging evidence suggests that grapes may also have a favorable effect on blood lipids, decrease inflammation and reduce blood pressure in certain populations. Studies to date have shown that berries can have a beneficial effect on reducing LDL oxidation. Limited data suggest that berries may have a favorable effect on endothelial health and blood pressure. This review summarizes the current literature on human clinical studies examining the cardioprotective benefits of grapes and berries. Collectively, these data support the recommendation to incorporate products made with grapes and other berries into a heart-healthy diet.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112107719</affiliation-url><afid>112107719</afid><affilname>Welch Foods, Inc.</affilname><name-variant>Welch Foods, Inc.</name-variant><affiliation-city>Concord</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009841</affiliation-url><afid>60009841</afid><affilname>Central Michigan University</affilname><name-variant>Central Michigan University</name-variant><affiliation-city>Mount Pleasant</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005962514</author-url><authid>7005962514</authid><authname>Wightman J.</authname><surname>Wightman</surname><given-name>Jolynne D.</given-name><initials>J.D.</initials><afid>112107719</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506922452</author-url><authid>6506922452</authid><authname>Heuberger R.</authname><surname>Heuberger</surname><given-name>Roschelle A.</given-name><initials>R.A.</initials><afid>60009841</afid></author><authkeywords>Berry | Cardiovascular health | Endothelial function | Flavonoids | Grape | LDL oxidation</authkeywords><intid>35801784</intid><source-id>33928</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928981034"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928981034?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928981034&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928981034&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928981034</prism:url><dc:identifier>SCOPUS_ID:84928981034</dc:identifier><eid>2-s2.0-84928981034</eid><dc:title>The ability of the Vigileo-FloTrac system to measure cardiac output and track cardiac output changes during one-lung ventilation</dc:title><dc:creator>Suehiro K.</dc:creator><prism:publicationName>Journal of Clinical Monitoring and Computing</prism:publicationName><prism:issn>13871307</prism:issn><prism:eIssn>15732614</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>333-339</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10877-014-9609-z</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. This study was aimed at comparing the cardiac output (CO) measured by the Vigileo™-FloTrac™ system with that estimated by the thermodilution pulmonary artery catheter (PAC) during one-lung ventilation (OLV) and determining the reliability of this system in tracking phenylephrine-induced CO changes during OLV. Sixteen patients scheduled for descending aorta replacement were enrolled. The study was performed 30 min after starting OLV under stable hemodynamic conditions. We recorded hemodynamic variables, CO measured by PAC thermodilution (ICO), CO measured by Vigileo™-FloTrac™ system (Version 3.02, Edwards Lifesciences, Irvine, CA, USA) (APCO), and systemic vascular resistance index (SVRI) before (T0) and after (T1) phenylephrine (100 μg) administration. We used Bland–Altman analysis to compare ICO and APCO. Polar plot and four-quadrant plot were used to assess the tracking ability of the Vigileo™-FloTrac™ system against ICO after administration of phenylephrine. Ninety hemodynamic interventions were performed. Bland–Altman analysis revealed that the mean bias between APCO and ICO was 0.05 L/min and the percentage error, 46.9 %. Four-quadrant plot analysis showed a concordance rate of 24.7 %, while polar plot analysis showed that the concordance rate was 13.3 %; the angular bias, −45.9°; radial limit of agreement, 85.3°. The bias between APCO and ICO was significantly correlated with the SVRI value (p &lt; 0.001, r&lt;sup&gt;2&lt;/sup&gt; = 0.822). The reliability of the Vigileo™-FloTrac™ system during OLV to estimate CO and track phenylephrine-induced CO changes was not acceptable.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013722</affiliation-url><afid>60013722</afid><affilname>Osaka City University</affilname><name-variant>Osaka City University</name-variant><affiliation-city>Osaka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24779776400</author-url><authid>24779776400</authid><authname>Suehiro K.</authname><surname>Suehiro</surname><given-name>Koichi</given-name><initials>K.</initials><afid>60013722</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55741461300</author-url><authid>55741461300</authid><authname>Tanaka K.</authname><surname>Tanaka</surname><given-name>Katsuaki</given-name><initials>K.</initials><afid>60013722</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55746453700</author-url><authid>55746453700</authid><authname>Yamada T.</authname><surname>Yamada</surname><given-name>Tokuhiro</given-name><initials>T.</initials><afid>60013722</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23095053100</author-url><authid>23095053100</authid><authname>Matsuura T.</authname><surname>Matsuura</surname><given-name>Tadashi</given-name><initials>T.</initials><afid>60013722</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55745879000</author-url><authid>55745879000</authid><authname>Mori T.</authname><surname>Mori</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60013722</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602079217</author-url><authid>6602079217</authid><authname>Funao T.</authname><surname>Funao</surname><given-name>Tomoharu</given-name><initials>T.</initials><afid>60013722</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56377250000</author-url><authid>56377250000</authid><authname>Nishikawa K.</authname><surname>Nishikawa</surname><given-name>Kiyonobu</given-name><initials>K.</initials><afid>60013722</afid></author><authkeywords>Cardiac output | One-lung ventilation | Systemic vascular resistance | Vigileo-FloTrac system</authkeywords><intid>1535884444</intid><source-id>15872</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929346892"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929346892?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929346892&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929346892&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929346892</prism:url><dc:identifier>SCOPUS_ID:84929346892</dc:identifier><eid>2-s2.0-84929346892</eid><dc:title>Preliminary results for estimating pulse transit time using seismocardiogram</dc:title><dc:creator>Verma A.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030124</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026161</affiliation-url><afid>60026161</afid><affilname>University of North Dakota</affilname><name-variant>University of North Dakota</name-variant><affiliation-city>Grand Forks</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644020000</author-url><authid>56644020000</authid><authname>Verma A.</authname><surname>Verma</surname><given-name>Ajay K.</given-name><initials>A.K.</initials><afid>60026161</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23388874700</author-url><authid>23388874700</authid><authname>Fazel-Rezai R.</authname><surname>Fazel-Rezai</surname><given-name>Reza</given-name><initials>R.</initials><afid>60026161</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602329505</author-url><authid>6602329505</authid><authname>Zanetti J.</authname><surname>Zanetti</surname><given-name>John M.</given-name><initials>J.M.</initials><afid>60026161</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6505837295</author-url><authid>6505837295</authid><authname>Tavakolian K.</authname><surname>Tavakolian</surname><given-name>Kouhyar</given-name><initials>K.</initials><afid>60026161</afid></author><intid>35943239</intid><article-number>020916</article-number><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929152235"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929152235?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929152235&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929152235&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929152235</prism:url><dc:identifier>SCOPUS_ID:84929152235</dc:identifier><eid>2-s2.0-84929152235</eid><dc:title>Perioperative pulmonary management of the elderly patient</dc:title><dc:creator>Pfeifer K.</dc:creator><prism:publicationName>Current Geriatrics Reports</prism:publicationName><prism:eIssn>21967865</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>183-191</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13670-014-0116-3</prism:doi><dc:description>© 2015 Springer Science+Business Media New York. Advances in surgical and anesthetic techniques have led to steady reductions in perioperative complications. At the same time, improvements in public health and medical care have increased quality of life and life expectancy. As a result, an expanding population of elderly patients with chronic medical diseases is undergoing surgical procedures. Thorough risk assessment and management is required to assure optimal perioperative care for geriatric patients. This includes a full pulmonary evaluation, which is often over-shadowed by cardiovascular concerns. Recent literature has provided improved clarity in preoperative pulmonary risk assessment and potential options for risk management interventions. In this paper, we detail the current evidence for perioperative pulmonary care of elderly patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002746</affiliation-url><afid>60002746</afid><affilname>Harvard Medical School</affilname><name-variant>Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16444417700</author-url><authid>16444417700</authid><authname>Pfeifer K.</authname><surname>Pfeifer</surname><given-name>Kurt J.</given-name><initials>K.J.</initials><afid>60012553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36787794900</author-url><authid>36787794900</authid><authname>Slawski B.</authname><surname>Slawski</surname><given-name>Barbara A.</given-name><initials>B.A.</initials><afid>60012553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603604904</author-url><authid>6603604904</authid><authname>Smetana G.</authname><surname>Smetana</surname><given-name>Gerald W.</given-name><initials>G.W.</initials><afid>60002746</afid></author><authkeywords>Perioperative medicine | Postoperative care | Pulmonary complications</authkeywords><intid>1535918241</intid><source-id>21100358312</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928882807"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928882807?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928882807&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928882807&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928882807</prism:url><dc:identifier>SCOPUS_ID:84928882807</dc:identifier><eid>2-s2.0-84928882807</eid><dc:title>Three different up-titration regimens of ponesimod, an S1P&lt;inf&gt;1&lt;/inf&gt; receptor modulator, in healthy subjects</dc:title><dc:creator>Scherz M.</dc:creator><prism:publicationName>Journal of Clinical Pharmacology</prism:publicationName><prism:issn>00912700</prism:issn><prism:eIssn>15524604</prism:eIssn><prism:volume>55</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>688-697</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1002/jcph.467</prism:doi><dc:description>© 2015, The American College of Clinical Pharmacology. Ponesimod is a selective S1P&lt;inf&gt;1&lt;/inf&gt; receptor modulator, and induces dose-dependent reduction of circulating lymphocytes upon oral dosing. Previous studies showed that single doses up to 75 mg or multiple doses up to 40 mg once daily are well tolerated, and heart rate (HR) reduction and atrio-ventricular conduction delays upon treatment initiation are reduced by gradual up-titration to the maintenance dose. This single-center, open-label, randomized, multiple-dose, 3-treatment, 3-way crossover study compared the tolerability, safety, pharmacokinetics, cardiodynamics, and effects on lymphocytes of 3 different up-titration regimens of ponesimod in healthy male and female subjects. Up-titration regimens comprised escalating periods of b.i.d. dosing (2.5 or 5 mg) and q.d. dosing (10 or 20 mg or both). After the third up-titration period a variable-duration washout period of 1-3 days was followed by re-challenge with a single 20-mg dose of ponesimod. Adverse events were transient and mild to moderate in intensity, not different between regimens. HR decrease after the first dose was greater than after all subsequent doses, including up-titration doses. Little or no HR change was observed with morning doses of b.i.d. regimens, suggesting that 2.5 and 5 mg b.i.d. are sufficient to sustain cardiac desensitization for the 12-hours dosing interval.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002683</affiliation-url><afid>60002683</afid><affilname>Actelion Pharmaceuticals Ltd.</affilname><name-variant>Actelion Pharmaceuticals Ltd</name-variant><affiliation-city>Allschwil</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60095340</affiliation-url><afid>60095340</afid><affilname>PAREXEL International</affilname><name-variant>PAREXEL International</name-variant><affiliation-city>Waltham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601981854</author-url><authid>6601981854</authid><authname>Scherz M.</authname><surname>Scherz</surname><given-name>Michael W.</given-name><initials>M.W.</initials><afid>60002683</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55934757800</author-url><authid>55934757800</authid><authname>Brossard P.</authname><surname>Brossard</surname><given-name>Patrick</given-name><initials>P.</initials><afid>60002683</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005281990</author-url><authid>7005281990</authid><authname>D'Ambrosio D.</authname><surname>D'Ambrosio</surname><given-name>Daniele</given-name><initials>D.</initials><afid>60002683</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56522798000</author-url><authid>56522798000</authid><authname>Ipek M.</authname><surname>Ipek</surname><given-name>Murat</given-name><initials>M.</initials><afid>60095340</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15052974000</author-url><authid>15052974000</authid><authname>Dingemanse J.</authname><surname>Dingemanse</surname><given-name>Jasper</given-name><initials>J.</initials><afid>60002683</afid></author><authkeywords>desensitization | healthy subjects | ponesimod | S1P&lt;inf&gt;1&lt;/inf&gt; receptor modulator | up-titration regimen</authkeywords><intid>1535861819</intid><source-id>22983</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928956558"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928956558?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928956558&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928956558&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928956558</prism:url><dc:identifier>SCOPUS_ID:84928956558</dc:identifier><eid>2-s2.0-84928956558</eid><dc:title>Distinctive neck swelling in a patient with a vein of Galen arteriovenous malformation</dc:title><dc:creator>Agarwal A.</dc:creator><prism:publicationName>Journal of Ultrasound</prism:publicationName><prism:issn>19713495</prism:issn><prism:eIssn>18767931</prism:eIssn><prism:volume>18</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>197-200</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40477-014-0149-7</prism:doi><dc:description>© 2014, Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB). A vein of Galen arteriovenous malformation (VGAM) is a rare intracranial shunt lacking a capillary bed and resulting in subsequent aneurysmal enlargement. VGAM has been previously reported to present as cardiovascular abnormalities, including increased right-sided cardiac load and pressure, cardiac dilatation, pulmonary hypertension and retrograde flow into the aortic arch. We report the first case of VGAM presenting as a gross right-sided neck swelling in a 39-week-old immediately at birth. Transthoracic echocardiography detected dilatation of the superior vena cava and innominate vein, increased right ventricular and pulmonary arterial pressure, and retrograde flow into the aortic arch. Follow-up neck ultrasound revealed tortuous carotid artery and bilateral dilatation of neck veins. Transcranial ultrasound revealed abnormally dilated vessels posterior to the third ventricle, confirming VGAM. Our case demonstrates that while the differential diagnoses of neck swelling are extensive, such a presentation upon Doppler and echocardiographic investigation, may be suggestive of extracardiac causes such as VGAM. The management of such a condition remains critical due to risk of hemorrhage and extensive cerebral involvement.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023790</affiliation-url><afid>60023790</afid><affilname>McMaster Children's Hospital</affilname><name-variant>McMaster Children's Hospital</name-variant><affiliation-city>Hamilton</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55776182200</author-url><authid>55776182200</authid><authname>Agarwal A.</authname><surname>Agarwal</surname><given-name>Arnav</given-name><initials>A.</initials><afid>60016849</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56188847000</author-url><authid>56188847000</authid><authname>Firdouse M.</authname><surname>Firdouse</surname><given-name>Mohammed</given-name><initials>M.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56624108400</author-url><authid>56624108400</authid><authname>De Almeida C.</authname><surname>De Almeida</surname><given-name>Claudia Lace</given-name><initials>C.L.</initials><afid>60023790</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603854971</author-url><authid>6603854971</authid><authname>Mondal T.</authname><surname>Mondal</surname><given-name>Tapas</given-name><initials>T.</initials><afid>60023790</afid></author><authkeywords>Cerebral arteriovenous malformation | Gross neck mass | Pulsatile neck swelling | Vein of Galen</authkeywords><intid>2035871247</intid><source-id>6400153118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927130344"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927130344?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927130344&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927130344&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0531556515001059"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927130344</prism:url><dc:identifier>SCOPUS_ID:84927130344</dc:identifier><eid>2-s2.0-84927130344</eid><dc:title>Association of telomere length and mitochondrial DNA copy number in a community sample of healthy adults</dc:title><dc:creator>Tyrka A.</dc:creator><prism:publicationName>Experimental Gerontology</prism:publicationName><prism:issn>05315565</prism:issn><prism:eIssn>18736815</prism:eIssn><prism:volume>66</prism:volume><prism:pageRange>17-20</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.exger.2015.04.002</prism:doi><pii>S0531556515001059</pii><dc:description>© 2015. Cellular aging plays a role in longevity and senescence, and has been implicated in medical and psychiatric conditions, including heart disease, cancer, major depression and posttraumatic stress disorder. Telomere shortening and mitochondrial dysfunction are thought to be central to the cellular aging process. The present study examined the association between mitochondrial DNA (mtDNA) copy number and telomere length in a sample of medically healthy adults. Participants (total n. = 392) were divided into 4 groups based on the presence or absence of early life adversity and lifetime psychopathology: No Adversity/No Disorder, n. = 136; Adversity/No Disorder, n. = 91; No Adversity/Disorder, n. = 46; Adversity/Disorder, n. = 119. Telomere length and mtDNA copy number were measured using quantitative polymerase chain reaction. There was a positive correlation between mtDNA and telomere length in the entire sample (r. = 0.120, p. &lt;. 0.001) and in each of the four groups of participants (No Adversity/No Disorder, r. = 0.291, p. = 0.001; Adversity/No Disorder r. = 0.279, p. = 0.007; No Adversity/Disorder r. = 0.449, p. = 0.002; Adversity/Disorder, r. = 0.558, p. &lt;. 0.001). These correlations remained significant when controlling for age, smoking, and body mass index and establish an association between mtDNA and telomere length in a large group of women and men both with and without early adversity and psychopathology, suggesting co-regulation of telomeres and mitochondrial function. The mechanisms underlying this association may be important in the pathophysiology of age-related medical conditions, such as heart disease and cancer, as well as for stress-associated psychiatric disorders.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003486</affiliation-url><afid>60003486</afid><affilname>Butler Hospital</affilname><name-variant>Butler Hospital</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011460</affiliation-url><afid>60011460</afid><affilname>Brown University</affilname><name-variant>Brown University</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003486</affiliation-url><afid>60003486</afid><affilname>Butler Hospital</affilname><name-variant>Butler Hospital</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603316932</author-url><authid>6603316932</authid><authname>Tyrka A.</authname><surname>Tyrka</surname><given-name>Audrey R.</given-name><initials>A.R.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603316932</author-url><authid>6603316932</authid><authname>Tyrka A.</authname><surname>Tyrka</surname><given-name>Audrey R.</given-name><initials>A.R.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102689168</author-url><authid>7102689168</authid><authname>Carpenter L.</authname><surname>Carpenter</surname><given-name>Linda L.</given-name><initials>L.L.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102689168</author-url><authid>7102689168</authid><authname>Carpenter L.</authname><surname>Carpenter</surname><given-name>Linda L.</given-name><initials>L.L.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56537768000</author-url><authid>56537768000</authid><authname>Kao H.</authname><surname>Kao</surname><given-name>Hung Teh</given-name><initials>H.T.</initials><afid>60011460</afid><afid>60003486</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56537768000</author-url><authid>56537768000</authid><authname>Kao H.</authname><surname>Kao</surname><given-name>Hung Teh</given-name><initials>H.T.</initials><afid>60011460</afid><afid>60003486</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602580642</author-url><authid>6602580642</authid><authname>Porton B.</authname><surname>Porton</surname><given-name>Barbara</given-name><initials>B.</initials><afid>60011460</afid><afid>60003486</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602580642</author-url><authid>6602580642</authid><authname>Porton B.</authname><surname>Porton</surname><given-name>Barbara</given-name><initials>B.</initials><afid>60011460</afid><afid>60003486</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23478222500</author-url><authid>23478222500</authid><authname>Philip N.</authname><surname>Philip</surname><given-name>Noah S.</given-name><initials>N.S.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23478222500</author-url><authid>23478222500</authid><authname>Philip N.</authname><surname>Philip</surname><given-name>Noah S.</given-name><initials>N.S.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9432733600</author-url><authid>9432733600</authid><authname>Ridout S.</authname><surname>Ridout</surname><given-name>Samuel J.</given-name><initials>S.J.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9432733600</author-url><authid>9432733600</authid><authname>Ridout S.</authname><surname>Ridout</surname><given-name>Samuel J.</given-name><initials>S.J.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56433641400</author-url><authid>56433641400</authid><authname>Ridout K.</authname><surname>Ridout</surname><given-name>Kathryn K.</given-name><initials>K.K.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56433641400</author-url><authid>56433641400</authid><authname>Ridout K.</authname><surname>Ridout</surname><given-name>Kathryn K.</given-name><initials>K.K.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7201882386</author-url><authid>7201882386</authid><authname>Price L.</authname><surname>Price</surname><given-name>Lawrence H.</given-name><initials>L.H.</initials><afid>60003486</afid><afid>60011460</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7201882386</author-url><authid>7201882386</authid><authname>Price L.</authname><surname>Price</surname><given-name>Lawrence H.</given-name><initials>L.H.</initials><afid>60003486</afid><afid>60011460</afid></author><authkeywords>Mitochondria | Mitochondrial biogenesis | Mitochondrial DNA copy number | Telomere</authkeywords><intid>2035565220</intid><source-id>29003</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929159697"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929159697?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929159697&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929159697&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929159697</prism:url><dc:identifier>SCOPUS_ID:84929159697</dc:identifier><eid>2-s2.0-84929159697</eid><dc:title>Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation</dc:title><dc:creator>Wang Q.</dc:creator><prism:publicationName>Frontiers in Bioscience - Landmark</prism:publicationName><prism:issn>10939946</prism:issn><prism:eIssn>10934715</prism:eIssn><prism:volume>20</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>1116-1143</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><dc:description>© 2015, Frontiers in Bioscience. All rights reserved. The kynurenine (Kyn) pathway is the major route for tryptophan (Trp) metabolism, and it contributes to several fundamental biological processes. Trp is constitutively oxidized by tryptophan 2, 3-dioxygenase in liver cells. In other cell types, it is catalyzed by an alternative inducible indoleamine-pyrrole 2, 3-dioxygenase (IDO) under certain pathophysiological conditions, which consequently increases the formation of Kyn metabolites. IDO is up-regulated in response to inflammatory conditions as a novel marker of immune activation in early atherosclerosis. Besides, IDO and the IDO-related pathway are important mediators of the immunoinflammatory responses in advanced atherosclerosis. In particular, Kyn, 3-hydroxykynurenine, and quinolinic acid are positively associated with inflammation, oxidative stress (SOX), endothelial dysfunction, and carotid artery intima-media thickness values in end-stage renal disease patients. Moreover, IDO is a potential novel contributor to vessel relaxation and metabolism in systemic infections, which is also activated in acute severe heart attacks. The Kyn pathway plays a key role in the increased prevalence of cardiovascular disease by regulating inflammation, SOX, and immune activation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029833</affiliation-url><afid>60029833</afid><affilname>University of Oklahoma Health Sciences Center</affilname><name-variant>Univ. of Oklahoma Hlth. Sci. Center</name-variant><affiliation-city>Oklahoma City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105418585</affiliation-url><afid>105418585</afid><affilname>Hubei Provincial Corps Hospital</affilname><name-variant>Hubei Provincial Corps Hospital</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55943084400</author-url><authid>55943084400</authid><authname>Wang Q.</authname><surname>Wang</surname><given-name>Qiongxin</given-name><initials>Q.</initials><afid>60029833</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640044400</author-url><authid>56640044400</authid><authname>Liu D.</authname><surname>Liu</surname><given-name>Danxia</given-name><initials>D.</initials><afid>105418585</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56640568300</author-url><authid>56640568300</authid><authname>Song P.</authname><surname>Song</surname><given-name>Ping</given-name><initials>P.</initials><afid>60029833</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102088075</author-url><authid>7102088075</authid><authname>Zou M.</authname><surname>Zou</surname><given-name>Ming Hui</given-name><initials>M.H.</initials><afid>60029833</afid></author><authkeywords>Cardiovascular Diseases | Immune Activation | Inflammation | Kynurenines | Oxidative Stress | Review</authkeywords><intid>1535918041</intid><source-id>27974</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924954797"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924954797?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924954797&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924954797&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1095643315000161"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924954797</prism:url><dc:identifier>SCOPUS_ID:84924954797</dc:identifier><eid>2-s2.0-84924954797</eid><dc:title>Intermittent cold exposure results in visceral adipose tissue "browning" in the plateau pika (Ochotona curzoniae)</dc:title><dc:creator>Bai Z.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology -Part A : Molecular and Integrative Physiology</prism:publicationName><prism:issn>10956433</prism:issn><prism:eIssn>15314332</prism:eIssn><prism:volume>184</prism:volume><prism:pageRange>171-178</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpa.2015.01.019</prism:doi><pii>S1095643315000161</pii><dc:description>© 2015 Elsevier Inc. The plateau pika has developed tolerance to cold and hypoxia in order to adapt to living in the extreme environment of the Qinghai-Tibetan Plateau. One mammalian mechanism for cold adaptation is thermogenesis by brown adipose tissue (BAT), but the degree to which pika exploits this mechanism or how it may be modified by the additional stresses of high altitude is not known. Intermittent Cold Exposure (ICE) is an approachable method to study cold adaptation in rodents. To investigate the role of adipose tissue in the adaptation of pika to cold temperatures, we have studied pika during ICE. We find that pika kept in warm temperatures has little classical brown fat, but "browning" of white adipose tissues is observed rapidly upon cold exposure. This is demonstrated by the increased expression of several markers of brown fat differentiation including uncoupling protein 1 (UCP-1). Surprisingly, this occurs mainly in visceral rather than epididymal adipose tissue. In addition, ICE increases the expression of several general adipose differentiation markers at both the mRNA and protein levels. These substantial changes in the distribution of fat are accomplished without changes in weight or blood levels of glucose and triglycerides, suggesting that the adaptable changes are coordinated and self-compensated. Together, our results demonstrate that ICE promotes recruitment of BAT in pika, and unlike small mammals in at lower altitudes, pika can activate visceral WAT to adapt to cold stress without major changes overall energy balance.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112821007</affiliation-url><afid>112821007</afid><affilname>Qinghai University Medical School</affilname><name-variant>Qinghai University School of Medicine</name-variant><affiliation-city>Xining</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024978</affiliation-url><afid>60024978</afid><affilname>University of Utah School of Medicine</affilname><name-variant>Univ. of Utah School of Medicine</name-variant><affiliation-city>Salt Lake City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26631913000</author-url><authid>26631913000</authid><authname>Bai Z.</authname><surname>Bai</surname><given-name>Zhenzhong</given-name><initials>Z.</initials><afid>112821007</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55537953300</author-url><authid>55537953300</authid><authname>Wuren T.</authname><surname>Wuren</surname><given-name>Tana</given-name><initials>T.</initials><afid>112821007</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36137575300</author-url><authid>36137575300</authid><authname>Liu S.</authname><surname>Liu</surname><given-name>Shou</given-name><initials>S.</initials><afid>112821007</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56555504500</author-url><authid>56555504500</authid><authname>Han S.</authname><surname>Han</surname><given-name>Shirui</given-name><initials>S.</initials><afid>112821007</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56555615900</author-url><authid>56555615900</authid><authname>Chen L.</authname><surname>Chen</surname><given-name>Lin</given-name><initials>L.</initials><afid>112821007</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56556274900</author-url><authid>56556274900</authid><authname>McClain D.</authname><surname>McClain</surname><given-name>Donald</given-name><initials>D.</initials><afid>60024978</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005525095</author-url><authid>7005525095</authid><authname>Ge R.</authname><surname>Ge</surname><given-name>Ri Li</given-name><initials>R.L.</initials><afid>112821007</afid></author><authkeywords>Adaptation | Browning | Intermitted cold exposure | Plateau pika | Visceral fat | White adipose tissues</authkeywords><intid>1785234915</intid><source-id>3500148021</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929073610"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929073610?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929073610&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929073610&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929073610</prism:url><dc:identifier>SCOPUS_ID:84929073610</dc:identifier><eid>2-s2.0-84929073610</eid><dc:title>Review of Congenital Mitral Valve Stenosis: Analysis, Repair Techniques and Outcomes</dc:title><dc:creator>Baird C.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>167-173</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-015-0223-0</prism:doi><dc:description>© 2015, Biomedical Engineering Society. The spectrum of congenital mitral valve stenosis (MS) consists of a complex of defects that result in obstruction to left ventricular inflow. This spectrum includes patients with underdeveloped left heart structures (Fig. 1) to those with isolated congenital MS. The specific mitral valve defects can further be divided into categories based on the relationship to the mitral valve annulus including valvar, supravalvar and subvalvar components. Clinically, these patients present based on the degree of obstruction, associated mitral regurgitation, secondary pulmonary hypertension, associated lung disease and/or associated cardiac lesions. There are a number of factors that contribute to the successful outcomes in these patients including pre-operative imaging, aggressive surgical techniques and peri-operative management.[Figure not available: see fulltext.]</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030521</affiliation-url><afid>60030521</afid><affilname>Children's Hospital Boston</affilname><name-variant>Children's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:13610208600</author-url><authid>13610208600</authid><authname>Baird C.</authname><surname>Baird</surname><given-name>Christopher W.</given-name><initials>C.W.</initials><afid>60030521</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56637767300</author-url><authid>56637767300</authid><authname>Marx G.</authname><surname>Marx</surname><given-name>Gerald R.</given-name><initials>G.R.</initials><afid>60030521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56117061700</author-url><authid>56117061700</authid><authname>Borisuk M.</authname><surname>Borisuk</surname><given-name>Michele</given-name><initials>M.</initials><afid>60030521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56638039900</author-url><authid>56638039900</authid><authname>Emani S.</authname><surname>Emani</surname><given-name>Sitram</given-name><initials>S.</initials><afid>60030521</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006881026</author-url><authid>7006881026</authid><authname>del Nido P.</authname><surname>del Nido</surname><given-name>Pedro J.</given-name><initials>P.J.</initials><afid>60030521</afid></author><authkeywords>Anatomy | Congenital mitral stenosis | Repair</authkeywords><intid>35900998</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924994084"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924994084?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924994084&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924994084&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2214647415000124"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924994084</prism:url><dc:identifier>SCOPUS_ID:84924994084</dc:identifier><eid>2-s2.0-84924994084</eid><dc:title>Polymorphisms in IL-10 and INF-γ genes are associated with early atherosclerosis in coronary but not in carotid arteries: A study of 122 autopsy cases of young adults</dc:title><dc:creator>Esperança J.</dc:creator><prism:publicationName>BBA Clinical</prism:publicationName><prism:issn>22146474</prism:issn><prism:volume>3</prism:volume><prism:pageRange>214-220</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbacli.2015.02.005</prism:doi><pii>S2214647415000124</pii><dc:description>© 2015. Atherosclerosis is a complex disease, involving both genetic and environmental factors. However, the influence of genetic variations on its early development remains unclear. This study examined the association of 12 different polymorphisms with atherosclerosis severity in anterior descending coronary (DA, n= 103) and carotid arteries (CA, n= 66) of autopsied young adults (&lt;. 30. years old). Histological sections (H-E) were classified according to the American Heart Association. Polymorphisms in ACE, TNF-α (- 308G/A and - 238. G/A), IFN-γ (+. 874 A/T), MMP-9 (- 1562 C/T), IL-10 (- 1082 A/G and - 819 C/T), NOS3 (894. G/T), ApoA1 (rs964184), ApoE (E2E3E4 isoforms), and TGF-β (codons 25 and 10) genes were genotyped by gel electrophoresis or automatic DNA sequencing. Firearm projectile or car accident was the main cause of death, and no information about classical risk factors was available. Histological analysis showed high prevalence of type III atherosclerotic lesions in both DA (69%) and CA (39%) arteries, while severe type IV and V lesions were observed in 14% (DA) and 33% (CA). Allele frequencies and genotype distributions were determined. Among the polymorphisms studied, IFN-γ and IL-10 (- 1082 A/G) were related to atherosclerosis severity in DA artery. No association between genotypes and lesion severity was found in CA. In conclusion, we observed that the high prevalence of early atherosclerosis in young adults is associated with IFN-γ (p&lt;. 0.001) and IL-10 (p= 0.013) genotypes. This association is blood vessel dependent. Our findings suggest that the vascular system presents site specialization, and specific genetic variations may provide future biomarkers for early disease identification.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000036</affiliation-url><afid>60000036</afid><affilname>Universidade Federal do Rio de Janeiro</affilname><name-variant>Federal University of Rio de Janeiro</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000036</affiliation-url><afid>60000036</afid><affilname>Universidade Federal do Rio de Janeiro</affilname><name-variant>Federal University of Rio de Janeiro</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026004</affiliation-url><afid>60026004</afid><affilname>Fundacao Oswaldo Cruz</affilname><name-variant>Fundacao Oswaldo Cruz</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101513462</affiliation-url><afid>101513462</afid><affilname>Universidade do Grande Rio</affilname><name-variant>Universidade Do Grande Rio</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019077</affiliation-url><afid>60019077</afid><affilname>Universidade Federal do Rio de Janeiro, Centro de Ciencias da Saude Faculdade de Medicina</affilname><name-variant>Univ. Fed.</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56556429000</author-url><authid>56556429000</authid><authname>Esperança J.</authname><surname>Esperança</surname><given-name>José Carlos P</given-name><initials>J.C.P.</initials><afid>60000036</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:48061448300</author-url><authid>48061448300</authid><authname>Miranda W.</authname><surname>Miranda</surname><given-name>William R R</given-name><initials>W.R.R.</initials><afid>60000036</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56556335100</author-url><authid>56556335100</authid><authname>Netto J.</authname><surname>Netto</surname><given-name>José B.</given-name><initials>J.B.</initials><afid>60000036</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:54401189400</author-url><authid>54401189400</authid><authname>Lima F.</authname><surname>Lima</surname><given-name>Fabiane S.</given-name><initials>F.S.</initials><afid>60000036</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56556949800</author-url><authid>56556949800</authid><authname>Baumworcel L.</authname><surname>Baumworcel</surname><given-name>Leonardo</given-name><initials>L.</initials><afid>60000036</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:23007459900</author-url><authid>23007459900</authid><authname>Chimelli L.</authname><surname>Chimelli</surname><given-name>Leila</given-name><initials>L.</initials><afid>60000036</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:33968240800</author-url><authid>33968240800</authid><authname>Silva R.</authname><surname>Silva</surname><given-name>Rosane</given-name><initials>R.</initials><afid>60000036</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6602208611</author-url><authid>6602208611</authid><authname>Ürményi T.</authname><surname>Ürményi</surname><given-name>Turán P.</given-name><initials>T.P.</initials><afid>60000036</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004282058</author-url><authid>7004282058</authid><authname>Cabello P.</authname><surname>Cabello</surname><given-name>Pedro H.</given-name><initials>P.H.</initials><afid>60026004</afid><afid>101513462</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004282058</author-url><authid>7004282058</authid><authname>Cabello P.</authname><surname>Cabello</surname><given-name>Pedro H.</given-name><initials>P.H.</initials><afid>60026004</afid><afid>101513462</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003422131</author-url><authid>7003422131</authid><authname>Rondinelli E.</authname><surname>Rondinelli</surname><given-name>Edson</given-name><initials>E.</initials><afid>60000036</afid><afid>60019077</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003422131</author-url><authid>7003422131</authid><authname>Rondinelli E.</authname><surname>Rondinelli</surname><given-name>Edson</given-name><initials>E.</initials><afid>60000036</afid><afid>60019077</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6603430006</author-url><authid>6603430006</authid><authname>Faffe D.</authname><surname>Faffe</surname><given-name>Débora S.</given-name><initials>D.S.</initials><afid>60000036</afid></author><authkeywords>Atherosclerosis | Coronary artery disease | IL-10 | INF-γ | Polymorphisms</authkeywords><intid>1785233364</intid><source-id>21100317907</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927135583"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927135583?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927135583&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927135583&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002208"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927135583</prism:url><dc:identifier>SCOPUS_ID:84927135583</dc:identifier><eid>2-s2.0-84927135583</eid><dc:title>Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial</dc:title><dc:creator>Barbato E.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>351-354</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.03.045</prism:doi><pii>S0021915015002208</pii><dc:description>© 2015. Objective: The MEDCOR trial is a double-blind, randomized study aiming at demonstrating the superiority of molsidomine (direct NO donor) over placebo, used as add-on treatments, on improving endothelial function (EF) after 12 months, in stable angina patients undergoing percutaneous coronary intervention. Methods: EF was assessed by peripheral vasodilator response (i.e. Endoscore) using arterial tonometry and by several biomarkers, in terms of changes versus baseline after a one-year treatment. Results: The change in Endoscore was+75±130% in placebo group and+39±145% in molsidomine group (p=0.143). There was a decrease in sICAM-1 with molsidomine (-6%) and an increase with placebo (+6%). The MPO activity/antigen ratio slightly increased with placebo (+9%) and strongly decreased with molsidomine (-42%) (p=0.020). Conclusion: The MEDCOR trial was not able to demonstrate significant differences between molsidomine and placebo for all parameters, except the MPO activity/antigen ratio which significantly decreased with molsidomine (p=0.020 versus placebo).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068582</affiliation-url><afid>60068582</afid><affilname>Cardiovascular Center of Aalst</affilname><name-variant>Cardiovascular Center</name-variant><affiliation-city>Aalst</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>Berchem</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108232414</affiliation-url><afid>108232414</afid><affilname>Jessa Hospital</affilname><name-variant>Jessa Hospital</name-variant><affiliation-city>Hasselt</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069992</affiliation-url><afid>60069992</afid><affilname>Imelda Hospital</affilname><name-variant>Imelda Ziekenhuis</name-variant><affiliation-city>Bonheiden</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068606</affiliation-url><afid>60068606</afid><affilname>Centre Hospitalier Universitaire de Charleroi</affilname><name-variant>C.H.U. de Charleroi</name-variant><affiliation-city>Charleroi</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021078</affiliation-url><afid>60021078</afid><affilname>Centre Hospitalier Regional de La Citadelle</affilname><name-variant>Hôpital de la Citadelle</name-variant><affiliation-city>Liege</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113760292</affiliation-url><afid>113760292</afid><affilname>CHU Dinant-Godinne UCL Namur</affilname><name-variant>CHU Dinant-Godinne UCL Namur</name-variant><affiliation-city>Yvoir</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070037</affiliation-url><afid>60070037</afid><affilname>General Hospital St. Jan</affilname><name-variant>General Hospital St. Jan</name-variant><affiliation-city>Brugge</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069984</affiliation-url><afid>60069984</afid><affilname>Clinique Saint-Pierre of Ottignies</affilname><name-variant>Clinique Saint-Pierre</name-variant><affiliation-city>Ottignies</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100464528</affiliation-url><afid>100464528</afid><affilname>St Jean Hosp.</affilname><name-variant>Saint-Jean Hospital</name-variant><affiliation-city>Brussels</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003518203</author-url><authid>7003518203</authid><authname>Barbato E.</authname><surname>Barbato</surname><given-name>Emanuele</given-name><initials>E.</initials><afid>60068582</afid><afid>60017293</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003518203</author-url><authid>7003518203</authid><authname>Barbato E.</authname><surname>Barbato</surname><given-name>Emanuele</given-name><initials>E.</initials><afid>60068582</afid><afid>60017293</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202683471</author-url><authid>7202683471</authid><authname>Herman A.</authname><surname>Herman</surname><given-name>Arnold</given-name><initials>A.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603785904</author-url><authid>6603785904</authid><authname>Benit E.</authname><surname>Benit</surname><given-name>Edouard</given-name><initials>E.</initials><afid>108232414</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007049625</author-url><authid>7007049625</authid><authname>Janssens L.</authname><surname>Janssens</surname><given-name>Luc</given-name><initials>L.</initials><afid>60069992</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36483221400</author-url><authid>36483221400</authid><authname>Lalmand J.</authname><surname>Lalmand</surname><given-name>Jacques</given-name><initials>J.</initials><afid>60068606</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005471235</author-url><authid>7005471235</authid><authname>Hoffer E.</authname><surname>Hoffer</surname><given-name>Etienne</given-name><initials>E.</initials><afid>60021078</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6701587403</author-url><authid>6701587403</authid><authname>Chenu P.</authname><surname>Chenu</surname><given-name>Patrick</given-name><initials>P.</initials><afid>113760292</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004710124</author-url><authid>7004710124</authid><authname>Guédès A.</authname><surname>Guédès</surname><given-name>Antoine</given-name><initials>A.</initials><afid>113760292</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:23009439800</author-url><authid>23009439800</authid><authname>Missault L.</authname><surname>Missault</surname><given-name>Luc</given-name><initials>L.</initials><afid>60070037</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56633488600</author-url><authid>56633488600</authid><authname>Pirenne B.</authname><surname>Pirenne</surname><given-name>Bruno</given-name><initials>B.</initials><afid>60069984</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6506850336</author-url><authid>6506850336</authid><authname>Cardinal F.</authname><surname>Cardinal</surname><given-name>François</given-name><initials>F.</initials><afid>60069984</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:23020519700</author-url><authid>23020519700</authid><authname>Vercauteren S.</authname><surname>Vercauteren</surname><given-name>Steven</given-name><initials>S.</initials><afid>100464528</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7006420435</author-url><authid>7006420435</authid><authname>Wijns W.</authname><surname>Wijns</surname><given-name>William</given-name><initials>W.</initials><afid>60068582</afid></author><authkeywords>Atherosclerosis | Biomarkers | Molsidomine | Nitric oxide donor | Percutaneous coronary intervention | Reactive hyperemia-peripheral arterial tonometry | Stable angina</authkeywords><intid>1785571553</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928732759"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928732759?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928732759&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928732759&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0890623815000325"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928732759</prism:url><dc:identifier>SCOPUS_ID:84928732759</dc:identifier><eid>2-s2.0-84928732759</eid><dc:title>Evaluating the potential effect on fetal tissue after exposure to granisetron during pregnancy</dc:title><dc:creator>Smith J.</dc:creator><prism:publicationName>Reproductive Toxicology</prism:publicationName><prism:issn>08906238</prism:issn><prism:eIssn>18731708</prism:eIssn><prism:volume>53</prism:volume><prism:pageRange>92-98</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.reprotox.2015.02.011</prism:doi><pii>S0890623815000325</pii><dc:description>© 2015 Elsevier Inc. The objective of this study was to elucidate the possible toxic effects on the fetal tissues after exposure to two clinically relevant concentrations of granisetron. Primary cells were isolated from human fetal organs of 16-19 weeks gestational age and treated with 3. ng/mL or 30. ng/mL of granisetron. Cell cycle progression was evaluated by flow cytometry. ELISA was used to detect alterations in major apoptotic proteins.Up to 10% apoptosis in cardiac tissue was observed following treatment with 30. ng/mL granisetron. Neither concentration of granisetron caused alteration in cell cycle progression or alterations in apoptotic proteins in any of the other tissues.At 30. ng/mL granisetron concentration had the potential to induce up to 10% apoptosis in cardiac tissue; clinical significance needs further evaluation. At granisetron 3. ng/mL there was no detectable toxicity or on any fetal tissue in this study. Further research is needed to confirm these preliminary findings and determine if clinically significant.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021568</affiliation-url><afid>60021568</afid><affilname>University of Texas Medical School at Houston</affilname><name-variant>University of Texas Medical School at Houston</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021568</affiliation-url><afid>60021568</afid><affilname>University of Texas Medical School at Houston</affilname><name-variant>University of Texas Medical School at Houston</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35735151000</author-url><authid>35735151000</authid><authname>Smith J.</authname><surname>Smith</surname><given-name>Judith A.</given-name><initials>J.A.</initials><afid>60021568</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56313343600</author-url><authid>56313343600</authid><authname>Julius J.</authname><surname>Julius</surname><given-name>Justin M.</given-name><initials>J.M.</initials><afid>60015023</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15026287700</author-url><authid>15026287700</authid><authname>Gaikwad A.</authname><surname>Gaikwad</surname><given-name>Anjali</given-name><initials>A.</initials><afid>60021568</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602127399</author-url><authid>6602127399</authid><authname>Berens P.</authname><surname>Berens</surname><given-name>Pamela D.</given-name><initials>P.D.</initials><afid>60021568</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005470359</author-url><authid>7005470359</authid><authname>Alcorn J.</authname><surname>Alcorn</surname><given-name>Joseph</given-name><initials>J.</initials><afid>60021568</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005901536</author-url><authid>7005901536</authid><authname>Moise K.</authname><surname>Moise</surname><given-name>Kenneth J.</given-name><initials>K.J.</initials><afid>60021568</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602882013</author-url><authid>6602882013</authid><authname>Refuerzo J.</authname><surname>Refuerzo</surname><given-name>Jerrie S.</given-name><initials>J.S.</initials><afid>60021568</afid></author><authkeywords>5-HT&lt;inf&gt;3&lt;/inf&gt; receptor antagonists | Fetal toxicology | Granisetron | Pregnancy | Safety</authkeywords><intid>1785839541</intid><source-id>24028</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928683471"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928683471?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928683471&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928683471&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928683471</prism:url><dc:identifier>SCOPUS_ID:84928683471</dc:identifier><eid>2-s2.0-84928683471</eid><dc:title>Pathological changes by Hapalotrema postorchis Rao 1976 (Digenea: Spirorchiidae) in a green turtle Chelonia mydas Linnaeus 1758 (Testudines, Cheloniidae) from Brazil</dc:title><dc:creator>Werneck M.</dc:creator><prism:publicationName>Helminthologia (Poland)</prism:publicationName><prism:issn>04406605</prism:issn><prism:volume>52</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>148-154</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1515/helmin-2015-0027</prism:doi><dc:description>© 2015 Institute of Parasitology, SAS, Košice. This note reports the occurrence of Hapalotrema postorchis Rao 1976 collected from an aortic aneurysm in a green turtle (Chelonia mydas Linnaeus 1758) found on the coast of Brazil. Besides the vascular lesion, granulomatous reactions with foreign - body giant cells were found surrounding the parasite eggs in the heart, intestines, liver, pancreas, spleen, brain and kidneys. This paper presents the first report of H. postorchis and accompanying lesions in a green sea turtle from the western South Atlantic Ocean.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115135062</affiliation-url><afid>115135062</afid><affilname>Centro</affilname><name-variant>Centro</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115200036</affiliation-url><afid>115200036</afid><affilname>CTA - Serviços em Meio Ambiente</affilname><name-variant>CTA - Serviços em Meio Ambiente</name-variant><affiliation-city>Vitoria</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025875</affiliation-url><afid>60025875</afid><affilname>Universidade Estadual do Norte Fluminense</affilname><name-variant>Universidade Estadual do Norte Fluminense</name-variant><affiliation-city>Campos dos Goitacazes</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15046258200</author-url><authid>15046258200</authid><authname>Werneck M.</authname><surname>Werneck</surname><given-name>M. R.</given-name><initials>M.R.</initials><afid>115135062</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56609854300</author-url><authid>56609854300</authid><authname>Souza G.</authname><surname>Souza</surname><given-name>G. B.</given-name><initials>G.B.</initials><afid>115200036</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55927911700</author-url><authid>55927911700</authid><authname>Berger B.</authname><surname>Berger</surname><given-name>B. C.</given-name><initials>B.C.</initials><afid>115200036</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56610260200</author-url><authid>56610260200</authid><authname>Trazzi A.</authname><surname>Trazzi</surname><given-name>A.</given-name><initials>A.</initials><afid>115200036</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56334002500</author-url><authid>56334002500</authid><authname>Ribeiro R.</authname><surname>Ribeiro</surname><given-name>R. B.</given-name><initials>R.B.</initials><afid>60025875</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56609609500</author-url><authid>56609609500</authid><authname>Silva M.</authname><surname>Silva</surname><given-name>M. A.</given-name><initials>M.A.</initials><afid>60025875</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56610379800</author-url><authid>56610379800</authid><authname>Leandro H.</authname><surname>Leandro</surname><given-name>H. J.</given-name><initials>H.J.</initials><afid>60025875</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:21741996300</author-url><authid>21741996300</authid><authname>Carvalho E.</authname><surname>Carvalho</surname><given-name>E. C Q</given-name><initials>E.C.Q.</initials><afid>60025875</afid></author><authkeywords>Aneurism | Chelonia mydas | Hapalotrema postorchis | sea turtles | Spirorchiidae | spirorchiids lesions</authkeywords><intid>1785823984</intid><source-id>21981</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930201879"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930201879?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930201879&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930201879&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930201879</prism:url><dc:identifier>SCOPUS_ID:84930201879</dc:identifier><eid>2-s2.0-84930201879</eid><dc:title>MicroRNA-145-targeted drug and its preventive effect on pulmonary arterial hypertension (patent WO2012153135 A1)</dc:title><dc:creator>Ogorodnikova N.</dc:creator><prism:publicationName>Expert Opinion on Therapeutic Patents</prism:publicationName><prism:issn>13543776</prism:issn><prism:eIssn>17447674</prism:eIssn><prism:volume>25</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>723-727</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1517/13543776.2015.1025751</prism:doi><dc:description>© 2015 Informa UK, Ltd. Introduction: Pulmonary arterial hypertension (PAH) is a disease of various etiologies, characterized by progressive vascular remodeling that leads to right ventricular hypertrophy and heart failure. Although modern therapy improves life quality of patients, prognosis of PAH remains poor with a high mortality rate. Overexpression of microRNA (miR)-145, which was found in PAH patients, leads to progression of vascular remodeling. The current patent proposes a strategy using antisense oligonucleotides (ASOs) against miR-145 for prevention and treatment of PAH.Areas covered: Overexpression of miR-145 was shown in chronic hypoxia mouse models and PAH patients. Genetic ablation of miR-145 in hypoxic mice led to improved hemodynamic and vascular remodeling parameters. Furthermore, miR-145 inhibition by ASOs has been performed in chronic hypoxia mouse models. The experiments showed improved systolic right ventricular pressure and a decreased percentage of vascular remodeling.Expert opinion: Although the mouse model does not display the full pathology of PAH, the inhibition of miR-145 by modified ASOs is promising for prevention and reversion of vascular remodeling. Whether such ASOs can be efficiently delivered and will prevent progression of PAH pathology and may lead to an extended lifespan of PAH patients remains to be elucidated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000762</affiliation-url><afid>60000762</afid><affilname>Humboldt-Universitat zu Berlin</affilname><name-variant>Humboldt University</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663095900</author-url><authid>56663095900</authid><authname>Ogorodnikova N.</authname><surname>Ogorodnikova</surname><given-name>Natalia</given-name><initials>N.</initials><afid>60000762</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603725566</author-url><authid>6603725566</authid><authname>Arenz C.</authname><surname>Arenz</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60000762</afid></author><authkeywords>Antisense oligonucleotides | Locked nucleic acids | MicroRNA-145 | MicroRNA-targeted drug | Pulmonary arterial hypertension</authkeywords><intid>536087114</intid><source-id>21353</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928790629"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928790629?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928790629&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928790629&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928790629</prism:url><dc:identifier>SCOPUS_ID:84928790629</dc:identifier><eid>2-s2.0-84928790629</eid><dc:title>The Swiss Transplant Cohort Study: Lessons from the First 6 Years</dc:title><dc:creator>Berger C.</dc:creator><prism:publicationName>Current Infectious Disease Reports</prism:publicationName><prism:issn>15233847</prism:issn><prism:eIssn>15343146</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11908-015-0486-5</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Prospective cohort studies significantly contribute to answering specific research questions in a defined population. Since 2008, the Swiss Transplant Cohort Study (STCS) systematically enrolled &gt;95 % of all transplant recipients in Switzerland, collecting predefined data at determined time points. Designed as an open cohort, the STCS has included &gt;3900 patients to date, with a median follow-up of 2.96 years (IQR 1.44–4.73). This review highlights some relevant findings in the field of transplant-associated infections gained by the STCS so far. Three key general aspects have crystallized: (i) Well-run cohort studies are a powerful tool to conduct genetic studies, which are crucially dependent on a meticulously described phenotype. (ii) Long-term real-life observations are adding a distinct layer of information that cannot be obtained during randomized studies. (iii) The systemic collection of data, close interdisciplinary collaboration, and continuous analysis of some key outcome data such as infectious diseases endpoints can improve patient care.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002695</affiliation-url><afid>60002695</afid><affilname>Kinderspital Zurich</affilname><name-variant>University Children's Hospital</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000239</affiliation-url><afid>60000239</afid><affilname>Universitat Lausanne Schweiz</affilname><name-variant>University of Lausanne</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022646</affiliation-url><afid>60022646</afid><affilname>Kantonsspital St Gallen</affilname><name-variant>Cantonal Hospital St. Gallen</name-variant><affiliation-city>St Gallen</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020486</affiliation-url><afid>60020486</afid><affilname>Universitat Bern</affilname><name-variant>University of Berne</name-variant><affiliation-city>Bern</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028287</affiliation-url><afid>60028287</afid><affilname>Universitatsspital Basel</affilname><name-variant>University Hospital Basel</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60074270</affiliation-url><afid>60074270</afid><affilname>University of Basel, Institute for Medical Microbiology</affilname><name-variant>University of Basel</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028287</affiliation-url><afid>60028287</afid><affilname>Universitatsspital Basel</affilname><name-variant>University Hospital Basel</name-variant><affiliation-city>Basel</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009963</affiliation-url><afid>60009963</afid><affilname>Hopitaux universitaires de Geneve</affilname><name-variant>Geneva University Hospital</name-variant><affiliation-city>Geneve</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019619</affiliation-url><afid>60019619</afid><affilname>UniversitatsSpital Zurich</affilname><name-variant>University Hospital Zurich</name-variant><affiliation-city>Zurich</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101404862</affiliation-url><afid>101404862</afid><affilname>Clinica Luganese</affilname><name-variant>Clinica Luganese SA</name-variant><affiliation-city>Lugano</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56423156500</author-url><authid>56423156500</authid><authname>Berger C.</authname><surname>Berger</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60002695</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603277503</author-url><authid>6603277503</authid><authname>Bochud P.</authname><surname>Bochud</surname><given-name>Pierre Yves</given-name><initials>P.Y.</initials><afid>60000239</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56294927900</author-url><authid>56294927900</authid><authname>Boggian K.</authname><surname>Boggian</surname><given-name>Katja</given-name><initials>K.</initials><afid>60022646</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36143774900</author-url><authid>36143774900</authid><authname>Cusini A.</authname><surname>Cusini</surname><given-name>Alexia</given-name><initials>A.</initials><afid>60020486</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24073168700</author-url><authid>24073168700</authid><authname>Egli A.</authname><surname>Egli</surname><given-name>Adrian</given-name><initials>A.</initials><afid>60028287</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22957488700</author-url><authid>22957488700</authid><authname>Garzoni C.</authname><surname>Garzoni</surname><given-name>Christian</given-name><initials>C.</initials><afid>60020486</afid><afid>101404862</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22957488700</author-url><authid>22957488700</authid><authname>Garzoni C.</authname><surname>Garzoni</surname><given-name>Christian</given-name><initials>C.</initials><afid>60020486</afid><afid>101404862</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7202406848</author-url><authid>7202406848</authid><authname>Hirsch H.</authname><surname>Hirsch</surname><given-name>Hans H.</given-name><initials>H.H.</initials><afid>60074270</afid><afid>60028287</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7202406848</author-url><authid>7202406848</authid><authname>Hirsch H.</authname><surname>Hirsch</surname><given-name>Hans H.</given-name><initials>H.H.</initials><afid>60074270</afid><afid>60028287</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55754534800</author-url><authid>55754534800</authid><authname>Hoffmann M.</authname><surname>Hoffmann</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60022646</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7102045384</author-url><authid>7102045384</authid><authname>Khanna N.</authname><surname>Khanna</surname><given-name>Nina</given-name><initials>N.</initials><afid>60028287</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:24174793000</author-url><authid>24174793000</authid><authname>Manuel O.</authname><surname>Manuel</surname><given-name>Oriol</given-name><initials>O.</initials><afid>60000239</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006287253</author-url><authid>7006287253</authid><authname>Meylan P.</authname><surname>Meylan</surname><given-name>Pascal</given-name><initials>P.</initials><afid>60000239</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7006553595</author-url><authid>7006553595</authid><authname>Nadal D.</authname><surname>Nadal</surname><given-name>David</given-name><initials>D.</initials><afid>60002695</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7003684255</author-url><authid>7003684255</authid><authname>van Delden C.</authname><surname>van Delden</surname><given-name>Christian</given-name><initials>C.</initials><afid>60009963</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003677837</author-url><authid>7003677837</authid><authname>Weisser M.</authname><surname>Weisser</surname><given-name>Maja</given-name><initials>M.</initials><afid>60028287</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7102575527</author-url><authid>7102575527</authid><authname>Mueller N.</authname><surname>Mueller</surname><given-name>Nicolas J.</given-name><initials>N.J.</initials><afid>60019619</afid></author><authkeywords>Cohort studies | Genetic studies | Infectious diseases | Observational studies | Transplantation</authkeywords><intid>1035846388</intid><source-id>20760</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928031489"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928031489?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928031489&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928031489&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0021915015002282"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928031489</prism:url><dc:identifier>SCOPUS_ID:84928031489</dc:identifier><eid>2-s2.0-84928031489</eid><dc:title>Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: Consecutive survivors and population-based controls</dc:title><dc:creator>Krajcoviechova A.</dc:creator><prism:publicationName>Atherosclerosis</prism:publicationName><prism:issn>00219150</prism:issn><prism:eIssn>18791484</prism:eIssn><prism:volume>240</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>446-452</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.atherosclerosis.2015.04.010</prism:doi><pii>S0021915015002282</pii><dc:description>© 2015 Elsevier Ireland Ltd. Objective: Due to contradictory results of previous studies evaluating the association between ischemic stroke (IS) and thrombophilic polymorphisms, their routine screening in IS patients, particularly those older than 60 years, is not recommended. We evaluated the differences in the distribution of rs6025 and rs1799963 polymorphisms according to IS subtypes and their interaction with smoking. Methods: We conducted a case-control study of 423 hospital-based consecutive survivors of their first-ever IS and 614 population-based controls. Survivors (18-81 years) with IS documented by brain imagining were examined at a median of 16 months after the index event. The stroke subtype was categorized using the Causative Classification of Stroke System. Controls (50-75 years) were free of a history of stroke/TIA, coronary heart disease, and venous thromboembolism. Results: Age- and gender-adjusted prevalence of individuals carrying at least one copy of the rs1799963A minor allele was 5.3% among stroke survivors (by subtypes: 3.1% in large artery atherosclerosis, 2.0% in cardio-aortic embolism, 2.4% in small artery occlusion, and 10.3% in undetermined stroke) vs. 2.4% among controls. In multinomial multivariate adjusted analysis, rs1799963 was exclusively associated with undetermined stroke (OR: 3.67; 95% CI: 1.52-8.85; p=0.004). There was strong evidence of rs1799963×smoking synergistic interaction (OR: 5.14; 95% CI: 1.65-16.01; p=0.005). There was no association of rs6025 with IS in general, or with any subtype. Conclusions: In our consecutive IS survivors, carriage of the rs1799963A allele is associated with undetermined stroke. This effect appears to be confined to smokers.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016605</affiliation-url><afid>60016605</afid><affilname>Charles University in Prague</affilname><name-variant>Charles University in Prague</name-variant><affiliation-city>Prague</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Neurology of Thomayer Hospital in Prague</affilname><affiliation-city/><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016605</affiliation-url><afid>60016605</afid><affilname>Charles University in Prague</affilname><name-variant>Charles University in Prague</name-variant><affiliation-city>Prague</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016605</affiliation-url><afid>60016605</afid><affilname>Charles University in Prague</affilname><name-variant>Charles University in Prague</name-variant><affiliation-city>Prague</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009507</affiliation-url><afid>60009507</afid><affilname>Universite de Montreal</affilname><name-variant>University of Montreal</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36015426500</author-url><authid>36015426500</authid><authname>Krajcoviechova A.</authname><surname>Krajcoviechova</surname><given-name>A.</given-name><initials>A.</initials><afid>60016605</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:9232678100</author-url><authid>9232678100</authid><authname>Wohlfahrt P.</authname><surname>Wohlfahrt</surname><given-name>P.</given-name><initials>P.</initials><afid>60016605</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005998758</author-url><authid>7005998758</authid><authname>Mayer O.</authname><surname>Mayer</surname><given-name>O.</given-name><initials>O.</initials><afid>60016605</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005452820</author-url><authid>7005452820</authid><authname>Vanek J.</authname><surname>Vanek</surname><given-name>J.</given-name><initials>J.</initials><afid>60016605</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26424657100</author-url><authid>26424657100</authid><authname>Hajkova J.</authname><surname>Hajkova</surname><given-name>J.</given-name><initials>J.</initials><afid>60016605</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56598108800</author-url><authid>56598108800</authid><authname>Hlinovsky D.</authname><surname>Hlinovsky</surname><given-name>D.</given-name><initials>D.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602087901</author-url><authid>6602087901</authid><authname>Kvasnicka T.</authname><surname>Kvasnicka</surname><given-name>T.</given-name><initials>T.</initials><afid>60016605</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56601837300</author-url><authid>56601837300</authid><authname>Tremblay J.</authname><surname>Tremblay</surname><given-name>J.</given-name><initials>J.</initials><afid>60009507</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56601761900</author-url><authid>56601761900</authid><authname>Hamet P.</authname><surname>Hamet</surname><given-name>P.</given-name><initials>P.</initials><afid>60009507</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:12774824000</author-url><authid>12774824000</authid><authname>Filipovsky J.</authname><surname>Filipovsky</surname><given-name>J.</given-name><initials>J.</initials><afid>60016605</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7102891179</author-url><authid>7102891179</authid><authname>Kvasnicka J.</authname><surname>Kvasnicka</surname><given-name>J.</given-name><initials>J.</initials><afid>60016605</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004832017</author-url><authid>7004832017</authid><authname>Cifkova R.</authname><surname>Cifkova</surname><given-name>R.</given-name><initials>R.</initials><afid>60016605</afid></author><authkeywords>Factor V Leiden (rs6025) | Genetic epidemiology | Hypercoagulopathy | Ischemic stroke | Prothrombin G20210A (rs1799963) | Smoking</authkeywords><intid>1035711421</intid><source-id>22483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84920410592"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84920410592?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84920410592&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84920410592&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814614020007"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84920410592</prism:url><dc:identifier>SCOPUS_ID:84920410592</dc:identifier><eid>2-s2.0-84920410592</eid><dc:title>Comparing antioxidant capacity of purine alkaloids: A new, efficient trio for screening and discovering potential antioxidants in vitro and in vivo</dc:title><dc:creator>Tsoi B.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>176</prism:volume><prism:pageRange>411-419</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.12.087</prism:doi><pii>S0308814614020007</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. The most commonly applied strategies for the evaluation of antioxidant capacity are the chemical- or cell-based approaches. However, the results obtained from these methods might not reflect the antioxidant ability of test samples within organisms. In this study, we propose a combination of experiments, including oxygen radical absorbance capacity (ORAC), cellular antioxidant activity assay (CAA), and the chick embryo model, as an efficient trio to evaluate antioxidant capacity of food components. Taking purine alkaloids as example, results demonstrate that chemical and cellular method might misinterpret their true ability on antioxidation. In chick embryo model, caffeine and theacrine can significantly improve vessel density on chorioallantoic membrane and myocardial apoptosis. The mechanism can be involving multiple targets within the organism. We believe that the trio proposed can be widely utilized in screening massive number of antioxidant in a cost-effective way. It will also help discovering new antioxidants that are easily being omitted due to their relatively poor in vitro activities.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103801</affiliation-url><afid>60103801</afid><affilname>University of Jinan</affilname><name-variant>Jinan University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:41762921200</author-url><authid>41762921200</authid><authname>Tsoi B.</authname><surname>Tsoi</surname><given-name>Bun</given-name><initials>B.</initials><afid>60103801</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55613378800</author-url><authid>55613378800</authid><authname>Yi R.</authname><surname>Yi</surname><given-name>Ruo Nan</given-name><initials>R.N.</initials><afid>60103801</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56424564600</author-url><authid>56424564600</authid><authname>Cao L.</authname><surname>Cao</surname><given-name>Ling Fang</given-name><initials>L.F.</initials><afid>60103801</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56282413300</author-url><authid>56282413300</authid><authname>Li S.</authname><surname>Li</surname><given-name>Shan Bing</given-name><initials>S.B.</initials><afid>60103801</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56468682300</author-url><authid>56468682300</authid><authname>Tan R.</authname><surname>Tan</surname><given-name>Rui Rong</given-name><initials>R.R.</initials><afid>60103801</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56468231500</author-url><authid>56468231500</authid><authname>Chen M.</authname><surname>Chen</surname><given-name>Min</given-name><initials>M.</initials><afid>60103801</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56468294700</author-url><authid>56468294700</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiao Xiao</given-name><initials>X.X.</initials><afid>60103801</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56469180300</author-url><authid>56469180300</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Chen</given-name><initials>C.</initials><afid>60103801</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35201245800</author-url><authid>35201245800</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yi Fang</given-name><initials>Y.F.</initials><afid>60103801</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7202403232</author-url><authid>7202403232</authid><authname>Kurihara H.</authname><surname>Kurihara</surname><given-name>Hiroshi</given-name><initials>H.</initials><afid>60103801</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:26422899900</author-url><authid>26422899900</authid><authname>He R.</authname><surname>He</surname><given-name>Rong Rong</given-name><initials>R.R.</initials><afid>60103801</afid></author><authkeywords>Antioxidant capacity | CAA | Caffeine | Chick embryo | ORAC | Purine alkaloids | Theacrine</authkeywords><intid>1534481273</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924981041"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924981041?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924981041&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924981041&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2352340915000165"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924981041</prism:url><dc:identifier>SCOPUS_ID:84924981041</dc:identifier><eid>2-s2.0-84924981041</eid><dc:title>Data for proteomic analysis of murine cardiomyocytic HL-1 cells treated with siRNA against tissue factor</dc:title><dc:creator>Brioschi M.</dc:creator><prism:publicationName>Data in Brief</prism:publicationName><prism:eIssn>23523409</prism:eIssn><prism:volume>3</prism:volume><prism:pageRange>117-119</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.dib.2015.02.005</prism:doi><pii>S2352340915000165</pii><dc:description>© 2015 The Authors. This data article is related to the research article entitled Proteomics of Tissue Factor silencing in cardiomyocytic cells reveals a new role for this coagulation factor in splicing machinery control by Lento et al. [1].Tissue Factor (TF) is a key player in the coagulation cascade, but it has additional functions ranging from angiogenesis, tumour invasion and, in the heart, the maintenance of the integrity of cardiac cells. This article reports the nano-LC-MSE analysis of the cardiomyocytic HL-1 cell line proteome and describes the results obtained from a Gene Ontology analysis of those proteins affected by TF-gene silencing.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073816</affiliation-url><afid>60073816</afid><affilname>IRCCS Centro Cardiologico Monzino</affilname><name-variant>Centro Cardiologico Monzino</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011520</affiliation-url><afid>60011520</afid><affilname>King's College London</affilname><name-variant>King's College London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011520</affiliation-url><afid>60011520</afid><affilname>King's College London</affilname><name-variant>King's College London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008524</affiliation-url><afid>60008524</afid><affilname>University of Bradford</affilname><name-variant>University of Bradford</name-variant><affiliation-city>Bradford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030318</affiliation-url><afid>60030318</afid><affilname>Universita degli Studi di Milano</affilname><name-variant>University of Milan</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55237102700</author-url><authid>55237102700</authid><authname>Brioschi M.</authname><surname>Brioschi</surname><given-name>Maura</given-name><initials>M.</initials><afid>60073816</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:50561746100</author-url><authid>50561746100</authid><authname>Lento S.</authname><surname>Lento</surname><given-name>Sabrina</given-name><initials>S.</initials><afid>60073816</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23967964400</author-url><authid>23967964400</authid><authname>Barcella S.</authname><surname>Barcella</surname><given-name>Simona</given-name><initials>S.</initials><afid>60073816</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36893008700</author-url><authid>36893008700</authid><authname>Nasim M.</authname><surname>Nasim</surname><given-name>Md Talat</given-name><initials>M.T.</initials><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36893008700</author-url><authid>36893008700</authid><authname>Nasim M.</authname><surname>Nasim</surname><given-name>Md Talat</given-name><initials>M.T.</initials><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36893008700</author-url><authid>36893008700</authid><authname>Nasim M.</authname><surname>Nasim</surname><given-name>Md Talat</given-name><initials>M.T.</initials><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55813922500</author-url><authid>55813922500</authid><authname>Ghilardi S.</authname><surname>Ghilardi</surname><given-name>Stefania</given-name><initials>S.</initials><afid>60073816</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8718600000</author-url><authid>8718600000</authid><authname>Barbieri S.</authname><surname>Barbieri</surname><given-name>Silvia Stella</given-name><initials>S.S.</initials><afid>60073816</afid><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid><afid>60030318</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8718600000</author-url><authid>8718600000</authid><authname>Barbieri S.</authname><surname>Barbieri</surname><given-name>Silvia Stella</given-name><initials>S.S.</initials><afid>60073816</afid><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid><afid>60030318</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8718600000</author-url><authid>8718600000</authid><authname>Barbieri S.</authname><surname>Barbieri</surname><given-name>Silvia Stella</given-name><initials>S.S.</initials><afid>60073816</afid><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid><afid>60030318</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8718600000</author-url><authid>8718600000</authid><authname>Barbieri S.</authname><surname>Barbieri</surname><given-name>Silvia Stella</given-name><initials>S.S.</initials><afid>60073816</afid><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid><afid>60030318</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8718600000</author-url><authid>8718600000</authid><authname>Barbieri S.</authname><surname>Barbieri</surname><given-name>Silvia Stella</given-name><initials>S.S.</initials><afid>60073816</afid><afid>60011520</afid><afid>60011520</afid><afid>60008524</afid><afid>60030318</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006057885</author-url><authid>7006057885</authid><authname>Tremoli E.</authname><surname>Tremoli</surname><given-name>Elena</given-name><initials>E.</initials><afid>60073816</afid><afid>60030318</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006057885</author-url><authid>7006057885</authid><authname>Tremoli E.</authname><surname>Tremoli</surname><given-name>Elena</given-name><initials>E.</initials><afid>60073816</afid><afid>60030318</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603951888</author-url><authid>6603951888</authid><authname>Banfi C.</authname><surname>Banfi</surname><given-name>Cristina</given-name><initials>C.</initials><afid>60073816</afid></author><intid>535235056</intid><source-id>21100372856</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923912751"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923912751?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923912751&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923912751&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0925753515000363"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923912751</prism:url><dc:identifier>SCOPUS_ID:84923912751</dc:identifier><eid>2-s2.0-84923912751</eid><dc:title>A methodological extension to human reliability analysis for cargo tank cleaning operation on board chemical tanker ships</dc:title><dc:creator>Akyuz E.</dc:creator><prism:publicationName>Safety Science</prism:publicationName><prism:issn>09257535</prism:issn><prism:eIssn>18791042</prism:eIssn><prism:volume>75</prism:volume><prism:pageRange>146-155</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ssci.2015.02.008</prism:doi><pii>S0925753515000363</pii><dc:description>© 2015 Elsevier Ltd. This is an article that conducts an empirical human reliability analysis for tank cleaning process on-board chemical tanker ship to enhance safety and operational reliability in maritime industry, providing a methodological extension through the integration of the AHP technique into the HEART approach. The paper provides a methodological development on decision making and human factors via extending a new approach to weight the proportion of the effect for calculating error producing conditions through operations. The model demonstration illustrates that cleaning of residues from hazardous cargoes such as acetic acid has required performing various critical tasks supported with recovery solutions. This research also provides practical insights along with reliability monitoring in ship operational level.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104504</affiliation-url><afid>60104504</afid><affilname>Piri Reis Universitesi</affilname><name-variant>Piri Reis University Turkey</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022002</affiliation-url><afid>60022002</afid><affilname>Istanbul Teknik Universitesi</affilname><name-variant>Istanbul Technical University</name-variant><affiliation-city>Istanbul</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56136095500</author-url><authid>56136095500</authid><authname>Akyuz E.</authname><surname>Akyuz</surname><given-name>Emre</given-name><initials>E.</initials><afid>60104504</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23049358700</author-url><authid>23049358700</authid><authname>Celik M.</authname><surname>Celik</surname><given-name>Metin</given-name><initials>M.</initials><afid>60022002</afid></author><authkeywords>Decision-making | Human error probability | Human reliability | Maritime safety | Tank cleaning</authkeywords><intid>535080202</intid><source-id>12332</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926167944"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926167944?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926167944&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926167944&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S096007601500093X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926167944</prism:url><dc:identifier>SCOPUS_ID:84926167944</dc:identifier><eid>2-s2.0-84926167944</eid><dc:title>Cytotoxicity of cardiotonic steroids in sensitive and multidrug-resistant leukemia cells and the link with Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase</dc:title><dc:creator>Zeino M.</dc:creator><prism:publicationName>Journal of Steroid Biochemistry and Molecular Biology</prism:publicationName><prism:issn>09600760</prism:issn><prism:eIssn>18791220</prism:eIssn><prism:volume>150</prism:volume><prism:pageRange>97-111</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jsbmb.2015.03.008</prism:doi><pii>S096007601500093X</pii><dc:description>© 2015 Elsevier Ltd. All rights reserved. Cardiotonic steroids have long been in clinical use for treatment of heart failure and are now emerging as promising agents in various diseases, especially cancer. Their main target is Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase, a membrane protein involved in cellular ion homeostasis. Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase has been implicated in cancer biology by affecting several cellular events and signaling pathways in both sensitive and drug-resistant cancer cells. Hence, we investigated the cytotoxic activities of 66 cardiotonic steroids and cardiotonic steroid derivatives in sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. Data were then subjected to quantitative structure-activity relationship analysis (QSAR) and molecular docking into Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase, which both indicated a possible differential expression of the pump in the mentioned cell lines. This finding was confirmed by western blotting, intracellular potassium labeling and next generation sequencing which showed that Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase was less expressed in multidrug-resistant than in sensitive cells.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031216</affiliation-url><afid>60031216</afid><affilname>Johannes Gutenberg Universitat Mainz</affilname><name-variant>University of Mainz</name-variant><affiliation-city>Mainz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031216</affiliation-url><afid>60031216</afid><affilname>Johannes Gutenberg Universitat Mainz</affilname><name-variant>University of Mainz</name-variant><affiliation-city>Mainz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025988</affiliation-url><afid>60025988</afid><affilname>Universitat Wien</affilname><name-variant>Universität Wien</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025988</affiliation-url><afid>60025988</afid><affilname>Universitat Wien</affilname><name-variant>Universität Wien</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55695822300</author-url><authid>55695822300</authid><authname>Zeino M.</authname><surname>Zeino</surname><given-name>Maen</given-name><initials>M.</initials><afid>60031216</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506155026</author-url><authid>6506155026</authid><authname>Brenk R.</authname><surname>Brenk</surname><given-name>Ruth</given-name><initials>R.</initials><afid>60031216</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:40261574500</author-url><authid>40261574500</authid><authname>Gruber L.</authname><surname>Gruber</surname><given-name>Lisa</given-name><initials>L.</initials><afid>60031216</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506168841</author-url><authid>6506168841</authid><authname>Zehl M.</authname><surname>Zehl</surname><given-name>Martin</given-name><initials>M.</initials><afid>60025988</afid><afid>60025988</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506168841</author-url><authid>6506168841</authid><authname>Zehl M.</authname><surname>Zehl</surname><given-name>Martin</given-name><initials>M.</initials><afid>60025988</afid><afid>60025988</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006236494</author-url><authid>7006236494</authid><authname>Urban E.</authname><surname>Urban</surname><given-name>Ernst</given-name><initials>E.</initials><afid>60025988</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004691489</author-url><authid>7004691489</authid><authname>Kopp B.</authname><surname>Kopp</surname><given-name>Brigitte</given-name><initials>B.</initials><afid>60025988</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005243974</author-url><authid>7005243974</authid><authname>Efferth T.</authname><surname>Efferth</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60031216</afid></author><authkeywords>Cardiotonic steroids | Multidrug resistance | Na+/K+-ATPase signalosome | Next generation sequencing</authkeywords><intid>35681634</intid><source-id>14102</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929091986"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929091986?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929091986&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929091986&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929091986</prism:url><dc:identifier>SCOPUS_ID:84929091986</dc:identifier><eid>2-s2.0-84929091986</eid><dc:title>Morphological characterisation and identification of four species of Cardicola Short, 1953 (Trematoda: Aporocotylidae) infecting the Atlantic bluefin tuna Thunnus thynnus (L.) in the Mediterranean Sea</dc:title><dc:creator>Palacios-Abella J.</dc:creator><prism:publicationName>Systematic Parasitology</prism:publicationName><prism:issn>01655752</prism:issn><prism:volume>91</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>101-117</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11230-015-9568-x</prism:doi><dc:description>© 2015, Springer Science+Business Media Dordrecht. Blood flukes of the genus Cardicola Short, 1953 are considered the most potentially pathogenic parasites in bluefin tuna cultures. Morphological study and genetic analyses of the ribosomal internal transcribed spacer ITS-2 and the mitochondrial cytochrome c oxidase 1 (cox1) gene fragments revealed the occurrence of four aporocotylid species (C. forsteri Cribb, Daintith &amp; Munday, 2000, C. orientalis Ogawa, Tanaka, Sugihara &amp; Takami, 2010, C. opisthorchis Ogawa, Ishimaru, Shirakashi, Takami &amp; Grabner, 2011 and Cardicola sp.) in 421 Thunnus thynnus (L.) from the Western Mediterranean (274 fished from the wild and 147 from sea-cages). Cardicola opisthorchis was the most abundant species, with higher prevalence in the cage-reared fish than in those fished in the wild (21 vs 6%, p &lt; 0.05). Adults of three species were recovered: C. forsteri from both gills and heart, C. opisthorchis from heart and C. orientalis from gills. The secondary gill lamellae were profusely infected by eggs of C. orientalis. A fourth species was found in four tunas, based on the molecular analyses of eggs apparently indistinguishable in size and shape from the eggs of C. orientalis. The findings provided evidence that infections with Cardicola spp. differed in relation to locality, host origin (wild vs cage-reared) and site of infection. It is necessary to estimate the possible different pathogenic effects of each species of Cardicola in order to take appropriate control measures.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002644</affiliation-url><afid>60002644</afid><affilname>Universitat de ValEncia</affilname><name-variant>Universitat de València</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010110</affiliation-url><afid>60010110</afid><affilname>Universita degli Studi di Sassari</affilname><name-variant>University of Sassari</name-variant><affiliation-city>Sassari</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56638478800</author-url><authid>56638478800</authid><authname>Palacios-Abella J.</authname><surname>Palacios-Abella</surname><given-name>José F.</given-name><initials>J.F.</initials><afid>60002644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56638504300</author-url><authid>56638504300</authid><authname>Rodríguez-Llanos J.</authname><surname>Rodríguez-Llanos</surname><given-name>Javier</given-name><initials>J.</initials><afid>60002644</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35325300900</author-url><authid>35325300900</authid><authname>Mele S.</authname><surname>Mele</surname><given-name>Salvatore</given-name><initials>S.</initials><afid>60010110</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36146286500</author-url><authid>36146286500</authid><authname>Montero F.</authname><surname>Montero</surname><given-name>Francisco E.</given-name><initials>F.E.</initials><afid>60002644</afid></author><intid>1535900898</intid><source-id>14307</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929120668"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929120668?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929120668&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929120668&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929120668</prism:url><dc:identifier>SCOPUS_ID:84929120668</dc:identifier><eid>2-s2.0-84929120668</eid><dc:title>Loperamide toxicokinetics: Serum concentrations in the overdose setting</dc:title><dc:creator>Eggleston W.</dc:creator><prism:publicationName>Clinical Toxicology</prism:publicationName><prism:issn>15563650</prism:issn><prism:eIssn>15569519</prism:eIssn><prism:volume>53</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>495-496</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.3109/15563650.2015.1026971</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018741</affiliation-url><afid>60018741</afid><affilname>State University of New York Upstate Medical University</affilname><name-variant>SUNY Upstate Medical University</name-variant><affiliation-city>Syracuse</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56638335800</author-url><authid>56638335800</authid><authname>Eggleston W.</authname><surname>Eggleston</surname><given-name>William</given-name><initials>W.</initials><afid>60018741</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36236975500</author-url><authid>36236975500</authid><authname>Nacca N.</authname><surname>Nacca</surname><given-name>Nicholas</given-name><initials>N.</initials><afid>60018741</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6505979686</author-url><authid>6505979686</authid><authname>Marraffa J.</authname><surname>Marraffa</surname><given-name>Jeanna M.</given-name><initials>J.M.</initials><afid>60018741</afid></author><intid>1035896763</intid><source-id>4000148406</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929080493"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929080493?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929080493&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929080493&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929080493</prism:url><dc:identifier>SCOPUS_ID:84929080493</dc:identifier><eid>2-s2.0-84929080493</eid><dc:title>Special Mitral Valve Issue</dc:title><dc:creator>Kunzelman K.</dc:creator><prism:publicationName>Cardiovascular Engineering and Technology</prism:publicationName><prism:issn>1869408X</prism:issn><prism:eIssn>18694098</prism:eIssn><prism:volume>6</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>93-94</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13239-015-0222-1</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008279</affiliation-url><afid>60008279</afid><affilname>University of Maine</affilname><name-variant>University of Maine</name-variant><affiliation-city>Orono</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004123413</author-url><authid>7004123413</authid><authname>Kunzelman K.</authname><surname>Kunzelman</surname><given-name>Karyn S.</given-name><initials>K.S.</initials><afid>60008279</afid></author><intid>1035896531</intid><source-id>19600166325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929076147"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929076147?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929076147&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929076147&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929076147</prism:url><dc:identifier>SCOPUS_ID:84929076147</dc:identifier><eid>2-s2.0-84929076147</eid><dc:title>Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers</dc:title><dc:creator>Kaland M.</dc:creator><prism:publicationName>Clinical Toxicology</prism:publicationName><prism:issn>15563650</prism:issn><prism:eIssn>15569519</prism:eIssn><prism:volume>53</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>477-485</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.3109/15563650.2015.1027903</prism:doi><dc:description>Copyright © 2015 Informa Healthcare USA, Inc. Context. Lisdexamfetamine is a pro-drug stimulant that requires the enzymatic hydrolysis of lysine from dexamphetamine for pharmacologic effects. There is limited information comparing non-therapeutic lisdexamfetamine and dextroamphetamine exposures. Objective. The objective was to compare lisdexamfetamine exposures with dextroamphetamine/amphetamine extended release and dextroamphetamine/amphetamine immediate release. Methods. A retrospective observational case series of single-substance exposures to lisdexamfetamine, dextroamphetamine/amphetamine extended release, or dextroamphetamine/amphetamine immediate release reported to the National Poison Data System from 2007 to 2012 was performed. Data were analyzed for demographics, reason, clinical effects, management site, and outcomes. Results. There were 23,553 exposures: lisdexamfetamine (7,113), dextroamphetamine/amphetamine extended release (6,245), and dextroamphetamine/amphetamine immediate release (10,195). The most frequent clinical effects observed for lisdexamfetamine, dextroamphetamine/amphetamine extended release, and dextroamphetamine/amphetamine immediate release were agitation (19.8%, 21.7%, and 25.1%, respectively) and tachycardia (19.2%, 22.8%, and 23.9%, respectively). The reason was most often exploratory (93.4%) in children &lt; 6 years and therapeutic error (65.6%) in children aged 6-12 years. In adolescents and adults most common reasons were suicide attempts (28.4%) followed by abuse (19.5%) and therapeutic errors (18.8%). Overall, 61.6% of cases were managed in a health care facility, with the majority treated in the emergency department only. The majority of cases (76.0%) experienced no or minor effects. More serious outcomes (moderate/major/death) occurred in 21.2% of lisdexamfetamine, 24.7% of dextroamphetamine/amphetamine extended release, and 25.5% of dextroamphetamine/amphetamine immediate release. There were 4 deaths (1 dextroamphetamine/amphetamine extended release and 3 dextroamphetamine/amphetamine immediate release). In patients aged 6 years and more, abuse/misuse was more frequently reported for dextroamphetamine/amphetamine immediate release (32.5%) and dextroamphetamine/amphetamine extended release (23.0%) than that for lisdexamfetamine (13.5%). The odds of abuse/misuse was 2.3 (95% confidence interval [CI]: 2.0-2.4) times higher for dextroamphetamine/amphetamine immediate release than that for lisdexamfetamine and dextroamphetamine/amphetamine extended release combined; the odds of dextroamphetamine/amphetamine extended release abuse/misuse was 1.9 (95% CI: 1.7-2.2) times higher than lisdexamfetamine. In 2011, the number of lisdexamfetamine abuse/misuse cases exceeded dextroamphetamine/amphetamine extended release by approximately 26% and plateaued in 2012, but was significantly lower (∼75%) than dextroamphetamine/amphetamine immediate release. Conclusions. Toxic effects were similar for all three drugs. Although the majority of cases were treated at health care facilities, the majority of patients experienced no effects or minor toxicity. Serious outcomes occurred in approximately 21% of lisdexamfetamine and 25% of dextroamphetamine/amphetamine extended release and dextroamphetamine/amphetamine immediate release. Lisdexamfetamine may have less abuse potential, especially compared with the immediate-release dextroamphetamine/amphetamine formulation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024261</affiliation-url><afid>60024261</afid><affilname>University of Maryland School of Pharmacy</affilname><name-variant>Univ. Maryland Sch. Pharm.</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56578606200</author-url><authid>56578606200</authid><authname>Kaland M.</authname><surname>Kaland</surname><given-name>Mingzohn Ellen</given-name><initials>M.E.</initials><afid>60024261</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004024845</author-url><authid>7004024845</authid><authname>Klein-Schwartz W.</authname><surname>Klein-Schwartz</surname><given-name>Wendy</given-name><initials>W.</initials><afid>60024261</afid></author><authkeywords>Abuse | ADHD | Overdose | Toxicity</authkeywords><intid>1035896168</intid><source-id>4000148406</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928944586"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928944586?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928944586&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928944586&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928944586</prism:url><dc:identifier>SCOPUS_ID:84928944586</dc:identifier><eid>2-s2.0-84928944586</eid><dc:title>Volumetric blood flow measurement using Doppler ultrasound: concerns about the technique</dc:title><dc:creator>Blanco P.</dc:creator><prism:publicationName>Journal of Ultrasound</prism:publicationName><prism:issn>19713495</prism:issn><prism:eIssn>18767931</prism:eIssn><prism:volume>18</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>201-204</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40477-015-0164-3</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115102694</affiliation-url><afid>115102694</afid><affilname>Hospital Dr. Emilio Ferreyra</affilname><name-variant>Hospital Dr. Emilio Ferreyra</name-variant><affiliation-city/><affiliation-country>Argentina</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56336807000</author-url><authid>56336807000</authid><authname>Blanco P.</authname><surname>Blanco</surname><given-name>Pablo</given-name><initials>P.</initials><afid>115102694</afid></author><intid>1785877407</intid><source-id>6400153118</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929313489"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929313489?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929313489&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929313489&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0020729214005049"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929313489</prism:url><dc:identifier>SCOPUS_ID:84929313489</dc:identifier><eid>2-s2.0-84929313489</eid><dc:title>QGUARD System to Detect Coronary Events With Patient Alerting</dc:title><dc:creator>Johnson S.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>1-2</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030116</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100730870</affiliation-url><afid>100730870</afid><affilname>Angel Medical Systems, Inc.</affilname><name-variant>Angel Medical Systems</name-variant><affiliation-city>Shrewsbury</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643593500</author-url><authid>56643593500</authid><authname>Johnson S.</authname><surname>Johnson</surname><given-name>Steven R.</given-name><initials>S.R.</initials><afid>100730870</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602977081</author-url><authid>6602977081</authid><authname>Fischell D.</authname><surname>Fischell</surname><given-name>David R.</given-name><initials>D.R.</initials><afid>100730870</afid></author><intid>2035938546</intid><source-id>11700154387</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929306990"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929306990?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929306990&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929306990&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929306990</prism:url><dc:identifier>SCOPUS_ID:84929306990</dc:identifier><eid>2-s2.0-84929306990</eid><dc:title>Assessment of Reactive Hyperemia Using Peripheral Arterial Tonometry</dc:title><dc:creator>Singal A.</dc:creator><prism:publicationName>Journal of Medical Devices, Transactions of the ASME</prism:publicationName><prism:issn>19326181</prism:issn><prism:eIssn>1932619X</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>1-3</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1115/1.4030112</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006832176</author-url><authid>7006832176</authid><authname>Singal A.</authname><surname>Singal</surname><given-name>Ashish</given-name><initials>A.</initials><afid>60005745</afid><afid>60005745</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006832176</author-url><authid>7006832176</authid><authname>Singal A.</authname><surname>Singal</surname><given-name>Ashish</given-name><initials>A.</initials><afid>60005745</afid><afid>60005745</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643641400</author-url><authid>56643641400</authid><authname>Johnson E.</authname><surname>Johnson</surname><given-name>Evan</given-name><initials>E.</initials><afid>60005745</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56644880900</author-url><authid>56644880900</authid><authname>Kelner H.</authname><surname>Kelner</surname><given-name>Harrison</given-name><initials>H.</initials><afid>60005745</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644462600</author-url><authid>56644462600</authid><authname>Eckman P.</authname><surname>Eckman</surname><given-name>P. Peter</given-name><initials>P.P.</initials><afid>60005745</afid></author><intid>35945988</intid><source-id>11700154387</source-id></entry></search-results>
